diff --git a/NEWS.md b/NEWS.md
index 39f2117ba..055782a50 100644
--- a/NEWS.md
+++ b/NEWS.md
@@ -9,11 +9,11 @@ It also adds a `site` argument to `as.sir()`, stores EUCAST MIC breakpoints exac
 * `include_screening` in `as.sir()` now defaults to `NULL`, using screening breakpoints for screening agents only. `include_screening = FALSE` now also returns `NA`, with a note, for a screening agent (#328)
 * EUCAST's breakpoints in brackets are no longer in `clinical_breakpoints`. They were blocking rows, so `as.sir()` can now use PK/PD breakpoints or the breakpoints of a broader taxon instead, e.g., for aminoglycosides in EUCAST 2020-2023. They stay available in [`data-raw/breakpoints_eucast_raw.csv`](https://github.com/msberends/AMR/blob/main/data-raw/breakpoints_eucast_raw.csv) (#327)
 * With unknown `uti`, a blocking row without UTI status no longer overrides a UTI breakpoint at the same taxonomic level, e.g., amikacin in *Acinetobacter* now gives S or R instead of `NA`, which is noted in `sir_interpretation_history()`. Use `uti = FALSE` to prevent this
-* If several breakpoints fit and no `site` is set, `as.sir()` now takes the one for the most systemic site, instead of the first one in the data set. Use `site` to choose another one
+* If several breakpoints fit and no `site` is set, `as.sir()` now takes the one for the most systemic site, instead of the first one in the data set. This means, e.g., that a meningitis breakpoint now precedes a non-meningitis breakpoint, such as for benzylpenicillin in *S. pneumoniae*. Use `site` to choose another one
 
 ### New
 * **Site of infection**
-  * `as.sir()` gained the argument `site`, in fixed codes such as `"meningitis"`, `"iv"` and `"uti"`, which can also be a column name. A breakpoint for a contradicting site is left out, a breakpoint without a site still applies, and the result is `NA` if only contradicting sites are available, without using PK/PD breakpoints. `uti = TRUE` stays available and equals `site = "uti"`
+  * `as.sir()` gained the argument `site`, in fixed codes such as `"meningitis"`, `"iv"`, `"uti"` and, for animals, `"mastitis"` and `"respiratory"`, which can also be a column name. A breakpoint for a contradicting site is left out, a breakpoint without a site still applies, and the result is `NA` if only contradicting sites are available, without using PK/PD breakpoints. `"other"` takes a breakpoint for other infections or without a site, and leaves out those limited to an indication. `uti = TRUE` stays available and equals `site = "uti"`
   * `sir_interpretation_history()` now holds the site of the breakpoint used, and notes every assumption about sites
 * **Screening agents**
   * 13 screening agents in the `antimicrobials` data set: `CHL-S`, `CIP-S`, `COL-S`, `ERY-S`, `FUS-S`, `GEN-S`, `LVX-S`, `MUP-S`, `NEO-S`, `OFX-S`, `RTP-S`, `STR1-S` and `TOB-S` (#328)
diff --git a/R/sir.R b/R/sir.R
index a52ddfe76..039fe0224 100755
--- a/R/sir.R
+++ b/R/sir.R
@@ -41,7 +41,7 @@ VALID_SIR_LEVELS <- c("S", "SDD", "I", "R", "NI", "WT", "NWT", "NS")
 #' @param uti (Urinary Tract Infection) a vector (or column name) with [logical]s (`TRUE` or `FALSE`) to specify whether a UTI specific interpretation from the guideline should be chosen. For using [as.sir()] on a [data.frame], this can also be a column containing [logical]s or when left blank, the data set will be searched for a column 'specimen', and rows within this column containing 'urin' (such as 'urine', 'urina') will be regarded isolates from a UTI. If `uti` is `NA` (unknown), non-UTI breakpoints are preferred, and UTI breakpoints are only used if no non-UTI breakpoints exist for the drug-bug combination, which is noted in [sir_interpretation_history()]. With `uti = FALSE`, UTI breakpoints are never used. See *Examples*.
 #' @inheritParams first_isolate
 #' @param guideline A guideline name (or column name) to use for SIR interpretation. Defaults to `r AMR::clinical_breakpoints$guideline[1]` (the latest implemented EUCAST guideline in the [AMR::clinical_breakpoints] data set), but can be set with the package option [`AMR_guideline`][AMR-options]. Currently supports EUCAST (`r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "EUCAST")$guideline)))`-`r max(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "EUCAST")$guideline)))`) and CLSI (`r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "CLSI")$guideline)))`-`r max(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "CLSI")$guideline)))`), see *Details*. Using a column name allows for straightforward interpretation of historical data, which must be analysed in the context of, for example, different years.
-#' @param site The site or route that the isolate is interpreted for: a [character] vector or a column name, in the fixed codes `"meningitis"`, `"non-meningitis"`, `"endocarditis"`, `"non-endocarditis"`, `"pneumonia"`, `"non-pneumonia"`, `"systemic"`, `"extraintestinal"`, `"other"`, `"intestinal"`, `"skin"`, `"inhaled"`, `"oral"`, `"prophylaxis"`, `"uti"`, `"iv"` and `"topical"`, which can be combined with a comma, e.g. `"iv, meningitis"`. If `site` is `NA` (default), any breakpoint matching all other criteria can apply, taken from most to least systemic site in the order just given, with `"iv"` directly after `"endocarditis"`; a breakpoint without a site is taken after `"other"`. If `site` is set, a breakpoint for a contradicting site is left out, e.g. `"meningitis"` leaves out `Non-meningitis`, while a breakpoint without a site still applies. The result is `NA` if only contradicting sites are available, also when PK/PD breakpoints exist. All choices are noted in [sir_interpretation_history()].
+#' @param site The site or route that the isolate is interpreted for: a [character] vector or a column name, in the fixed codes `"systemic"`, `"iv"`, `"meningitis"`, `"endocarditis"`, `"pneumonia"`, `"mastitis"`, `"respiratory"`, `"metritis"`, `"genital"`, `"intestinal"`, `"other"`, `"non-meningitis"`, `"non-endocarditis"`, `"non-pneumonia"`, `"extraintestinal"`, `"soft tissue"`, `"skin"`, `"wounds"`, `"inhaled"`, `"oral"`, `"prophylaxis"`, `"uti"` and `"topical"`, which can be combined with a comma, e.g. `"iv, meningitis"`. If `site` is `NA` (default), any breakpoint matching all other criteria can apply, taken from most to least systemic site in the order just given; a breakpoint without a site takes the position of `"other"`, as both mean any site that is not listed next to it. If `site` is set, a breakpoint for a contradicting site is left out, e.g. `"meningitis"` leaves out `Non-meningitis`, while a breakpoint without a site still applies. `"other"` leaves out every breakpoint limited to an indication, and prefers a breakpoint without a site. Related sites do not contradict each other: `"pneumonia"` and `"respiratory"`, `"metritis"` and `"genital"`, and `"soft tissue"`, `"skin"` and `"wounds"`. The code `"mastitis"` includes `Mammary gland`, and `"wounds"` includes `Abscesses`. The result is `NA` if only contradicting sites are available, also when PK/PD breakpoints exist. All choices are noted in [sir_interpretation_history()].
 #' @param capped_mic_handling A [character] string that controls how MIC values with a cap (i.e., starting with `<`, `<=`, `>`, or `>=`) are interpreted. Supports the following options:
 #'
 #' `"none"`
@@ -1257,23 +1257,29 @@ convert_host <- function(x, lang = NULL) {
   x_out
 }
 
-# Sites in clinical_breakpoints and in the `site` argument, from most to least systemic. Every value in the `site` column consists of one or more of these, see sir_site_tokens(). A breakpoint without a site is taken right after "other".
-SIR_SITE_ORDER <- c("meningitis", "endocarditis", "iv", "pneumonia", "systemic", "non-meningitis", "non-endocarditis", "non-pneumonia", "extraintestinal", "other", NA, "intestinal", "skin", "inhaled", "oral", "prophylaxis", "uti", "topical", "screen")
+# Sites in clinical_breakpoints and in the `site` argument, from most to least systemic. Every value in the `site` column consists of one or more of these, see sir_site_tokens(). A breakpoint without a site takes the same position as "other": both mean any site that is not listed next to it. That single position gives both meanings: below "meningitis", as "other" then means non-meningitis, and above "uti", as "other" then means non-UTI.
+SIR_SITE_ORDER <- c("systemic", "iv", "meningitis", "endocarditis", "pneumonia", "mastitis", "respiratory", "metritis", "genital", "intestinal", "other", "non-meningitis", "non-endocarditis", "non-pneumonia", "extraintestinal", "soft tissue", "skin", "wounds", "inhaled", "oral", "prophylaxis", "uti", "topical", "screen")
 
 # all notations in the `site` column of clinical_breakpoints and of the `site` argument
 SIR_SITE_PATTERNS <- c(
+  systemic = "systemic( infections)?",
+  iv = "(iv|intravenous|parenteral)",
   meningitis = "meningitis",
   endocarditis = "endocarditis",
-  iv = "(iv|intravenous|parenteral)",
   pneumonia = "((community-acquired )?pneumonia)",
-  systemic = "systemic( infections)?",
+  mastitis = "(mastitis|mammary gland)",
+  respiratory = "respiratory",
+  metritis = "metritis",
+  genital = "genital",
+  intestinal = "intestinal",
+  other = "other( infections)?",
   `non-meningitis` = "non-meningitis",
   `non-endocarditis` = "non-endocarditis",
   `non-pneumonia` = "non-pneumonia",
   extraintestinal = "extraintestinal",
-  other = "other( infections)?",
-  intestinal = "intestinal",
+  `soft tissue` = "soft tissue",
   skin = "skin",
+  wounds = "(wounds?|abscess(es)?)",
   inhaled = "inhaled",
   oral = "oral",
   prophylaxis = "prophylaxis",
@@ -1281,6 +1287,8 @@ SIR_SITE_PATTERNS <- c(
   topical = "topical",
   screen = "screen"
 )
+# sites of which one is part of the other, or which are hard to tell apart, and so do not contradict each other
+SIR_SITE_RELATED <- list(c("pneumonia", "respiratory"), c("metritis", "genital"), c("soft tissue", "skin", "wounds"))
 # parts of the `site` column that do not say anything about where a breakpoint applies
 SIR_SITE_NOT_A_SITE <- c("liposomal", "investigational agent")
 
@@ -1315,6 +1323,11 @@ sir_site_normalise <- function(x) {
   normalised[match(x, unique_x)]
 }
 
+# the sites of the user, with the sites that are related to them
+sir_site_expand <- function(tokens) {
+  unique(c(tokens, unlist(SIR_SITE_RELATED[vapply(SIR_SITE_RELATED, function(related) any(tokens %in% related), logical(1))])))
+}
+
 # whether a breakpoint with these sites does not contradict the sites set by the user
 sir_site_fits <- function(breakpoint_tokens, user_tokens) {
   negated <- function(tokens) sub("^non-", "", tokens[startsWith(tokens, "non-")])
@@ -1325,10 +1338,13 @@ sir_site_fits <- function(breakpoint_tokens, user_tokens) {
   if (("systemic" %in% breakpoint_tokens && "uti" %in% user_tokens) || ("uti" %in% breakpoint_tokens && "systemic" %in% user_tokens)) {
     return(FALSE)
   }
-  groups <- list(
-    route = c("iv", "oral", "topical", "inhaled"),
-    indication = c("meningitis", "endocarditis", "pneumonia", "uti", "intestinal", "extraintestinal", "skin", "prophylaxis")
-  )
+  indications <- c("meningitis", "endocarditis", "pneumonia", "mastitis", "respiratory", "metritis", "genital", "uti", "intestinal", "extraintestinal", "soft tissue", "skin", "wounds", "prophylaxis")
+  # "other" is any site that is not listed, so it contradicts every breakpoint that is limited to an indication
+  if ("other" %in% user_tokens && !any(user_tokens %in% indications) && any(breakpoint_tokens %in% indications)) {
+    return(FALSE)
+  }
+  groups <- list(route = c("iv", "oral", "topical", "inhaled"), indication = indications)
+  user_tokens <- sir_site_expand(user_tokens)
   for (group in groups) {
     from_user <- intersect(user_tokens, group)
     from_breakpoint <- intersect(breakpoint_tokens, group)
@@ -1339,13 +1355,19 @@ sir_site_fits <- function(breakpoint_tokens, user_tokens) {
   TRUE
 }
 
-# the position in SIR_SITE_ORDER, of the most systemic site if there are more
+# whether a breakpoint holds one of the sites that the user set, where "other" is also a breakpoint without a site
+sir_site_given <- function(breakpoint_tokens, user_tokens) {
+  any(breakpoint_tokens %in% sir_site_expand(user_tokens)) || ("other" %in% user_tokens && length(breakpoint_tokens) == 0)
+}
+
+# The position in SIR_SITE_ORDER, of the most systemic site if there are more. The other sites are the decimals, so that "Intravenous, Meningitis" comes before "Intravenous, Non-meningitis".
 sir_site_rank <- function(x) {
   tokens <- sir_site_tokens(x)
   if (length(tokens) == 0) {
-    return(match(NA_character_, SIR_SITE_ORDER))
+    return(as.double(match("other", SIR_SITE_ORDER)))
   }
-  min(match(tokens, SIR_SITE_ORDER))
+  ranks <- sort(match(tokens, SIR_SITE_ORDER))
+  sum(ranks / 100^(seq_along(ranks) - 1))
 }
 
 # Whether a blocking row has any effect, which is the definition used for clinical_breakpoints (#326): as.sir() must give another result without it. This takes one row number and the rows of one guideline, agent and method.
@@ -2081,7 +2103,7 @@ as_sir_method <- function(method_short,
 
     # sort on taxonomic rank first (this will e.g. prefer 'species' breakpoints over 'order' breakpoints), within a rank on the site that the user set, then on whether it is a blocking row, on most to least systemic site, and finally on UTI
     site_tokens_current <- if (is.na(site_current)) character(0) else strsplit(site_current, ",", fixed = TRUE)[[1]]
-    site_not_given <- vapply(breakpoints_current$site, function(s) !any(sir_site_tokens(s) %in% site_tokens_current), logical(1), USE.NAMES = FALSE)
+    site_not_given <- vapply(breakpoints_current$site, function(s) !sir_site_given(sir_site_tokens(s), site_tokens_current), logical(1), USE.NAMES = FALSE)
     if (length(site_tokens_current) == 0) {
       site_not_given[] <- FALSE
     }
diff --git a/R/sysdata.rda b/R/sysdata.rda
index 51f869e04..84768f3c1 100755
Binary files a/R/sysdata.rda and b/R/sysdata.rda differ
diff --git a/README.md b/README.md
index a048c90c3..3f1d3b4bd 100755
--- a/README.md
+++ b/README.md
@@ -15,7 +15,7 @@ Overview:
 - Generates **antibiograms** - WISCA for empiric coverage estimates, or
   traditional/syndromic for AMR surveillance
 - Provides the **full microbiological taxonomy** of ~103 000 distinct
-  species and extensive info of ~630 antimicrobial drugs
+  species and extensive info of ~640 antimicrobial drugs
 - Applies **CLSI 2011-2026** and **EUCAST 2011-2026** clinical and
   veterinary breakpoints, and ECOFFs, for MIC and disk zone
   interpretation
diff --git a/data-raw/ab.md5 b/data-raw/ab.md5
index f8d97b918..9a03f931b 100644
--- a/data-raw/ab.md5
+++ b/data-raw/ab.md5
@@ -1 +1 @@
-81db4bcdb760c4028a188437289e9f54
+7bb0d7533000dd60d71dd2eb4297e4e8
diff --git a/data-raw/clin_break.md5 b/data-raw/clin_break.md5
index 6bf602a7b..83aeebced 100644
--- a/data-raw/clin_break.md5
+++ b/data-raw/clin_break.md5
@@ -1 +1 @@
-bbd1671f1e29c7510e23471aeb3245d3
+56c3254d6c81a4b3b82d3dc345fdaa68
diff --git a/data-raw/datasets/antimicrobials.dta b/data-raw/datasets/antimicrobials.dta
index 4e81e7e09..536225a83 100644
Binary files a/data-raw/datasets/antimicrobials.dta and b/data-raw/datasets/antimicrobials.dta differ
diff --git a/data-raw/datasets/antimicrobials.feather b/data-raw/datasets/antimicrobials.feather
index 623bbef27..f17843677 100644
Binary files a/data-raw/datasets/antimicrobials.feather and b/data-raw/datasets/antimicrobials.feather differ
diff --git a/data-raw/datasets/antimicrobials.parquet b/data-raw/datasets/antimicrobials.parquet
index 349390b64..af81b0cdf 100644
Binary files a/data-raw/datasets/antimicrobials.parquet and b/data-raw/datasets/antimicrobials.parquet differ
diff --git a/data-raw/datasets/antimicrobials.rds b/data-raw/datasets/antimicrobials.rds
index 61a1ab3f0..ca2eebf02 100644
Binary files a/data-raw/datasets/antimicrobials.rds and b/data-raw/datasets/antimicrobials.rds differ
diff --git a/data-raw/datasets/antimicrobials.sav b/data-raw/datasets/antimicrobials.sav
index 459f57291..3d9751bcc 100644
Binary files a/data-raw/datasets/antimicrobials.sav and b/data-raw/datasets/antimicrobials.sav differ
diff --git a/data-raw/datasets/antimicrobials.txt b/data-raw/datasets/antimicrobials.txt
index b228ec54d..47a74a828 100644
--- a/data-raw/datasets/antimicrobials.txt
+++ b/data-raw/datasets/antimicrobials.txt
@@ -140,11 +140,13 @@
 "CED"	38103	"Cephradine"	"Cephalosporins (1st gen.),Cephalosporins,Beta-lactams"	"NA"	"Other beta-lactam antibacterials"	"First-generation cephalosporins"	"cephra,cfra,cfrd"	"anspor,cefradin,cefradina,cefradine,cefradinum,cekodin,cephradin,ecosporina,eskacef,infexin,megacef,sefril,velocef,velosef"					"168-5,169-3,170-1,171-9,18902-7,55646-4"
 "CTO"	71402	"Cetocycline"	"Tetracyclines"	"NA"			"NA"	"cetocyline,cetotetrine,chelocardin"					"NA"
 "CHL"	5959	"Chloramphenicol"	"Phenicols"	"D06AX02,D10AF03,G01AA05,J01BA01,QD06AX02,QD10AF03,QG01AA05,QJ01BA01,QJ51BA01,QS01AA01,QS02AA01,QS03AA08,S01AA01,S02AA01,S03AA08"	"Amphenicols"	"Amphenicols"	"c,chl,chlo,chlora,cl"	"alficetyn,ambofen,amphicol,amseclor,anacetin,aquamycetin,austracil,austracol,biocetin,biophenicol,catilan,chemicetin,chemicetina,chlomin,chlomycol,chloramex,chloramfenikol,chloramficin,chloramfilin,chloramphenicole,chloramphenicolum,chloramsaar,chlorasol,chlorbiotic,chloricol,chlornitromycin,chloroamphenicol,chlorocaps,chlorocid,chlorocide,chlorocin,chlorocol,chlorofair,chloromax,chloromycetin,chloromycetny,chloromyxin,chloronitrin,chloroptic,chlorovules,cidocetine,ciplamycetin,cloramfen,cloramfenicol,cloramfenicolo,cloramficin,cloramicol,cloramidina,cloranfenicol,cloroamfenicolo,clorocyn,cloromisan,clorosintex,comycetin,cylphenicol,desphen,detreomycin,detreomycine,dextramycin,dextromycetin,doctamicina,econochlor,embacetin,emetren,enteromycetin,erbaplast,ertilen,farmicetina,globenicol,glorous,gloveticol,halcetin,halomycetin,hortfenicol,intramycetin,isicetin,ismicetina,isophenicol,juvamycetin,kamaver,kemicetina,kemicetine,kloramfenikol,klorita,laevomycetinum,leukamycin,leukomyan,leukomycin,levocin,levomicetina,levomitsetin,levomycetin,levoplast,levosin,levovetin,loromisan,loromisin,mastiphen,maybridge,mediamycetine,medichol,micloretin,micochlorine,micoclorina,microcetina,mychel,mycinol,myclocin,mycochlorin,novochlorocap,novomycetin,novophenicol,ocuphenicol,oftalent,oleomycetin,opclor,opelor,ophthochlor,ophthocort,ophtochlor,optomycin,otachron,otophen,pantovernil,paraxin,pentamycetin,petnamycetin,quemicetina,rivomycin,romphenil,ronphenil,septicol,sificetina,sintomicetin,sintomicetina,soluthor,stanomycetin,synthomycetin,synthomycetine,synthomycine,syntomycin,tevcocin,tevcosin,tifomycin,tifomycine,tiromycetin,treomicetina,tyfomycine,unimycetin,veticol,viceton"	3	"g"	3	"g"	"15101-9,16603-3,16604-1,172-7,173-5,174-3,175-0,18903-5,25247-8,29214-4,29346-4,29347-2,3455-3,7001-1"
+"CHL-S"		"Chloramphenicol screening test"	"Phenicols"	""			"chl screen"	""					""
 "CTE"	54675777	"Chlortetracycline"	"Tetracyclines"	"A01AB21,D06AA02,J01AA03,QA01AB21,QD06AA02,QG51AA08,QJ01AA03,QJ51AA03,QS01AA02,S01AA02"	"Tetracyclines"	"Tetracyclines"	"chltet"	"acronize,alexomycin,aueromycin,aureocarmyl,aureociclina,aureocina,aureocycline,aureomycin,aureomykoin,aurofac,auxeomycin,biomitsin,biomycin,chlormax,chlorotetracycline,chlortetracyclinum,chrysomykine,clorocipan,clortetraciclina,clortetrin,declomycin,declostatin,deganol,demeclor,demeplus,demetraciclina,demetraclin,detracin,detravis,diuciclin,duomycin,elkamicina,flamycin,isphamycin,ledermicina,ledermycin,ledermycine,mexocine,novotriclina,pennchlor,perciclina,periciclina,sumaclina,uromycin,veraciclina"	1	"g"			"176-8,177-6,178-4,179-2,18904-3,55655-5,87600-3"
 "CIC"	19003	"Ciclacillin"	"Penicillins,Beta-lactams"	"NA"			"cyclac"	"bastcillin,calthor,ciclacilina,ciclacilline,ciclacillinum,ciclacillum,citosarin,cyclacillin,cyclapen,noblicil,orfilina,peamezin,syngacillin,ultracillin,vastcillin,vipicil,wyvital"					"NA"
 "CIX"		"Ciclopirox"	"Antifungals"	"D01AE14,G01AX12,QD01AE14,QG01AX12"	"Antifungals for topical use"	"Other antifungals for topical use"	"cipx"	"NA"					"NA"
 "CIN"	2762	"Cinoxacin"	"Quinolones"	"J01MB06,QJ01MB06"	"Quinolone antibacterials"	"Other quinolones"	"cino,cinoxa,cnox"	"cinobac,cinobactin,cinoxacine,cinoxacino,cinoxacinum,clinoxacin,noxigram,uronorm"	1	"g"			"180-0,181-8,182-6,183-4,18905-0,55656-3"
 "CIP"	2764	"Ciprofloxacin"	"Fluoroquinolones,Quinolones"	"J01MA02,QJ01MA02,QS01AE03,QS02AA15,QS03AA07,S01AE03,S02AA15,S03AA07"	"Quinolone antibacterials"	"Fluoroquinolones"	"ci,cip,cipr,ciprof,cp"	"alcipro,bacquinor,baflox,belmacina,bernoflox,catex,cenin,ceprimax,cetraxal,ciflan,ciflosin,cifloxin,cilab,cilox,ciloxan,cipad,ciplus,ciprecu,ciprenit,ciprine,ciprinol,cipro,ciprobay,ciprocinal,ciprocinol,ciprodar,ciproflox,ciprofloxacina,ciprofloxacine,ciprofloxacino,ciprofloxacinum,ciprofur,ciprogis,ciproktan,ciprolin,ciprolon,cipromycin,cipronex,ciprooxacin,cipropol,ciproquinol,ciprowin,ciproxan,ciproxin,ciproxina,ciproxine,ciriax,citeral,citopcin,cixan,corsacin,cunesin,cycin,cyprobay,cyproxan,disfabac,felixene,fimoflox,flociprin,floxacipron,flunas,globuce,inkamil,ipiflox,italnik,keefloxin,linhaliq,loxacid,loxan,lypro,megaflox,microgan,nixin,novidat,novoquin,ofitin,oftacilox,ophaflox,otiprio,phaproxin,piprol,plenolyt,probiox,proflaxin,proksi,proquin,proxacin,quinoflox,quinolid,quintor,quipro,rancif,renator,roflazin,roxytal,sepcen,septicide,septocipro,siprogut,sophixin,spitacin,strox,suiflox,superocin,supraflox,uritent,utiminx,velmonit,zumaflox"	1	"g"	0.8	"g"	"101500-7,14031-9,14032-7,14058-2,14059-0,184-2,185-9,186-7,187-5,18906-8,20377-8,23621-6,25180-1,25181-9,25188-4,25189-2,25248-6,34636-1,3484-3,42644-5,55194-5,7002-9"
+"CIP-S"		"Ciprofloxacin screening test"	"Fluoroquinolones,Quinolones"	""			"cip screen"	""					""
 "CIM"		"Ciprofloxacin/metronidazole"	"Fluoroquinolones,Quinolones"	"J01RA10,QJ01RA10"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
 "CIO"		"Ciprofloxacin/ornidazole"	"Fluoroquinolones,Quinolones"	"J01RA12,QJ01RA12"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
 "CIT"		"Ciprofloxacin/tinidazole"	"Fluoroquinolones,Quinolones"	"J01RA11,QJ01RA11"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
@@ -161,6 +163,7 @@
 "CTR"	2812	"Clotrimazole"	"Antifungals"	"A01AB18,D01AC01,G01AF02,QA01AB18,QD01AC01,QG01AF02,QJ02AB90"			"clot"	"alevazol,bisphenyl,canesten,canestene,canestine,canifug,chlotrimazole,clomatin,clotrimaderm,clotrimazol,clotrimazolum,coltrimazole,cutistad,diphenylmethane,empecid,esparol,femmesil,footlogix,fortinia,gynix,imidazole,jidesheng,klotrimazole,lakesia,lombazol,lombazole,lombazolum,lotrimax,lotrimin,monobaycuten,mycelax,mycelex,mycofug,mycosporin,mykosporin,nalbix,otomax,pedesil,pedisafe,ringworm,stiemazol,tibatin,trimysten,trivagizole"					"10653-4,10654-2,18909-2,54177-1,55663-9"
 "CLO"	6098	"Cloxacillin"	"Isoxazolylpenicillins,Penicillins,Beta-lactams"	"J01CF02,QJ01CF02,QJ51CF02,QS01AA90"	"Beta-lactam antibacterials, penicillins"	"Beta-lactamase resistant penicillins"	"clox,cloxac"	"ankerbin,austrastaph,biocloxin,brispen,chloroxacillin,ciclex,clocil,clossacillina,cloxacilina,cloxacillinanhydrous,cloxacilline,cloxacillinsalt,cloxacillinum,cloxapen,constaphyl,dariclox,dichlorstapenor,diclocil,dicloxacillinhydrate,diflor,digloxilline,dynapen,ekvacillin,gelstaph,novapen,noxaben,orbenin,pathocil,stampen,staphybiotic,syntarpen,syntarpensalt,tegopen"	2	"g"	2	"g"	"16628-0,18910-0,196-6,197-4,198-2,199-0,25250-2,55664-7"
 "COL"	5311054	"Colistin"	"Polymyxins"	"A07AA10,J01XB01,QA07AA10,QJ01XB01,QJ51XB01"	"Other antibacterials"	"Polymyxins"	"cl,coli,colist,cs,cst,ct"	"colimycin,colisticin,colisticina,colistina,colistine,colistinum,colobreathe,colomycin,kangdisu,kolimitsin,kolimycin,promixin,sogecoli,totazina"	9	"MU"	9	"MU"	"16645-4,18912-6,204-8,205-5,206-3,207-1,29493-4,33333-6"
+"COL-S"		"Colistin screening test"	"Polymyxins"	""			"col screen"	""					""
 "COP"		"Colistin/polysorbate"	"Other"	"NA"			"NA"	"NA"					"NA"
 "CYC"	6234	"Cycloserine"	"Oxazolidinones"	"J04AB01,QJ04AB01"	"Drugs for treatment of tuberculosis"	"Antibiotics"	"cycl,cyclos"	"cicloserina,closina,cyclorin,cycloserin,cycloserinum,farmiserina,levcicloserina,levcycloserine,levcycloserinum,micoserina,miroserina,miroseryn,novoserin,oxamicina,oxamycin,seromycin,tebemicina,wasserina"	0.75	"g"			"16702-3,18914-2,212-1,213-9,214-7,215-4,23608-3,25207-2,25208-0,25209-8,25251-0,3519-6,55667-0"
 "DAL"	23724878	"Dalbavancin"	"Lipoglycopeptides,Glycopeptides,Peptides"	"J01XA04,QJ01XA04"	"Other antibacterials"	"Glycopeptide antibacterials"	"dalb,dalbav"	"dalbavancina,dalvance,xydalba,zeven"			1.5	"g"	"41688-3,41689-1,41690-9,41734-5"
@@ -187,6 +190,7 @@
 "ERV"	54726192	"Eravacycline"	"Tetracyclines"	"J01AA13,QJ01AA13"	"Tetracyclines"	"Tetracyclines"	"erav"	"xerava"			0.14	"g"	"100049-6,85423-2,93767-2"
 "ETP"	150610	"Ertapenem"	"Carbapenems,Beta-lactams"	"J01DH03,QJ01DH03"	"Other beta-lactam antibacterials"	"Carbapenems"	"erta,ertape,etp"	"ertapenemsalt,invanz"			1	"g"	"101486-9,35799-6,35800-2,35801-0,35802-8"
 "ERY"	12560	"Erythromycin"	"Macrolides"	"D10AF02,J01FA01,QD10AF02,QJ01FA01,QJ51FA01,QS01AA17,S01AA17"	"Macrolides, lincosamides and streptogramins"	"Macrolides"	"e,em,ery,ery32,eryt,eryth"	"abboticin,abomacetin,acneryne,acnesol,aknemycin,aknin,benzamycin,derimer,deripil,dotycin,dumotrycin,emgel,emuvin,emycin,endoeritrin,erecin,erisone,eritomicina,eritrocina,eritromicina,ermycin,eryacne,eryacnen,erycen,erycette,erycinum,eryderm,erydermer,erygel,eryhexal,erymax,erymed,erysafe,erytab,erythro,erythroderm,erythrogran,erythroguent,erythromast,erythromid,erythromycine,erythromycinum,erytop,erytrociclin,ilocaps,ilosone,iloticina,ilotycin,inderm,latotryd,lederpax,mephamycin,mercina,oftamolets,pantoderm,pantodrin,pantomicina,pharyngocin,primacine,propiocine,proterytrin,retcin,robimycin,sansac,spotex,staticin,stiemicyn,stiemycin,tiprocin,torlamicina,wemid"	2	"g"	1	"g"	"100050-4,11576-6,12298-6,16829-4,16830-2,18919-1,18920-9,20380-2,232-9,233-7,234-5,235-2,236-0,23633-1,237-8,238-6,239-4,25224-7,25275-9,3597-2,7009-4"
+"ERY-S"		"Erythromycin screening test"	"Macrolides"	""			"ery screen"	""					""
 "ETH"	14052	"Ethambutol"	"Antimycobacterials"	"J04AK02,QJ04AK02"	"Drugs for treatment of tuberculosis"	"Other drugs for treatment of tuberculosis"	"emb,etha,ethamb"	"aethambutolum,dadibutol,diambutol,etambutol,etambutolo,ethambutolum,myambutol,purderal,servambutol,tibutol"	1.2	"g"	1.2	"g"	"100051-2,16841-9,18921-7,20381-0,23625-7,240-2,241-0,242-8,243-6,25187-6,25194-2,25195-9,25230-4,25404-5,3607-9,42645-2,42646-0,55154-9,55674-6,56025-0,7010-2,89491-5"
 "ETI"	456476	"Ethambutol/isoniazid"	"Antimycobacterials"	"J04AM03,QJ04AM03"	"Drugs for treatment of tuberculosis"	"Combinations of drugs for treatment of tuberculosis"	"NA"	"NA"					"NA"
 "ETI1"	2761171	"Ethionamide"	"Antimycobacterials"	"J04AD03,QJ04AD03"	"Drugs for treatment of tuberculosis"	"Thiocarbamide derivatives"	"ethi,ethion"	"aethionamidum,aetina,aetiva,amidazin,amidazine,atina,ethimide,ethina,ethinamide,ethionamidum,ethioniamide,ethylisothiamide,ethyonomide,etimid,etiocidan,etionamid,etionamida,etionamide,etioniamid,etionid,etionizin,etionizina,etionizine,fatoliamid,iridocin,iridozin,isothin,isotiamida,itiocide,nicotion,nisotin,nizotin,rigenicid,sertinon,teberus,thianid,thianide,thioamide,thiodine,thiomid,thioniden,tianid,tiomid,trecator,trekator,trescatyl,trescazide,tubenamide,tubermin,tuberoid,tuberoson"	0.75	"g"			"16099-4,16845-0,18922-5,20382-8,23617-4,25183-5,25196-7,25198-3,25231-2,41693-3,42647-8,42648-6,7011-0,96110-2"
@@ -211,11 +215,13 @@
 "FUR"	6870646	"Furazidin"	"Nitrofurans"	"J01XE03,QJ01XE03"	"Other antibacterials"	"Nitrofuran derivatives"	"NA"	"akritoin,furagin,furaginum,furamag,furazidine,hydantoin"	0.3	"g"			"NA"
 "FRZ"	5323714	"Furazolidone"	"Nitrofurans"	"G01AX06,QG01AX06,QJ01XE90"			"furazo"	"bifuron,corizium,coryzium,diafuron,enterotoxon,furall,furanzolidone,furaxon,furaxone,furazolidine,furazolidon,furazolidona,furazolidonum,furazolum,furidon,furmethoxadone,furovag,furoxal,furoxane,furoxon,furoxone,furozolidine,giardil,giarlam,medaron,neftin,nicolen,nifulidone,nifuran,nifurazolidone,nifurazolidonum,nitrofuradoxon,nitrofurazolidone,nitrofurazolidonum,nitrofuroxon,optazol,ortazol,puradin,roptazol,sclaventerol,tikofuran,topazone,trichofuron,tricofuron,tricoron,trifurox,viofuragyn"					"69574-2,87794-4"
 "FUS"	3000226	"Fusidic acid"	"Fusidanes"	"D06AX01,D09AA02,J01XC01,QD06AX01,QD09AA02,QJ01XC01,QS01AA13,S01AA13"	"Other antibacterials"	"Steroid antibacterials"	"fa,fusaci,fusi"	"flucidin,fucidate,fucidina,fucidine,fucithalmic,fusidate,fusidicacid,fusidin,fusidine,taksta"	1.5	"g"	1.5	"g"	"NA"
+"FUS-S"		"Fusidic acid screening test"	"Fusidanes"	""			"fus screen"	""					""
 "GAM"	59364992	"Gamithromycin"	"Macrolides"	"QJ01FA95"			"NA"	"zactran"					"100054-6,88376-9,88378-5"
 "GRN"	124093	"Garenoxacin"	"Fluoroquinolones,Quinolones"	"J01MA19,QJ01MA19"			"gareno"	"ganefloxacin,garenfloxacin"	0.4	"g"			"35811-9,35812-7,35813-5"
 "GAT"	5379	"Gatifloxacin"	"Fluoroquinolones,Quinolones"	"J01MA16,QJ01MA16,QS01AE06,S01AE06"	"Quinolone antibacterials"	"Fluoroquinolones"	"gati,gatifl"	"acorafloxacin,avarofloxacin,balofloxacin,balofox,bazucin,bilimin,bonoq,gaity,gatiflo,gatifloxacine,gatifloxcin,gatilox,gatiquin,gatispan,kinome,tequin,tymer,zymar,zymaxid,zymer"	0.4	"g"	0.4	"g"	"31036-7,31038-3,31040-9,31042-5,41494-6"
 "GEM"	9571107	"Gemifloxacin"	"Fluoroquinolones,Quinolones"	"J01MA15,QJ01MA15"	"Quinolone antibacterials"	"Fluoroquinolones"	"gemifl"	"factiv,gemifioxacin,gemifloxacine,gemifloxacino,gemifloxacinum"	0.32	"g"	0.2	"g"	"35814-3,35815-0,35816-8,41697-4"
 "GEN"	3467	"Gentamicin"	"Aminoglycosides"	"D06AX07,J01GB03,QA07AA91,QD06AX07,QG01AA91,QG51AA04,QJ01GB03,QJ51GB03,QS01AA11,QS02AA14,QS03AA06,S01AA11,S02AA14,S03AA06"	"Aminoglycoside antibacterials"	"Other aminoglycosides"	"cn,ge1000,ge2000,gen,gen128,gen500,gent,genta1,gentam,gm"	"centicin,cidomycin,garamicin,garamycin,gentacycol,gentamicina,gentamicine,gentamicins,gentamicinum,gentamycins,gentamycinum,gentocin,lyramycin,oksitselanim,septigen,septocin"			0.24	"g"	"101494-3,13561-6,13562-4,15106-8,18928-2,18929-0,22746-2,22747-0,266-7,267-5,268-3,269-1,31091-2,31092-0,31093-8,35668-3,35817-6,3663-2,3664-0,3665-7,39082-3,47109-4,50630-3,59379-8,7016-9,7017-7,7018-5,80971-5,88111-0,89481-6"
+"GEN-S"		"Gentamicin screening test"	"Aminoglycosides"	""			"gen screen"	""					""
 "GEH"		"Gentamicin-high"	"Aminoglycosides"	"NA"			"gehi,gehl,genta high,gentamicin high"	"NA"					"18929-0,35817-6,7017-7,7018-5"
 "GEP"	25101874	"Gepotidacin"	"Other"	"J01XX13,QJ01XX13"			"NA"	"gepotidacina,gepotidacine"					"NA"
 "GRX"	72474	"Grepafloxacin"	"Fluoroquinolones,Quinolones"	"J01MA11,QJ01MA11"	"Quinolone antibacterials"	"Fluoroquinolones"	"grep,grepaf"	"grepafloxacine,grepafloxacino,lungaskin,raxar,vaxar"	0.4	"g"			"21316-5,23638-0,23639-8,35818-4"
@@ -248,6 +254,7 @@
 "LMU"	25185057	"Lefamulin"	"Other"	"J01XX12,QJ01XX12"			"NA"	"lefamulinacetate,xenleta"					"85425-7,99281-8"
 "LEN"	65646	"Lenampicillin"	"Penicillins,Beta-lactams"	"NA"			"NA"	"lenampicilina,lenampicilline,lenampicillinum,takacillin,valacillin,varacillin"					"NA"
 "LVX"	149096	"Levofloxacin"	"Fluoroquinolones,Quinolones"	"J01MA12,QJ01MA12,QS01AE05,S01AE05"	"Quinolone antibacterials"	"Fluoroquinolones"	"le,lev,levo,levofl,lvx"	"aeroquin,cravit,dextrofloxacin,dynaquin,elequine,iquix,levaquin,levofiexacin,levofloxacine,levofloxacino,levofloxacinum,loxof,ofloxcacin,oftaquix,quinsair,quixin,tavanic,unibiotic,venaxan"	0.5	"g"	0.5	"g"	"101501-5,20396-8,20629-2,21367-8,21368-6,30532-6,30533-4,48173-9,53716-7,7026-8,76040-5,76041-3,76042-1"
+"LVX-S"		"Levofloxacin screening test"	"Fluoroquinolones,Quinolones"	""			"lvx screen"	""					""
 "LEO"		"Levofloxacin/ornidazole"	"Fluoroquinolones,Quinolones"	"J01RA05,QJ01RA05"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
 "LND"	9850038	"Levonadifloxacin"	"Fluoroquinolones,Quinolones"	"J01MA24,QJ01MA24"			"NA"	"NA"					"NA"
 "LSP"		"Linco-spectin"	"Other"	"NA"			"lincomycin/spectinomycin"	"NA"					"NA"
@@ -286,6 +293,7 @@
 "MRN"	70374	"Morinamide"	"Antimycobacterials"	"J04AK04,QJ04AK04"	"Drugs for treatment of tuberculosis"	"Other drugs for treatment of tuberculosis"	"NA"	"morfazinamide,morfazinammide,morfgazinamide,morinamida,morinamidum,morphazinamid,morphazinamide,piazofolina,piazolin,piazolina"					"NA"
 "MFX"	152946	"Moxifloxacin"	"Fluoroquinolones,Quinolones"	"J01MA14,QJ01MA14,QS01AE07,S01AE07"	"Quinolone antibacterials"	"Fluoroquinolones"	"mox,moxi,moxifl,mxf"	"actira,actura,avalox,avelox,avolex,izilox,moxeza,moxifloxacine,moxifloxacino,octegra,vegamox,vigamox,zimoxin"	0.4	"g"	0.4	"g"	"31037-5,31039-1,31041-7,31043-3,41502-6,43751-7,45223-5,76043-9,76044-7,76045-4,80540-8,88707-5,93497-6,96112-8"
 "MUP"	446596	"Mupirocin"	"Other"	"D06AX09,QD06AX09,QR01AX06,R01AX06"			"mup,mupi,mupiro"	"bactoderm,bactroban,centany,mupirocina,mupirocine,mupirocinum,plasimine,turixin"					"20389-3,35822-6,35823-4,60542-8,60543-6,7033-4"
+"MUP-S"		"Mupirocin screening test"	"Other"	""			"mup screen"	""					""
 "NAC"	73386748	"Nacubactam"	"Beta-lactamase inhibitors"	"NA"			"NA"	"NA"					"NA"
 "NAD"	4410	"Nadifloxacin"	"Fluoroquinolones,Quinolones"	"D10AF05,QD10AF05"			"NA"	"acuatim,nadifloxacine,nadifloxacino,nadifloxacinum,nadixa,nadoxin"					"NA"
 "NAF"	8982	"Nafcillin"	"Penicillins,Beta-lactams"	"J01CF06,QJ01CF06"			"nafcil"	"nafcil,nafcilin,nafcilina,nafcillinanhydrous,nafcilline,nafcillinhydrate,nafcillinmonohydrate,nafcillinsalt,nafcillinum,naftopen,nallpen,naphcillin,naphthicillin,unipen"			3	"g"	"10993-4,18951-4,25232-0,346-7,347-5,348-3,349-1,41704-8"
@@ -295,6 +303,7 @@
 "NAR"	65452	"Narasin"	"Ionophores"	"QP51BB04"			"narasi"	"monteban,narasine,narasino,narasinum,skycis"					"87570-8"
 "NEM"	11993740	"Nemonoxacin"	"Fluoroquinolones,Quinolones"	"J01MB08,QJ01MB08"	"Quinolone antibacterials"	"Other quinolones"	"NA"	"NA"					"NA"
 "NEO"		"Neomycin"	"Aminoglycosides"	"A01AB08,A07AA01,B05CA09,D06AX04,J01GB05,QA01AB08,QA07AA01,QB05CA09,QD06AX04,QJ01GB05,QR02AB01,QS01AA03,QS02AA07,QS03AA01,R02AB01,S01AA03,S02AA07,S03AA01"	"Aminoglycoside antibacterials"	"Other aminoglycosides"	"neom,neomyc"	"NA"	5	"g"	1	"g"	"10995-9,18953-0,25262-7,354-1,355-8,356-6,357-4,41705-5"
+"NEO-S"		"Neomycin screening test"	"Aminoglycosides"	""			"neo screen"	""					""
 "NET"	441306	"Netilmicin"	"Aminoglycosides"	"J01GB07,QJ01GB07,QS01AA23,S01AA23"	"Aminoglycoside antibacterials"	"Other aminoglycosides"	"neti,netilm"	"netillin,netilmicina,netilmicine,netilmicinum,netilyn,netira,netromicine,netromycin,nettacin,ntromicine,ntromycin,vectacin,zetamicin"	0.35	"g"	0.35	"g"	"18954-8,25263-5,358-2,359-0,360-8,361-6,3848-9,3849-7,3850-5,47385-0,59565-2,59566-0,59567-8,7035-9"
 "NIC"	9507	"Nicarbazin"	"Other"	"NA"			"NA"	"nicarb,nicarbasin,nicarbazine,nicarmix,nicoxin,nicrazin,nicrazine,nirazin"					"NA"
 "NIF"	71946	"Nifuroquine"	"Fluoroquinolones,Quinolones"	"NA"			"NA"	"abimasten,nifuroquina,nifuroquinum,quinaldofur"					"NA"
@@ -311,6 +320,7 @@
 "NOV"	54675769	"Novobiocin"	"Aminocoumarins"	"QJ01XX95"			"novo,novobi"	"albadry,albamix,albamycin,biotexin,cardelmycin,cardelmycinsalt,cathocin,cathomycin,inabiocin,novobiocina,novobiocine,novobiocinsalt,novobiocinum,robiocina,sirbiocina,spheromycin,stilbiocina,streptonivicin,streptonivicinsalt,vulcamicina,vulcamycin,vulkamycin"					"17378-1,18957-1,370-7,371-5,372-3,373-1,41706-3"
 "NYS"	6433272	"Nystatin"	"Ionophores,Antifungals"	"A07AA02,D01AA01,G01AA01,QA07AA02,QD01AA01,QG01AA01"			"nyst,nystan"	"biofanal,diastatin,herniocid,moronal,myconystatin,mycostatin,mykostatyna,nilstat,nistatin,nistatina,nyotran,nystan,nystatyna,nystavescent,nystex"	1.5	"MU"			"10697-1,10698-9,18958-9,35824-2,55689-4"
 "OFX"	4583	"Ofloxacin"	"Fluoroquinolones,Quinolones"	"J01MA01,QJ01MA01,QS01AE01,QS02AA16,S01AE01,S02AA16"	"Quinolone antibacterials"	"Fluoroquinolones"	"of,ofl,oflo,ofloxa,ofx"	"exocin,exocine,flobacin,floxil,floxin,monoflocet,oflocet,ofloxacina,ofloxacine,ofloxacino,ofloxacinum,ofloxaxin,oxaldin,tarivid,visiren,zanocin"	0.4	"g"	0.4	"g"	"18959-7,20384-4,23948-3,25264-3,374-9,375-6,376-4,377-2,3877-8,41408-6,41409-4,41410-2,42653-6,7038-3,72168-8"
+"OFX-S"		"Ofloxacin screening test"	"Fluoroquinolones,Quinolones"	""			"ofx screen"	""					""
 "OOR"		"Ofloxacin/ornidazole"	"Fluoroquinolones,Quinolones"	"J01RA09,QJ01RA09"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
 "OLE"	72493	"Oleandomycin"	"Macrolides"	"J01FA05,QJ01FA05"	"Macrolides, lincosamides and streptogramins"	"Macrolides"	"oleand"	"amimycin,landomycin,matromycin,oleandomicina,oleandomycine,oleandomycinum,romicil"	1	"g"			"18960-5,378-0,379-8,380-6,381-4,55690-2"
 "OMC"	54697325	"Omadacycline"	"Tetracyclines"	"J01AA15,QJ01AA15"			"NA"	"amadacycline"	0.3	"g"	0.1	"g"	"73594-4,73616-5,73639-7"
@@ -371,6 +381,7 @@
 "RAM"	16132338	"Ramoplanin"	"Glycopeptides,Peptides"	"NA"			"ramopl"	"NA"					"41710-5,41711-3,41712-1,41737-8"
 "RZM"	10993211	"Razupenem"	"Carbapenems,Beta-lactams"	"NA"			"razupe"	"NA"					"73590-2,73612-4,73635-5"
 "RTP"	6918462	"Retapamulin"	"Pleuromutilins"	"D06AX13,QD06AX13"	"Antibiotics for topical use"	"Other antibiotics for topical use"	"ret"	"altabax,altargo,rebapamulin,retapamulina"					"NA"
+"RTP-S"		"Retapamulin screening test"	"Pleuromutilins"	""			"rtp screen"	""					""
 "RZF"		"Rezafungin"	"Antifungals"	"NA"			"NA"	"NA"					"NA"
 "RBC"	44631912	"Ribociclib"	"Antifungals"	"L01EF02,QL01EF02"	"Antimycotics for systemic use"	"Triazole derivatives"	"ribo"	"kisqali"	0.45	"g"			"NA"
 "RST"	33042	"Ribostamycin"	"Aminoglycosides"	"J01GB10,QJ01GB10"	"Aminoglycoside antibacterials"	"Other aminoglycosides"	"NA"	"exaluren,hetangmycin,ribastamin,ribostamicina,ribostamycine,ribostamycinum,vistamycin,xylostatin"			1	"g"	"NA"
@@ -406,6 +417,7 @@
 "SPM"		"Spiramycin/metronidazole"	"Other"	"J01RA04,QJ01RA04"	"Combinations of antibacterials"	"Combinations of antibacterials"	"NA"	"NA"					"NA"
 "STR"		"Streptoduocin"	"Aminoglycosides"	"J01GA02,QJ01GA02"	"Aminoglycoside antibacterials"	"Streptomycins"	"NA"	"NA"			1	"g"	"NA"
 "STR1"	19649	"Streptomycin"	"Aminoglycosides"	"A07AA04,J01GA01,QA07AA04,QJ01GA01"	"Aminoglycoside antibacterials"	"Streptomycins"	"s,st1000,st2000,stm,str,stre,strept"	"agrept,agrimycin,chemform,estreptomicina,gerox,neodiestreptopab,strepcen,streptomicina,streptomycine,streptomycinum,streptomyzin"			1	"g"	"18982-9,18983-7,20462-8,23626-5,25185-0,25205-6,25206-4,35841-6,4039-4,42658-5,42659-3,459-8,460-6,461-4,462-2,46719-1,48177-0,6933-6,7048-2,7049-0,96114-4"
+"STR1-S"		"Streptomycin screening test"	"Aminoglycosides"	""			"str1 screen"	""					""
 "STH"		"Streptomycin-high"	"Aminoglycosides"	"NA"			"sthi,sthl,strepto high,streptomycin high"	"NA"					"18983-7,35841-6,6933-6,7049-0"
 "STI"		"Streptomycin/isoniazid"	"Antimycobacterials"	"J04AM01,QJ04AM01"	"Drugs for treatment of tuberculosis"	"Combinations of drugs for treatment of tuberculosis"	"NA"	"NA"					"NA"
 "SUL"	130313	"Sulbactam"	"Beta-lactamase inhibitors"	"J01CG01,QJ01CG01"	"Beta-lactam antibacterials, penicillins"	"Beta-lactamase inhibitors"	"sulbac"	"betamaze,sulbactamum"			1	"g"	"41716-2,41717-0,41718-8,41739-4"
@@ -484,6 +496,7 @@
 "TXC"	65788	"Tioxacin"	"Fluoroquinolones,Quinolones"	"NA"			"NA"	"tioxacine,tioxacino,tioxacinum"					"NA"
 "TIZ"	394397	"Tizoxanide"	"Other"	"NA"			"NA"	"NA"					"73585-2,73607-4,73629-8"
 "TOB"	36294	"Tobramycin"	"Aminoglycosides"	"J01GB01,QJ01GB01,QS01AA12,S01AA12"	"Aminoglycoside antibacterials"	"Other aminoglycosides"	"nn,tm,to,tob,tobr,tobram"	"aktob,bethkis,distobram,gotabiotic,kitabis,nebcin,nebicin,nebramycin,tenebrimycin,tenemycin,tobacin,tobracin,tobradex,tobradistin,tobralex,tobramaxin,tobramicin,tobramicina,tobramitsetin,tobramycetin,tobramycine,tobramycinum,tobrased,tobrex"			0.24	"g"	"101496-8,13584-8,17808-7,18996-9,22750-4,22751-2,22752-0,25227-0,25800-4,31094-6,31095-3,31096-1,35239-3,35670-9,4057-6,4058-4,4059-2,507-4,508-2,509-0,50927-3,510-8,52962-8,59380-6,7055-7,80966-5"
+"TOB-S"		"Tobramycin screening test"	"Aminoglycosides"	""			"tob screen"	""					""
 "TOH"		"Tobramycin-high"	"Aminoglycosides"	"NA"			"tobra high,tobramycin high,tohl"	"NA"					"NA"
 "TFX"	5517	"Tosufloxacin"	"Fluoroquinolones,Quinolones"	"J01MA22,QJ01MA22,QS01AE09,S01AE09"			"tosufl"	"NA"	0.45	"g"			"100061-1,76146-0"
 "TMP"	5578	"Trimethoprim"	"Trimethoprims"	"J01EA01,QJ01EA01,QJ51EA01"	"Sulfonamides and trimethoprim"	"Trimethoprim and derivatives"	"t,tmp,tr,tri,trim,w"	"abaprim,anitrim,antrima,antrimox,bacdan,bacidal,bacide,bacin,bacterial,bacticel,bactifor,bactoprim,bactramin,bencole,bethaprim,biosulten,briscotrim,chemotrin,colizole,conprim,cotrimel,deprim,dosulfin,duocide,esbesul,espectrin,euctrim,exbesul,fermagex,fortrim,futin,ikaprim,infectotrimet,instalac,kombinax,lagatrim,lastrim,lescot,monoprim,monotrim,monotrimin,novotrimel,omstat,pancidim,proloprim,protrin,purbal,resprim,roubac,roubal,salvatrim,setprin,sinotrim,stopan,streptoplus,sugaprim,sulfamar,sulfoxaprim,sulthrim,sultrex,syraprim,tiempe,trimethioprim,trimethoprime,trimethoprimum,trimethopriom,trimetoprim,trimetoprima,trimexol,trimezol,trimogal,trimono,trimopan,triprim,trisul,trisulcom,trisulfam,trisural,uretrim,urobactrim,utetrin,velaten,wellcoprim,wellcoprin,xeroprim,zamboprim"	0.4	"g"	0.4	"g"	"101495-0,11005-6,17747-7,18997-7,18998-5,20387-7,23614-1,23631-5,25273-4,32342-8,4079-0,4080-8,4081-6,511-6,512-4,513-2,514-0,515-7,516-5,517-3,518-1,55584-7,7056-5,7057-3,80552-3,80973-1"
diff --git a/data-raw/datasets/antimicrobials.xlsx b/data-raw/datasets/antimicrobials.xlsx
index 64df9f15d..af3719073 100644
Binary files a/data-raw/datasets/antimicrobials.xlsx and b/data-raw/datasets/antimicrobials.xlsx differ
diff --git a/data-raw/datasets/clinical_breakpoints.dta b/data-raw/datasets/clinical_breakpoints.dta
index 018ad9dac..72de6b4f2 100644
Binary files a/data-raw/datasets/clinical_breakpoints.dta and b/data-raw/datasets/clinical_breakpoints.dta differ
diff --git a/data-raw/datasets/clinical_breakpoints.feather b/data-raw/datasets/clinical_breakpoints.feather
index 575f93704..fbb2db4ca 100644
Binary files a/data-raw/datasets/clinical_breakpoints.feather and b/data-raw/datasets/clinical_breakpoints.feather differ
diff --git a/data-raw/datasets/clinical_breakpoints.parquet b/data-raw/datasets/clinical_breakpoints.parquet
index 1a5da575b..366f29528 100644
Binary files a/data-raw/datasets/clinical_breakpoints.parquet and b/data-raw/datasets/clinical_breakpoints.parquet differ
diff --git a/data-raw/datasets/clinical_breakpoints.rds b/data-raw/datasets/clinical_breakpoints.rds
index 4d3ffcfd6..ddca90a83 100644
Binary files a/data-raw/datasets/clinical_breakpoints.rds and b/data-raw/datasets/clinical_breakpoints.rds differ
diff --git a/data-raw/datasets/clinical_breakpoints.sav b/data-raw/datasets/clinical_breakpoints.sav
index d5332d5f6..7c910aee2 100644
Binary files a/data-raw/datasets/clinical_breakpoints.sav and b/data-raw/datasets/clinical_breakpoints.sav differ
diff --git a/data-raw/datasets/clinical_breakpoints.txt b/data-raw/datasets/clinical_breakpoints.txt
index be8e4c745..e4b62d8e3 100644
--- a/data-raw/datasets/clinical_breakpoints.txt
+++ b/data-raw/datasets/clinical_breakpoints.txt
@@ -1,208 +1,40 @@
 "guideline"	"type"	"host"	"method"	"site"	"mo"	"rank_index"	"ab"	"ref_tbl"	"disk_dose"	"breakpoint_S"	"breakpoint_R"	"uti"	"is_SDD"	"note"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2.1	"FDC"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2.1	"FDC"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"MEM"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	26	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"MEM"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"		1	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	26	26	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FPE"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FPE"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		4	4	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		2	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		2	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The \"IE\" in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"		4	4	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CAZ"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CCV"	"ECOFF"		16	16	FALSE	FALSE	
@@ -250,27 +82,16 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"ECOFF"	"2 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"NIT"	"ECOFF"	"100 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"NOR"	"ECOFF"	"10 mcg"	11	11	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"ECOFF"	"1 unit"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
@@ -280,25 +101,14 @@
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -318,7 +128,7 @@
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -328,28 +138,24 @@
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"AMX"	"ECOFF"	"10 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"AMX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_BCLLS_ANTH"	2	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.25	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"IPM"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -360,19 +166,16 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	23	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"ECOFF"	"1 unit"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"RIF"	"ECOFF"	"5 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (12), R (12)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"TCY"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	26	26	FALSE	FALSE	
@@ -380,14 +183,10 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"VAN"	"ECOFF"	"5 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	
@@ -422,30 +221,21 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	27	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"CRO"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"CRO"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (30), R (30)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"DOX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"GEN"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.5), R (0.5)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"RIF"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"RIF"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"STR1"	"ECOFF"	"10 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"STR1"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"SXT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -460,18 +250,17 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"ECOFF"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	
@@ -483,27 +272,19 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AZM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	18	18	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
@@ -521,18 +302,12 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
@@ -553,57 +328,48 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"CLI"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FDX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"FDX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FUS"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"IPM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MEM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"RIF"	"ECOFF"		0.004	0.004	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TCY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TZP"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	15	15	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
@@ -614,33 +380,29 @@
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"CLI"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
@@ -651,9 +413,9 @@
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	
@@ -661,21 +423,17 @@
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	26	26	FALSE	FALSE	"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CTX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"CTX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	39	39	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	34	34	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
@@ -683,23 +441,19 @@
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	33	33	FALSE	FALSE	"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"CRO"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"CRO"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"CTX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2.1	"CTX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTBCTR_AVDM"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTBCTR_AVDM"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	39	39	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -760,7 +514,6 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"MEM"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"NIT"	"ECOFF"	"100 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TMP"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TOB"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
@@ -771,31 +524,17 @@
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	19	19	FALSE	FALSE	"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_INNC"	2.1	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_INNC"	2.1	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRDM_PRFR"	2	"CLI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	19	19	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
@@ -818,15 +557,13 @@
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2.1	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	24	24	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	31	31	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_SPTC"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_SPTC"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -845,24 +582,15 @@
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	20	FALSE	FALSE	"[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2.1	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2.1	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2.1	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2.1	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_CTRDM_TRTM"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_CTRDM_TRTM"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
@@ -912,223 +640,35 @@
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	10	10	FALSE	FALSE	"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[1] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	TRUE	FALSE	"[1] Susceptibility can be inferred from ampicillin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"20 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FPE"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FPE"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	20	20	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_CSSL"	2.1	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
@@ -1176,12 +716,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FACM"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FACM"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FACM"	2	"VIR"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"AMP"	"ECOFF"	"2 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"AMP"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"AVI"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"CHL"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"CIP"	"ECOFF"	"5 mcg"	14	14	FALSE	FALSE	
@@ -1202,12 +738,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"GEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"GEN"	"ECOFF"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"GEN"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC_FCLS"	2.1	"GEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC_FCLS"	2	"GEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"IPM"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"LNZ"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"LNZ"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"LVX"	"ECOFF"	"5 mcg"	15	15	FALSE	FALSE	
@@ -1229,7 +764,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"PEN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"QDA"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"RIF"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"SAL"	"ECOFF"		4	4	FALSE	FALSE	
@@ -1247,7 +782,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"TZP"	"ECOFF"	"30/6 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	50	18	FALSE	FALSE	"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"VAN"	"ECOFF"	"5 mcg"	11	11	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
@@ -1298,15 +833,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"CZA"	"ECOFF"	"10/4 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"	"10 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
@@ -1327,10 +861,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOS"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FPE"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -1339,7 +871,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"GAT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"GEN"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2.1	"GEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"GEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"IMR"	"ECOFF"	"10/25 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"IPM"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
@@ -1385,7 +916,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"	"15 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
@@ -1403,12 +934,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	21	21	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	23	23	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	34	34	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	31	31	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -1424,19 +954,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FNGLD"	3	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FNGLD"	3	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2.1	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2.1	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	30	30	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"PEN"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -1444,21 +972,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCLT"	2	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCLT"	2.1	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2.1	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	30	30	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -1482,65 +1008,39 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"	"2 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CAZ"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"	"5 mcg"	32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	32	32	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CTB"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -1555,86 +1055,41 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[3] See table of dosages for dosing for different indications."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GAT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LMU"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
@@ -1642,136 +1097,71 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"NAL"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OMC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"	"1 unit"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TEM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"	"2/1 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"	"2 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CAZ"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"	"5 mcg"	32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -1781,142 +1171,86 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] See table of dosages for dosing for different indications."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GAT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LMU"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"NAL"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OMC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"	"1 unit"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_PRNF"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TEM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2026"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Mannheimia haemolytica"		2	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from benzylpenicillin susceptibility."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -1925,14 +1259,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"TCY"	"K.kingae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_KLBSL"	3	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_KLBSL"	3	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
@@ -1944,9 +1278,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CXM"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
@@ -2097,22 +1431,18 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"MFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"PEN"	"ECOFF"	"1 unit"	11	11	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MMPSS_BOVS"	2	"ENR"	"ECOFF"		1	1	FALSE	FALSE	
@@ -2178,59 +1508,25 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CEC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see table of topical agents."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see table of topical agents."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CPD"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
@@ -2238,159 +1534,59 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		4	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"ERY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FPE"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FPE"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"GAT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"ECOFF"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"NAL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TMP"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"AMK"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"CLR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"IPM"	"ECOFF"		64	64	FALSE	FALSE	
@@ -2411,234 +1607,88 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_LLRE"	2	"SXT"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_TBRC"	2	"AMK"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] For bedaquiline, breakpoints were determined using the EUCAST reference method."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. | [3] The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. | [4] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. | [3] The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"AZM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FPE"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"GEN"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"MFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		64	64	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"ECOFF"		0.008	0.008	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CXM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FPE"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PHN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"RIF"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY-S"	"N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3.1	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	21	21	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	32	32	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	37	37	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	19	19	FALSE	FALSE	"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	18	18	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	29	29	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3.1	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3.1	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTNP"	3	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTNP"	3	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	22	22	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -2655,10 +1705,20 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PPTST_ANRB"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PPTST_ANRB"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PROTS"	3.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 ug disk zone diameter <14 mm)."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PROTS"	3.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [7] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 ug disk zone diameter <14 mm)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"AMP"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
@@ -2680,7 +1740,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CXM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CZO"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
@@ -2720,7 +1780,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TCY"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TEM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TGC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"TMP"	"ECOFF"	"5 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TMP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -2757,34 +1817,26 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TGC"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2.1	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	29	29	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	40	40	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"MTR"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	31	31	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"PEN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2.1	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2.1	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVMN_MICR"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVMN_MICR"	2	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"AMC"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3.1	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMX"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	31	31	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
@@ -2799,193 +1851,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	20	20	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"SAM"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"TZP"	"Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FPE"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FPE"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		2	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"		16	16	FALSE	FALSE	
@@ -2994,9 +1886,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CSE"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"ECOFF"	"10/4 mcg"	16	16	FALSE	FALSE	
@@ -3026,8 +1918,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"	"10 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"ECOFF"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
@@ -3036,8 +1928,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"KAN"	"ECOFF"		256	256	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN_AERG"	2	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	20	14	FALSE	FALSE	
@@ -3051,7 +1943,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"	"10 mcg"	9	9	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SIT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SXT"	"ECOFF"		32	32	FALSE	FALSE	
@@ -3059,8 +1951,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
@@ -3068,28 +1960,21 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -3125,7 +2010,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_SERRT"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Serratia spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_SERRT"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Serratia spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_SERRT"	3	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	50	15	FALSE	FALSE	"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_SERRT"	3	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_SERRT"	3	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT_LQFC"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT_LQFC"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT_LQFC"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -3165,7 +2050,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_SERRT_MRCS"	2	"TZP"	"ECOFF"	"30/6 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT_MRCS"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"AMK"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_SLMNL_ENTR_ENTR"	1	"AMP"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"AMP"	"ECOFF"		4	4	FALSE	FALSE	
@@ -3210,224 +2095,61 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"FOX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"ATM"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"ATM"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"AZA"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 ug disk zone diameter <21 mm)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"AZA"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 ug disk zone diameter <21 mm)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"CAZ"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"CAZ"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"CIP"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"CIP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"CIP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"ERV"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STNTR_MLTP"	2	"FDC"	"ECOFF"	"30 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"FDC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FEP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FEP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"FPZ"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"LVX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"LVX"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"LVX"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"MNO"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"MNO"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"MNO"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"PIP"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TCY"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TGC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"TGC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"TGC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TZP"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	22	22	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FPE"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FPE"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	24	24	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -3438,13 +2160,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CEP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		16	16	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"	"5 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"ECOFF"		1	1	FALSE	FALSE	
@@ -3460,10 +2180,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CZO"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Community-acquired pneumonia"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Skin"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -3480,20 +2198,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOS"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"KAN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LIN"	"ECOFF"		2	2	FALSE	FALSE	
@@ -3505,8 +2220,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	22	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -3515,23 +2230,24 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MNO"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"	"200 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NET"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NVA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -3539,16 +2255,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters >=26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a \"cliff\"), then report resistant. If not sharp (reduction of growth towards zone edge,  like a \"beach\"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PHN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RTP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SIT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPT"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"STR1"	"ECOFF"		16	16	FALSE	FALSE	
@@ -3557,68 +2271,48 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"	"15 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIO"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZD"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	24	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	28	28	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D. | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -3626,16 +2320,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
@@ -3645,9 +2339,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERV"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -3668,19 +2360,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"TOB"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"NVA"	"ECOFF"		2	2	FALSE	FALSE	
@@ -3699,7 +2391,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"FOX"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"GEN"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -3709,9 +2401,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"OXA"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"RIF"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"AMP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"ENR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -3729,38 +2421,34 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TIL"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TUL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TYL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"BPR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"CLI"	"ECOFF"	"2 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"DFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"ECOFF"	"15 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"ECOFF"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"LMU"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"AMC"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"CLO"	"ECOFF"		1	1	FALSE	FALSE	
@@ -3770,15 +2458,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"ERY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"FLM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"FLR"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"GAM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"GEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"LEX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"LIN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"OXY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
@@ -3786,33 +2471,30 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TIP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TUL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TYL"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"BPR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CFR"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CRO"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"GEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"GEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"MEM"	"ECOFF"		1	1	FALSE	FALSE	
@@ -3820,204 +2502,69 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"		64	64	TRUE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"NOR"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"TEC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"TMP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FPE"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FPE"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		32	32	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		32	32	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_AGLC"	2	"AMP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -4068,20 +2615,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"CIP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"IPM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
@@ -4095,14 +2637,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"LIN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"SXT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"TLV"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -4145,70 +2682,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"OXY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"TCY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		64	64	TRUE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	18	18	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"AMX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"BPR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"DAP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"GEN"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LMU"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TLV"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TZP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
@@ -4230,132 +2730,63 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous, Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMX"	"ECOFF"		0.06	0.06	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CFM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CIP"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DAP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FPE"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FPE"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GAT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
@@ -4365,113 +2796,56 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"	"5 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.001	2	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MEM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"NOR"	"ECOFF"	"10 mcg"	9	9	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OMC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"OXA"	"ECOFF"	"1 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"1 mcg"	20	20	FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 ug zone diameters <20 mm. If benzylpenicillin zone >=14 mm, report benzylpenicillin \"susceptible, increased exposure\" (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	1	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PHN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"QDA"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SIT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TGC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLV"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TMP"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZD"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -4534,200 +2908,40 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"TYL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FPE"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FPE"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported \"devoid of linezolid resistance mechanisms\", but not as susceptible to linezolid."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	12	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	21	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_STTZR_STTZ"	2	"TZP"	"ECOFF"		4	4	FALSE	FALSE	
@@ -4735,12 +2949,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"AMC"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"AMP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2.1	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"AMX"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2.1	"CLI"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2.1	"ETP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"IPM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2	"MEM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	22	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -4753,8 +2962,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"SAM"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2	"TZP"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_THMSC_RAMS"	2.1	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_THMSC_RAMS"	2.1	"VAN"	"Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"AZM"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	16	16	FALSE	FALSE	"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"AZM"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CAZ"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	22	FALSE	FALSE	
@@ -4763,23 +2970,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CIP"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF-S"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	21	21	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"B_VIBRI_CHLR"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -4801,69 +3001,43 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2026"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"20/10 mcg"	50	19	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		32	32	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin (iv or oral) can be reported \"susceptible, increased exposure\" (I) to \"amoxicillin oral (infections originating from the urinary tract)\". Isolates resistant to ampicillin (iv or oral) can be reported resistant to \"amoxicillin oral (infections originating from the urinary tract)\". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1e-04	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.001	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30/20 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	1	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		16	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.125	0.125	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	1	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	24	FALSE	FALSE	
@@ -4871,79 +3045,39 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	1	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30/10 mcg"	22	22	FALSE	FALSE	"[7] See table of dosages for dosing for different indications."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		1	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	FALSE	FALSE	"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	19	19	FALSE	FALSE	"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FPE"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30/20 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FPE"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		4	4	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	8	FALSE	FALSE	
@@ -4952,201 +3086,114 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	22	22	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	24	24	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10/10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	TRUE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		0.5	0.5	FALSE	FALSE	"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2026"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2026"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		2	2	TRUE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2026"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 16.1)"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2026"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"AMB"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"AMB"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"ANI"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"CAS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"FLU"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"MIF"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"POS"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"POS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"VOR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2.1	"VOR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_MGTS"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"AMB"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2.1	"ANI"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2.1	"CAS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2.1	"FLU"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_MGTS"	2	"ISV"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"ISV"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_MGTS"	2	"ITR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"ITR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2.1	"MIF"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_MGTS"	2	"POS"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"POS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_MGTS"	2	"VOR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"VOR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NDLN"	2	"AMB"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"AMB"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"ANI"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"CAS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"FLU"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NDLN"	2	"ISV"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2	"ISV"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NDLN"	2	"ITR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2	"ITR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"MIF"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NDLN"	2	"POS"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2.1	"POS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NDLN"	2	"VOR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NDLN"	2	"VOR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NIGR"	2	"AMB"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2	"AMB"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"ANI"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"CAS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"FLU"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NIGR"	2	"ISV"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"ISV"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NIGR"	2	"ITR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"ITR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus. | [4] The MIC values for isolates of A. niger and A. versicolor are in general higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"MIF"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NIGR"	2	"POS"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"POS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_NIGR"	2	"VOR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_NIGR"	2.1	"VOR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_TERRS"	2	"AMB"	"Antifungal ECOFFs"		8	8	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"AMB"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"ANI"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"CAS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"FLU"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_TERRS"	2	"ISV"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2	"ISV"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_TERRS"	2	"ITR"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2	"ITR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when  sufficient exposure (>2 mg/L) is ensured via TDM."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"MIF"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_TERRS"	2	"POS"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2	"POS"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_TERRS"	2	"VOR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_ASPRG_TERRS"	2.1	"VOR"	"6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"ANI"	"Antifungal ECOFFs"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"FLU"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		2	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"ITR"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"MIF"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"POS"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"RZF"	"Antifungal ECOFFs"		0.008	0.008	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.008	0.008	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_ALBC"	2	"VOR"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.25	FALSE	FALSE	"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_ALBC"	2	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.25	FALSE	FALSE	"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"AMB"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"ANI"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"FLU"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		2	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"ITR"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"MIF"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"POS"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"RZF"	"Antifungal ECOFFs"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.016	0.016	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_DBLN"	2	"VOR"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.25	FALSE	FALSE	"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_DBLN"	2	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.25	FALSE	FALSE	"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"ANI"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		4	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"FLU"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		2	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"ITR"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"MIF"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"POS"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"RZF"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_PRPS"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		4	4	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_PRPS"	2	"VOR"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
@@ -5154,107 +3201,67 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"ANI"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"FLU"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		2	4	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"ITR"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"MIF"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"POS"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"RZF"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.032	0.032	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.03	0.03	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CANDD_TRPC"	2	"VOR"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CANDD_TRPC"	2	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.125	0.25	FALSE	FALSE	"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CLVSP_LSTN"	2	"AMB"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CLVSP_LSTN"	2	"ITR"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CNDDZ_AURS"	2	"AMB"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1e-04	2	FALSE	FALSE	"[1] The entire C. auris wild-type population is in the I category. The Susceptible category (<=0.001 mg/L) is simply to avoid missclassification of any WT strains as \"S\" strains."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.001	2	FALSE	FALSE	"[1] The entire C. auris wild-type population is in the I category. The Susceptible category (<=0.001 mg/L) is simply to avoid missclassification of any WT strains as \"S\" strains."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CNDDZ_AURS"	2	"ANI"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CNDDZ_AURS"	2	"FCT"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The fluconazole susceptibility of the earliest C. auris strains (likely representing the wild-type, e.g.CBS10913) was low (4 mg/L, determined in-house by EUCAST), and C. auris isolates with low azole MICs are still reported, particularly from South America. However, most C. auris isolates exhibit fluconazole MIC values >16 mg/L and harbour acquired resistance mechanisms. Due to the paucity of true wild-type, non-outbreak isolates, a fluconazole ECOFF cannot be established. Clinical data on isolates with lower MICs (<= 16 mg/L) are very limited. Therefore, EUCAST has insufficient data to support fluconazole therapy for C. auris, even when the MIC is low."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CNDDZ_AURS"	2	"MIF"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CNDDZ_AURS"	2	"RZF"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CNDDZ_AURS"	2.1	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CRYPT_GATT"	2	"AMB"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CRYPT_GATT"	2	"POS"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CRYPT_NFRM"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CRYPT_NFRM"	2	"POS"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_CRYPT_NFRM"	2	"VOR"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_CRYPT_NFRM"	2.1	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_FUSRM_JKRI"	2	"AMB"	"Antifungal ECOFFs"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_KLYVR_RXNS"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_KLYVR_RXNS"	2	"FLU"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_MYRZY_GLLR"	2	"AMB"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_MYRZY_GLLR"	2	"FLU"	"Antifungal ECOFFs"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_MYRZY_GLLR"	2	"ITR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_MYRZY_GLLR"	2	"POS"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_MYRZY_GLLR"	2.1	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NCSMS_SOLN"	2	"AMB"	"Antifungal ECOFFs"		8	8	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"ANI"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"FLU"	"Antifungal ECOFFs"		16	16	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1e-04	16	FALSE	FALSE	"[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (<=0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as \"S\" strains."
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.001	16	FALSE	FALSE	"[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (<=0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as \"S\" strains."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"ITR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2.1	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"MIF"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"POS"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2.1	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"RZF"	"Antifungal ECOFFs"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.016	0.016	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_NKSMY_BRTS"	2	"VOR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_NKSMY_BRTS"	2.1	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"AMB"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2	"AMB"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		1	1	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"ANI"	"Antifungal ECOFFs"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"CAS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have  been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2	"ANI"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"FLU"	"Antifungal ECOFFs"		128	128	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"FLU"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"ISV"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"ITR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"ITR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"MIF"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"MIF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [6] MICs for C. krusei are approximately three two-fold dilution steps higher than those for C. albicans  and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were only a small number of cases involving these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"POS"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"POS"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"RZF"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.032	0.032	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
+"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2	"RZF"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"		0.03	0.03	FALSE	FALSE	"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_PICHI_KDRV"	2	"VOR"	"Antifungal ECOFFs"		1	1	FALSE	FALSE	
-"EUCAST 2026"	"human"	"human"	"MIC"		"F_PICHI_KDRV"	2.1	"VOR"	"5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_SCCHR_CRVS"	2	"AMB"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_SCCHR_CRVS"	2	"ITR"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_TRCHP_INDT"	2	"AMO"	"Antifungal ECOFFs"		0.5	0.5	FALSE	FALSE	
@@ -5265,210 +3272,42 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_TRCHP_RBRM"	2	"ITR"	"Antifungal ECOFFs"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_TRCHP_RBRM"	2	"TRB"	"Antifungal ECOFFs"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2026"	"ECOFF"	"ECOFF"	"MIC"		"F_TRCHP_RBRM"	2	"VOR"	"Antifungal ECOFFs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2.1	"FDC"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2.1	"FDC"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"MEM"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	26	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"MEM"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"		1	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	26	26	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FPE"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FPE"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		2	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The \"IE\" in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CAZ"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CCV"	"ECOFF"		16	16	FALSE	FALSE	
@@ -5516,27 +3355,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"ECOFF"	"2 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"NIT"	"ECOFF"	"100 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"NOR"	"ECOFF"	"10 mcg"	11	11	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"ECOFF"	"1 unit"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
@@ -5546,25 +3374,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -5584,7 +3401,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	19	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -5594,28 +3411,24 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"AMX"	"ECOFF"	"10 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"AMX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_BCLLS_ANTH"	2	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.25	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"IPM"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -5626,19 +3439,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	23	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"ECOFF"	"1 unit"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"RIF"	"ECOFF"	"5 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (12), R (12)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"TCY"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	26	26	FALSE	FALSE	
@@ -5646,14 +3456,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"VAN"	"ECOFF"	"5 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BCLLS_ANTH"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	
@@ -5688,30 +3494,21 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	27	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"CRO"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"CRO"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (30), R (30)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"DOX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"GEN"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.5), R (0.5)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"RIF"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"RIF"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"STR1"	"ECOFF"	"10 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"STR1"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRCLL_MLTN"	2	"SXT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -5726,18 +3523,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"ECOFF"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	
@@ -5749,27 +3545,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_BRKHL_PSDM"	2	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AZM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
@@ -5787,18 +3575,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
@@ -5819,57 +3601,48 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"CLI"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FDX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FUS"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"IPM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MEM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"RIF"	"ECOFF"		0.004	0.004	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TCY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TZP"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	15	15	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
@@ -5880,33 +3653,29 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"CLI"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
@@ -5917,9 +3686,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	
@@ -5927,31 +3696,26 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	26	26	FALSE	FALSE	"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	39	39	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	34	34	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
@@ -5998,7 +3762,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"MEM"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"NIT"	"ECOFF"	"100 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TMP"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TOB"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
@@ -6009,7 +3772,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRDM_PRFR"	2	"CLI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	19	19	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
@@ -6078,221 +3840,35 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	10	10	FALSE	FALSE	"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[1] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	"[1] Susceptibility can be inferred from ampicillin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"20 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FPE"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FPE"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	20	20	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_CSSL"	2.1	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
@@ -6340,12 +3916,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FACM"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FACM"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FACM"	2	"VIR"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"AMP"	"ECOFF"	"2 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"AMP"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"AVI"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"CHL"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"CIP"	"ECOFF"	"5 mcg"	14	14	FALSE	FALSE	
@@ -6369,7 +3941,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"IPM"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"LNZ"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"LNZ"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"LVX"	"ECOFF"	"5 mcg"	15	15	FALSE	FALSE	
@@ -6391,7 +3963,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"PEN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"QDA"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"RIF"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"SAL"	"ECOFF"		4	4	FALSE	FALSE	
@@ -6409,7 +3981,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"TZP"	"ECOFF"	"30/6 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	50	18	FALSE	FALSE	"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_ENTRC_FCLS"	2	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRC_FCLS"	2	"VAN"	"ECOFF"	"5 mcg"	11	11	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC_FCLS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ENTRC_FCLS"	2	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
@@ -6460,15 +4032,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"CZA"	"ECOFF"	"10/4 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"	"10 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
@@ -6489,10 +4060,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOS"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FPE"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -6545,7 +4114,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"	"15 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
@@ -6561,16 +4130,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	30	30	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -6594,65 +4162,39 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"	"2 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis, Non-endocarditis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis, Non-endocarditis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CAZ"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"	"5 mcg"	32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	32	32	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CTB"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -6667,86 +4209,41 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[3] See table of dosages for dosing for different indications."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GAT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LMU"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
@@ -6754,136 +4251,71 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"NAL"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OMC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"	"1 unit"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TEM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"	"2/1 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"	"2 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis, Non-endocarditis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CAZ"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"	"5 mcg"	32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -6893,142 +4325,86 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] See table of dosages for dosing for different indications."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FPE"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GAT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LMU"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"NAL"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OMC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"	"1 unit"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_PRNF"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TEM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2025"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Mannheimia haemolytica"		2	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from benzylpenicillin susceptibility."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -7037,14 +4413,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"TCY"	"K.kingae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"CAZ"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CAZ"	"ECOFF"		1	1	FALSE	FALSE	
@@ -7054,9 +4430,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CXM"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
@@ -7205,22 +4581,18 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"MFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"PEN"	"ECOFF"	"1 unit"	11	11	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MMPSS_BOVS"	2	"ENR"	"ECOFF"		1	1	FALSE	FALSE	
@@ -7286,59 +4658,25 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CEC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see table of topical agents."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see table of topical agents."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CPD"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
@@ -7346,159 +4684,59 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		4	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"ERY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FPE"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FPE"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"GAT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"ECOFF"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"NAL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TMP"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"AMK"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"CLR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_ABSC"	2	"IPM"	"ECOFF"		64	64	FALSE	FALSE	
@@ -7519,202 +4757,77 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_LLRE"	2	"SXT"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_TBRC"	2	"AMK"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"AZM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FPE"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"GEN"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"MFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		64	64	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"ECOFF"		0.008	0.008	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CXM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FPE"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PHN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"RIF"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY-S"	"N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
@@ -7738,7 +4851,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CXM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CZO"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
@@ -7778,7 +4891,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TCY"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TEM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TGC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"TMP"	"ECOFF"	"5 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TMP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -7815,10 +4928,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TGC"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	31	31	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
@@ -7833,193 +4944,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	20	20	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FPE"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FPE"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		2	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"		16	16	FALSE	FALSE	
@@ -8028,9 +4979,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CSE"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"ECOFF"	"10/4 mcg"	16	16	FALSE	FALSE	
@@ -8060,8 +5011,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"	"10 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"ECOFF"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
@@ -8070,8 +5021,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"KAN"	"ECOFF"		256	256	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN_AERG"	2	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	20	14	FALSE	FALSE	
@@ -8085,7 +5036,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"	"10 mcg"	9	9	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SIT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SXT"	"ECOFF"		32	32	FALSE	FALSE	
@@ -8093,8 +5044,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
@@ -8102,28 +5053,21 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -8197,7 +5141,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_SERRT_MRCS"	2	"TZP"	"ECOFF"	"30/6 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT_MRCS"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"AMK"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_SLMNL_ENTR_ENTR"	1	"AMP"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"AMP"	"ECOFF"		4	4	FALSE	FALSE	
@@ -8242,222 +5186,62 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR_ENTR"	1	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"FOX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"ATM"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"ATM"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"AZA"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"AZA"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"CAZ"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"CAZ"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"CIP"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"CIP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"CIP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"ERV"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STNTR_MLTP"	2	"FDC"	"ECOFF"	"30 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"FDC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FEP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FEP"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"FPZ"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"LVX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"LVX"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"LVX"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"MNO"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"MNO"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"MNO"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"PIP"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TCY"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TGC"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"TGC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria are not available."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"TGC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"TZP"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	22	22	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FPE"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FPE"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -8468,13 +5252,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CEP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		16	16	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"	"5 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"ECOFF"		1	1	FALSE	FALSE	
@@ -8491,7 +5273,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Community-acquired pneumonia"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Skin"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -8508,20 +5289,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOS"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"KAN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LIN"	"ECOFF"		2	2	FALSE	FALSE	
@@ -8533,8 +5311,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	22	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -8543,23 +5321,24 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MNO"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"	"200 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NET"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NVA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OMC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -8567,16 +5346,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters >=26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a \"cliff\"), then report resistant. If not sharp (reduction of growth towards zone edge,  like a \"beach\"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PHN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RTP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SIT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPT"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"STR1"	"ECOFF"		16	16	FALSE	FALSE	
@@ -8585,68 +5362,48 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"	"15 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIO"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZD"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	24	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	28	28	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D. | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -8654,16 +5411,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
@@ -8673,9 +5430,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERV"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -8696,19 +5451,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"TOB"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"NVA"	"ECOFF"		2	2	FALSE	FALSE	
@@ -8727,7 +5482,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"DFX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"FOX"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"GEN"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LMU"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -8737,9 +5492,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"OXA"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"RIF"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"AMP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"AMX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"ENR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -8757,38 +5512,34 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TIL"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TUL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"TYL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"BPR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"CLI"	"ECOFF"	"2 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"DFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"ECOFF"	"15 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"ECOFF"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"LMU"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"AMC"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"CLO"	"ECOFF"		1	1	FALSE	FALSE	
@@ -8798,15 +5549,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"ERY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"FLM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"FLR"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"GAM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"GEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"LEX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"LIN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"OXY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
@@ -8814,236 +5562,99 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TIP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TUL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_PSDN"	2	"TYL"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"AMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"BPR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CFR"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CRO"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[4] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"MEM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"NIT"	"ECOFF"	"100 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"		64	64	TRUE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"NOR"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"TEC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"TMP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FPE"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FPE"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		32	32	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		32	32	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_AGLC"	2	"AMP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -9094,20 +5705,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"CIP"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"IPM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
@@ -9121,14 +5727,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"LIN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CANS"	2	"SXT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"TLV"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -9171,70 +5772,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"OXY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQUI_ZPDM"	1	"TCY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		64	64	TRUE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"AMX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"BPR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"DAP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"GEN"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LMU"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TLV"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"TZP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	23	23	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
@@ -9256,132 +5820,63 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMX"	"ECOFF"		0.06	0.06	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CFM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CIP"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CZT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DAP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FPE"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FPE"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GAT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
@@ -9391,113 +5886,56 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"	"5 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MEM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"NOR"	"ECOFF"	"10 mcg"	9	9	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OMC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"OXA"	"ECOFF"	"1 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"1 mcg"	20	20	FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 ug zone diameters <20 mm. If benzylpenicillin zone >=14 mm, report benzylpenicillin \"susceptible, increased exposure\" (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis, Non-endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	1	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis, Endocarditis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PHN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis)."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"QDA"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SIT"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TGC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLV"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TMP"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZD"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -9560,200 +5998,40 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_UBRS"	2	"TYL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous, Endocarditis"	"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FPE"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FPE"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported \"devoid of linezolid resistance mechanisms\", but not as susceptible to linezolid."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	12	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	21	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Endocarditis"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_STTZR_STTZ"	2	"TZP"	"ECOFF"		4	4	FALSE	FALSE	
@@ -9765,23 +6043,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CIP"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF-S"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	21	21	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"B_VIBRI_CHLR"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -9803,69 +6074,43 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2025"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"20/10 mcg"	50	19	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		32	32	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin (iv or oral) can be reported \"susceptible, increased exposure\" (I) to \"amoxicillin oral (infections originating from the urinary tract)\". Isolates resistant to ampicillin (iv or oral) can be reported resistant to \"amoxicillin oral (infections originating from the urinary tract)\". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1e-04	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.001	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30/20 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	1	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		16	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.125	0.125	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	1	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	24	FALSE	FALSE	
@@ -9873,77 +6118,39 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	1	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30/10 mcg"	22	22	FALSE	FALSE	"[7] See table of dosages for dosing for different indications."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		1	4	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	FALSE	FALSE	"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	19	19	FALSE	FALSE	"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FPE"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30/20 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FPE"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		4	4	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	8	FALSE	FALSE	
@@ -9952,83 +6159,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	22	22	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	24	24	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10/10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	TRUE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	4	FALSE	FALSE	"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		4	4	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2025"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2025"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		2	2	TRUE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2025"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2025"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 15.0)"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2025"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2025"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"AMB"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
 "EUCAST 2025"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2025"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Aspergillus"		1	2	FALSE	FALSE	
@@ -10194,198 +6351,36 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=17 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		2	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"COL"	"ECOFF"		2	2	FALSE	FALSE	
@@ -10404,25 +6399,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"ECOFF"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
@@ -10433,25 +6417,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"ECOFF"	"2 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -10471,7 +6444,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	19	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -10481,23 +6454,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_BCLLS_ANTH"	2	"AMX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.25	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CIP"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"CLI"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"DOX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"IPM"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -10506,29 +6475,22 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LNZ"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	23	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"LVX"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"ECOFF"	"1 unit"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"PEN"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"RIF"	"ECOFF"	"5 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (12), R (12)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"RIF"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2	"TCY"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2	"TCY"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BCLLS_ANTH"	2	"VAN"	"ECOFF"	"5 mcg"	10	10	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"B.anthracis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	
@@ -10541,38 +6503,28 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BCTRD"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	27	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (30), R (30)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"CRO"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"CIP"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"DOX"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"GEN"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"GEN"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.5), R (0.5)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"ECOFF"	"5 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"LVX"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"RIF"	"ECOFF"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"RIF"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRCLL_MLTN"	2	"STR1"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2.1	"STR1"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"SXT"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRCLL_MLTN"	2	"TCY"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	42	42	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BRCLL_MLTN"	2	"TCY"	"B.melitensis (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"ECOFF"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
@@ -10581,20 +6533,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_BRKHL_PSDM"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"ECOFF"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"ECOFF"	"15 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
@@ -10602,59 +6546,44 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_COLI"	2	"TCY"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"ECOFF"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CMPYL_JEJN"	2	"TCY"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	15	15	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"MEM"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
@@ -10662,29 +6591,25 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported \"susceptible, increased exposure\" (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"MEM"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
@@ -10692,9 +6617,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	
@@ -10702,31 +6627,26 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	26	26	FALSE	FALSE	"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	39	39	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	34	34	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
@@ -10749,7 +6669,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"CTX"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"GEN"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"MEM"	"ECOFF"	"10 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TMP"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_CTRBC_KOSR"	2	"TOB"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
@@ -10758,7 +6677,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	19	19	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
@@ -10793,213 +6711,34 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRBC_CLOC"	2	"TMP"	"ECOFF"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRBC_CLOC"	2	"TOB"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	10	8	FALSE	FALSE	"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		512	512	FALSE	FALSE	"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing.
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[1] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ENTRC_CSSL"	2.1	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Enterococcus casseliflavus ('enterococci other than E. casseliflavus and E. gallinarum')"
@@ -11072,15 +6811,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"CZA"	"ECOFF"	"10/4 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"	"10 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -11099,10 +6837,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOS"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"200 mcg"	24	24	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone (see pictures below)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous, Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] There is currently a lack of clinical evidence to support clinical breakpoints."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"FPT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -11155,7 +6891,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"	"15 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
@@ -11171,20 +6907,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	30	30	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	32	32	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -11199,54 +6934,30 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"	"2 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis."
@@ -11262,185 +6973,78 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[2] See table of dosages for dosing for different indications."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"NAL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"	"1 unit"	10	10	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"	"2/1 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"	"2 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"	"30 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"CRO"	"ECOFF"	"30 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -11449,116 +7053,60 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] See table of dosages for dosing for different indications."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"	"15 mcg"	10	10	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"ETP"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"	"5 mcg"	29	29	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"NAL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"	"1 unit"	10	10	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"RIF"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_PRNF"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"	"30/6 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2024"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Mannheimia haemolytica"		2	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -11567,20 +7115,20 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"TCY"	"K.kingae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"AMP"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"CAZ"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"	"5 mcg"	19	19	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp.(except K. aerogenes)')"
@@ -11664,19 +7212,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"ERY"	"ECOFF"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"PEN"	"ECOFF"	"1 unit"	11	11	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_MNNHM_HMLY"	2	"FLR"	"Histophilus somni"		2	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRGNL_MRGN"	2	"AMP"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRGNL_MRGN"	2	"CAZ"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
@@ -11686,370 +7230,119 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRGNL_MRGN"	2	"TZP"	"ECOFF"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see table of topical agents."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see table of topical agents."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		4	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"ERY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"ECOFF"	"10 mcg"	37	37	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"NAL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"	"30 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		64	64	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY-S"	"N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
+"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PROTS"	3.1	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Proteus spp. ('Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.')"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"AMC"	"ECOFF"	"20/10 mcg"	22	22	FALSE	FALSE	
@@ -12062,7 +7355,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"CTX"	"ECOFF"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"GEN"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"IPM"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
@@ -12074,7 +7367,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"NAL"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"TMP"	"ECOFF"	"5 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"TOB"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_MRBL"	2	"TZP"	"ECOFF"	"30/6 mcg"	23	23	FALSE	FALSE	
@@ -12083,10 +7376,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PROTS_VLGR"	2	"TZP"	"ECOFF"	"30/6 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PRVDN_RTTG"	2	"CTX"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	31	31	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
@@ -12101,189 +7392,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	20	20	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		2	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"	"30 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"	"30 mcg"	16	16	FALSE	FALSE	
@@ -12293,10 +7428,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"COL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"ECOFF"	"10/4 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10/4 mcg"	17	17	FALSE	FALSE	
@@ -12317,8 +7452,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"FPZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"	"10 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
@@ -12326,8 +7461,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN_AERG"	2	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	20	14	FALSE	FALSE	
@@ -12340,7 +7475,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"	"10 mcg"	9	9	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SIT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SXT"	"ECOFF"		32	32	FALSE	FALSE	
@@ -12349,34 +7484,27 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"	"30/6 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSTRL_MLTC"	2	"AMC"	"ECOFF"	"2/1 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_PSTRL_MLTC"	2	"FLR"	"Pasteurella multocida"		2	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_PSTRL_MLTC"	2	"NAL"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
@@ -12397,7 +7525,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_SERRT_MRCS"	2	"TZP"	"ECOFF"	"30/6 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_SHGLL_FLXN"	2	"PEF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR"	2	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_SLMNL_ENTR_ENTR"	1	"AMP"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_SLMNL_ENTR_ENTR"	1	"AZM"	"ECOFF"	"15 mcg"	12	12	FALSE	FALSE	
@@ -12414,599 +7542,294 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_HMRM"	1	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=20 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	22	22	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		16	16	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"	"5 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	17	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	20	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Community-acquired pneumonia"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Skin"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"20 mcg"	20	20	FALSE	FALSE	"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"ERY"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"	"10 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"LNZ"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	22	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	25	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MNO"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"	"200 mcg"	29	29	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
 ND = No ECOFF available."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
+ND = No ECOFF available."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
+ND = No ECOFF available."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S <=1, R >1 mg/L (disk diffusion with mupirocin 200 ug disk S >=30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S <=256, R >256 mg/L (disk diffusion S >=18 mm, R <18 mm) can be used.
 ND = No ECOFF available."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NET"	"ECOFF"	"10 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"ECOFF"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters >=26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a \"cliff\"), then report resistant. If not sharp (reduction of growth towards zone edge,  like a \"beach\"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"	"15 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (50), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (0.001), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"CLI"	"ECOFF"	"2 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"ERY"	"ECOFF"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"FOX"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"LNZ"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	24	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"ECOFF"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	28	28	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note D."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"NET"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"NOR"	"ECOFF"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"RIF"	"ECOFF"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"TCY"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_CONS"	2.5	"TOB"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"ECOFF"	"2 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"ERY"	"ECOFF"	"15 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"ECOFF"	"30 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"LNZ"	"ECOFF"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"NOR"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"RIF"	"ECOFF"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"TOB"	"ECOFF"	"10 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_HMNS"	2	"FOX"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_INTR"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_INTR"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"CLI"	"ECOFF"	"2 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"ECOFF"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"ECOFF"	"30 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"GEN"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"ECOFF"	"10 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"TOB"	"ECOFF"	"10 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CFR"	"ECOFF"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"	"5 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"NIT"	"ECOFF"	"100 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"		64	64	TRUE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"NOR"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_SPRP"	2	"TMP"	"ECOFF"	"5 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		32	32	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		32	32	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_AGLC"	2	"CLI"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
@@ -13014,23 +7837,13 @@ ND = No ECOFF available."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_AGLC"	2	"NIT"	"ECOFF"	"100 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_AGLC"	2	"PEN"	"ECOFF"	"1 unit"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_AGLC"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
@@ -13038,446 +7851,131 @@ ND = No ECOFF available."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_DYSG"	2	"ERY"	"ECOFF"	"15 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_DYSG"	2	"PEN"	"ECOFF"	"1 unit"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_DYSG"	2	"TCY"	"ECOFF"	"30 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		64	64	TRUE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPC"	2.5	"CHL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPC"	2.5	"ERY"	"ECOFF"	"15 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPC"	2.5	"MNO"	"ECOFF"	"30 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPC"	2.5	"TCY"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPC"	2.5	"TLT"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPG"	2.5	"CHL"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPG"	2.5	"ERY"	"ECOFF"	"15 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPG"	2.5	"MNO"	"ECOFF"	"30 mcg"	23	23	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPG"	2.5	"TCY"	"ECOFF"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_GRPG"	2.5	"TLT"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis)."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous, Meningitis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	0.5	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"	"15 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"NOR"	"ECOFF"	"10 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"OXA"	"ECOFF"	"1 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"1 mcg"	20	20	FALSE	FALSE	"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"PEN"	"ECOFF"	"1 unit"	26	26	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis)."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"	"1.25/23.75 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PYGN"	2	"CLI"	"ECOFF"	"2 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PYGN"	2	"ERY"	"ECOFF"	"15 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PYGN"	2	"PEN"	"ECOFF"	"1 unit"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STRPT_PYGN"	2	"TCY"	"ECOFF"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	21	12	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"AZM"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	16	16	FALSE	FALSE	"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
@@ -13488,23 +7986,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CIP"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF-S"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	21	21	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_VIBRI_FLVL"	2.1	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
@@ -13512,67 +8003,41 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2024"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"20/10 mcg"	50	19	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		32	32	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin (iv or oral) can be reported \"susceptible, increased exposure\" (I) to \"amoxicillin oral (infections originating from the urinary tract)\". Isolates resistant to ampicillin (iv or oral) can be reported resistant to \"amoxicillin oral (infections originating from the urinary tract)\". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1e-04	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.001	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	1	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		16	16	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		16	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.125	0.125	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	1	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	25	22	FALSE	FALSE	
@@ -13580,75 +8045,37 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	1	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30/10 mcg"	22	22	FALSE	FALSE	"[6] See table of dosages for dosing for different indications."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		1	4	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	8	FALSE	FALSE	
@@ -13657,83 +8084,33 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	22	22	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	"[3] Fluoroquinolone breakpoints are available for other agents."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	24	24	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10/10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	TRUE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	4	FALSE	FALSE	"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		4	4	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2024"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2024"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		2	2	TRUE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2024"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2024"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 14.0)"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2024"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2024"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"AMB"	"Antifungal ECOFFs"		4	4	FALSE	FALSE	
 "EUCAST 2024"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Antifungal ECOFFs"		2	2	FALSE	FALSE	
 "EUCAST 2024"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Aspergillus"		1	2	FALSE	FALSE	
@@ -13883,200 +8260,68 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=17 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10/25 mcg"	24	24	FALSE	FALSE	"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		2	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
@@ -14097,25 +8342,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -14124,25 +8359,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -14162,7 +8387,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	19	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -14172,12 +8397,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -14194,16 +8417,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCTRD"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (23), R (23)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BCTRD"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	
@@ -14225,7 +8443,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
@@ -14234,7 +8452,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IPM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
@@ -14254,57 +8472,37 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
@@ -14313,25 +8511,21 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	29	29	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	15	15	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CLI"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Wild-type C. ulcerans is less susceptible to clindamycin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"MEM"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
@@ -14339,29 +8533,25 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_DPHT"	2.1	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium diphtheriae ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"AMX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CIP"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	15	FALSE	FALSE	"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from tetracycline."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"CTX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"DOX"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility to doxycycline can be inferred from tetracycline."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"ERY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"LNZ"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"MEM"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	"[A] Isolates \"susceptible, increased exposure\" (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant."
@@ -14369,9 +8559,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2.1	"MFX"	"Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Corynebacterium ulcerans ('Corynebacterium spp.other than C. diphtheriae and C. ulcerans')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	50	12	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"PEN"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"RIF"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CRYNB_ULCR"	2	"SXT"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CRYNB_ULCR"	2	"TCY"	"C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	
@@ -14382,24 +8572,23 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	26	26	FALSE	FALSE	"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"CRO"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"CTX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	39	39	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	34	34	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"LNZ"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -14408,13 +8597,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	19	19	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
@@ -14436,214 +8623,67 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	10	8	FALSE	FALSE	"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	8	FALSE	FALSE	"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
@@ -14692,15 +8732,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"CZA"	"ECOFF"	"10/4 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -14771,7 +8810,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	TRUE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"	"15 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
@@ -14787,20 +8826,19 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	27	27	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	30	30	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"ETP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	36	36	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	35	35	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	33	33	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	32	32	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
@@ -14814,48 +8852,28 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
@@ -14869,271 +8887,142 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[2] See table of dosages for dosing for different indications."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	12	12	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_PRNF"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2023"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Mannheimia haemolytica"		2	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -15142,17 +9031,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"TCY"	"K.kingae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	TRUE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp. (except K. aerogenes)')"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli and Klebsiella spp. (except K. aerogenes)')"
@@ -15233,7 +9122,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
@@ -15242,7 +9131,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"IPM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
@@ -15265,395 +9154,230 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_LISTR_MNCY"	2	"AMP"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"ERY"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_LISTR_MNCY"	2.1	"LNZ"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"MEM"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_LISTR_MNCY"	2.1	"MFX"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_MNNHM_HMLY"	2	"FLR"	"Histophilus somni"		2	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see table of topical agents."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see table of topical agents."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		4	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"ERY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	23	23	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] A provisional screen value of <=2 mg/L can be used for antimicrobial susceptibility testing with Mycobacteria Growth Indicator Tube (MGIT, Becton Dickinson). There are insufficient MIC data with the reference method to set a clinical breakpoint."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		64	64	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY-S"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_DORE"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PHCCL_VLGT"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	14	14	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	29	29	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"IPM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	28	28	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	25	25	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors."
+"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	24	24	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PRBCT"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[Scope] Breakpoints for Bacteroides spp. are also valid for Parabacteroides spp. and for Phocaeicola dorei/vulgatus (previously named Bacteroides dorei/vulgatus). | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	17	TRUE	FALSE	"[F] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"AMC"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PRVTL"	3.1	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3	"AMX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	31	31	FALSE	FALSE	"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
@@ -15671,188 +9395,58 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"SAM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	26	26	FALSE	FALSE	"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PRVTL"	3.1	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Systemic infections"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		2	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
@@ -15862,10 +9456,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"COL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10/4 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
@@ -15884,8 +9478,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"FPZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"	"10 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
@@ -15893,8 +9487,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN_AERG"	2	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	20	14	FALSE	FALSE	
@@ -15907,7 +9501,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SIT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SXT"	"ECOFF"		32	32	FALSE	FALSE	
@@ -15916,1016 +9510,501 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"	"30/6 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMC"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMP"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"AMX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CIP"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"CTX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"DOX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"NAL"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"LVX"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"NAL-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"PEN"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3	"SXT"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_PSTRL"	3.1	"TCY"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL"	3	"TCY-S"	"Pasteurella (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2023"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_PSTRL_MLTC"	2	"FLR"	"Pasteurella multocida"		2	4	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"DISK"		"B_SHGLL_FLXN"	2	"PEF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR"	2	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_HMRM"	1	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=20 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	22	22	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [3] Breakpoints for fosfomycin iv are currently under review."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY"	3	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		32	32	FALSE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		16	16	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	21	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	17	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	20	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] A disk diffusion test awaits action from the responsible pharmaceutical company."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Community-acquired pneumonia"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Skin"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"20 mcg"	20	20	FALSE	FALSE	"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	25	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"200 mcg"	30	18	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	256	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters >=26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a \"cliff\"), then report resistant. If not sharp (reduction of growth towards zone edge,  like a \"beach\"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.001	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"		64	64	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"ERY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		32	32	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		32	32	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	18	18	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and G. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		64	64	TRUE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation) | [3] Breakpoints for trimethoprim are currently under review."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	"[3] Breakpoints for trimethoprim are currently under review."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test awaits action from the responsible pharmaceutical company."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis)."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous, Meningitis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	0.5	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	22	22	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"ERY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.001	2	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis)."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		4	4	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"1 mcg"	20	20	FALSE	FALSE	"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	21	12	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"1 unit"	21	21	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 ug disk) should be excluded. When excluded, the isolate should be reported \"devoid of rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -16937,23 +10016,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CIP"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"15 mcg"	12	12	FALSE	FALSE	"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF-S"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	21	21	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	20	20	FALSE	FALSE	"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_VIBRI_FLVL"	2.1	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
@@ -16961,67 +10033,41 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2023"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"20/10 mcg"	50	19	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		32	32	TRUE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Isolates susceptible to ampicillin (iv or oral) can be reported \"susceptible, increased exposure\" (I) to \"amoxicillin oral (infections originating from the urinary tract)\". Isolates resistant to ampicillin (iv or oral) can be reported resistant to \"amoxicillin oral (infections originating from the urinary tract)\". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1e-04	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.001	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 ug disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	1	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		16	16	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 ug disk). For chloramphenicol treatment in meningitis, see table of dosages."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		16	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	"[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.125	0.125	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	1	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	25	22	FALSE	FALSE	
@@ -17029,75 +10075,43 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	1	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30/10 mcg"	22	22	FALSE	FALSE	"[6] See table of dosages for dosing for different indications."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		1	4	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints apply to E. coli only' | [D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		32	32	FALSE	FALSE	"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				TRUE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.5	1	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	8	FALSE	FALSE	
@@ -17106,85 +10120,35 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	24	24	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	"[A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 ug screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10/10 mcg"	14	14	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	TRUE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	4	FALSE	FALSE	"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		4	4	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2023"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2023"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		2	2	TRUE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). Reporting S or I should be avoided and if considered necessary, there should be a comment to explain the need for adjunctive measures as mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2023"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2023"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 13.1)"		2	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2023"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2023"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2023"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Aspergillus"		1	2	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Aspergillus"		1	1	FALSE	FALSE	
 "EUCAST 2023"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"AMB"	"Aspergillus"		1	1	FALSE	FALSE	
@@ -17280,202 +10244,69 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=17 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10/25 mcg"	24	24	FALSE	FALSE	"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		2	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
@@ -17496,25 +10327,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -17523,25 +10344,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -17561,7 +10372,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	19	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -17571,12 +10382,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -17593,12 +10402,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (10), R (10)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BCTRD"	3.1	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	28	28	FALSE	FALSE	"[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BCTRD"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BCTRD"	3	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -17618,7 +10424,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
@@ -17627,7 +10433,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IPM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
@@ -17648,59 +10454,37 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST Guidance Document on Burkholderia cepacia complex.'"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates categorised as screen negative can be reported \"susceptible increased exposure\" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDX"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CRDDS_DFFC"	2.1	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
@@ -17709,7 +10493,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	29	29	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	30	25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
@@ -17719,14 +10503,13 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	24	24	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTBCTR_ACNS"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_CTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	"[5] Agar dilution is the reference method for mecillinam MIC determination."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
@@ -17742,216 +10525,68 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_CTRDM_PRFR"	2	"VAN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRBC"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	"[5] Agar dilution is the reference method for mecillinam MIC determination."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	10	8	FALSE	FALSE	"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
@@ -18000,15 +10635,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"CZA"	"ECOFF"	"10/4 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CZT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test is not yet developed. Perform an MIC test."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"	"10 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -18079,7 +10713,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TEM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"	"15 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
@@ -18094,11 +10728,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	30	30	FALSE	FALSE	"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	35	35	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"MTR"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_FSBCTR_NCRP"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	32	32	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_FSBCTR_NCRP"	2	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HLCBCT_PYLR"	2	"AMX"	"H.pylori (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
@@ -18110,47 +10744,27 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
@@ -18164,273 +10778,143 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[2] See table of dosages for dosing for different indications."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_INFL"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_HMPHL_PRNF"	2	"TCY-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2022"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Mannheimia haemolytica"		2	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -18439,17 +10923,17 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"TCY"	"K.kingae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	"[5] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	TRUE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
@@ -18530,7 +11014,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
@@ -18539,7 +11023,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"IPM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST Guidance Document on Legionella pneumophila susceptibility testing.'"
@@ -18568,385 +11052,185 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_MNNHM_HMLY"	2	"FLR"	"Histophilus somni"		2	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see tables of topical agents."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see tables of topical agents."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		4	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	23	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_MRXLL_CTRR"	2	"TCY-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		64	64	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_NESSR_MNNG"	2	"TCY-S"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	"[5] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	31	31	FALSE	FALSE	"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PRVTL"	3	"CLI"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PRVTL"	3	"MEM"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	34	34	FALSE	FALSE	
@@ -18957,190 +11241,60 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PRVTL"	3	"PEN"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PRVTL"	3	"TZP"	"Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of  tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Systemic infections"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		2	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"75 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"	"30 mcg"	18	18	FALSE	FALSE	
@@ -19150,10 +11304,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"COL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10/4 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
@@ -19172,8 +11326,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"FPZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"	"10 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
@@ -19181,8 +11335,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN_AERG"	2	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	20	14	FALSE	FALSE	
@@ -19195,7 +11349,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SIT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"SXT"	"ECOFF"		32	32	FALSE	FALSE	
@@ -19204,1030 +11358,506 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"	"30/6 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_PSTRL_MLTC"	2	"FLR"	"Pasteurella multocida"		2	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"P.multocida (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"DISK"		"B_SHGLL_FLXN"	2	"PEF"	"ECOFF"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 ug disk. See Note B. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_SLMNL"	3.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | [2] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR"	2	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_HMRM"	1	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=20 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	18	18	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	22	22	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[3] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	21	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	21	21	FALSE	FALSE	"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"ERY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY"	3	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		32	32	FALSE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	19	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY"	3	"TCY-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	20	20	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		16	16	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	21	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	17	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	20	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] A disk diffusion test is not yet developed. Perform an MIC test."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Community-acquired pneumonia"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Skin"	"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"20 mcg"	20	20	FALSE	FALSE	"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	25	25	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"200 mcg"	30	18	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	256	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a \"cliff\"), then report resistant. If not sharp (reduction of growth towards zone edge,  like a \"beach\"), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CGLN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CGLN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (20), R (20)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most  staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"		64	64	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[3] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		32	32	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		32	32	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_ABCG"	2.5	"TCY-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		64	64	TRUE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	19	19	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis)."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous, Meningitis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	21	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	22	19	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	10	10	FALSE	FALSE	"[B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis)."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		4	4	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	2	FALSE	FALSE	"[2] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	22	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_PNMN"	2	"TCY-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
+"EUCAST 2022"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	18	18	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"1 unit"	18	18	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -20239,23 +11869,16 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CIP"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"DOX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	12	12	FALSE	FALSE	"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"ERY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"ERY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"15 mcg"	12	12	FALSE	FALSE	"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"LVX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"MEM"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"PEF"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"PEF-S"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	18	18	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"SXT"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3.1	"TCY"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_VIBRI"	3	"TCY-S"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	20	20	FALSE	FALSE	"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_VIBRI"	3	"TZP"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_VIBRI_FLVL"	2.1	"CTX"	"Vibrio (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
@@ -20263,57 +11886,36 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2022"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		32	32	TRUE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella spp. For wild-type isolates of both species, the MICs are <=16 mg/L and the inhibition zone diameters for the azithromycin 15 ug disk >=12 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella spp. For wild-type isolates of both species, the MICs are <=16 mg/L and the inhibition zone diameters for the azithromycin 15 ug disk >=12 mm."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	1	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	17	17	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		16	16	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		16	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.125	0.125	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	1	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	25	22	FALSE	FALSE	
@@ -20321,75 +11923,42 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	1	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30/10 mcg"	22	22	FALSE	FALSE	"[6] See table of dosages for dosing for different indications."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		1	4	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints apply to E. coli only' | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		32	32	FALSE	FALSE	"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	8	FALSE	FALSE	
@@ -20398,84 +11967,34 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	22	22	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		0.25	0.25	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	4	FALSE	FALSE	"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"75 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	16	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		4	4	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2022"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
 "EUCAST 2022"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		2	2	TRUE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets distinguish between isolates without and with phenotypically detectable resistance mechanisms. They are based on ECOFFs but since they may serve more than one species, the value may represent a best fit. For these agents, clinical evidence as monotherapy is usually lacking but for a specific indication or in combination with another active agent or measure they may still be used. Isolates with resistance can be reported R (resistant). If S or I are reported, there must be a comment to explain the caveat mentioned above. | [1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2022"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2022"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 12.0)"		2	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2022"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2022"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2022"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"Aspergillus"		1	2	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Aspergillus"		1	1	FALSE	FALSE	
 "EUCAST 2022"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"AMB"	"Aspergillus"		1	1	FALSE	FALSE	
@@ -20572,214 +12091,82 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"SXT"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)"	"30/6 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACHRMB_XYLS"	2	"TZP"	"A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		8	8	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"DOR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"DOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=17 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FDC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"GRN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10/25 mcg"	24	24	FALSE	FALSE	"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"IPM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LMU"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"DOR"	"ECOFF"		1	1	FALSE	FALSE	
@@ -20805,25 +12192,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_LWFF"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -20832,25 +12209,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -20874,181 +12241,90 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ATM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"AZM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"BPR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CAZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CHL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CLI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"COL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CRO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"DOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"ETP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FDC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FEP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FLC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FUS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-NEG"	6.1	"FOS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"GEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"IMR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"IPM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LEX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LMU"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LNZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LVX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		2	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MNO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NET"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ORI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OXA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"PHN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"QDA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RIF"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"SAM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TCC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TCY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TGC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TOB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TZD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TZP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"VAN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"DOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FDC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FUS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-POS"	6.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"IMR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LMU"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		2	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RIF"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TGC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"VAN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"CLI"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"ERY"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	24	24	FALSE	FALSE	
@@ -21058,12 +12334,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LNZ"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	23	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS"	3	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	21	FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported \"susceptible increased exposure\" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	10	10	FALSE	FALSE	"[A] Non-wild type isolates were not available when developing the disk diffusion method."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS"	3	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"CIP"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
@@ -21080,8 +12354,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"LVX"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"MEM"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"NOR"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_BCLLS_ANTH"	2.1	"NOR-S"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BCLLS_ANTH"	2.1	"VAN"	"Bacillus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Bacillus anthracis ('Bacillus spp. except B. anthracis')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_BCTRD_FRGL"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
@@ -21112,7 +12385,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
@@ -21121,7 +12394,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_BRKHL_CEPC-C"	2.6	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"IPM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
@@ -21142,37 +12415,28 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility inferred from tetracycline disk diffusion screen test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	23	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	23	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMX"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AZM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
@@ -21187,18 +12451,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
@@ -21211,106 +12469,36 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"TLT"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"CLI"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAP"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"ERY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDX"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FUS"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FUS"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Not used clinically. May be tested for epidemiological purposes only (ECOFF 2 mg/L)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"IMR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LMU"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MFX"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"RIF"	"ECOFF"		0.004	0.004	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RIF"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [6] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.004 mg/L)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TCY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TGC"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.25 mg/L)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"C.difficile (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CRNBC_SKZK"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
@@ -21319,7 +12507,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	29	29	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	30	25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
@@ -21365,7 +12553,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"FEP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -21413,216 +12600,68 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC_DSSL"	1	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	10	8	FALSE	FALSE	"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FDC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LMU"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	"[C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC"	3	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
@@ -21751,11 +12790,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	TRUE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test is not yet developed. Perform an MIC test."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOX"	"ECOFF"		4	4	FALSE	FALSE	
@@ -21802,7 +12840,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TCC"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	18	18	FALSE	FALSE	"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
@@ -21834,64 +12872,44 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CDR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	28	28	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPO"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[4] The breakpoints also apply to meningitis."
@@ -21904,79 +12922,46 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30/10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] See table of dosages for dosing for different indications."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	23	23	FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GAT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LEX"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LNZ"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -21984,133 +12969,74 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"NAL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PHN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SPX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TOB"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous, Non-meningitis"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CDR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CLR"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPO"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [4] The breakpoints also apply to meningitis."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -22118,29 +13044,21 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [4] The breakpoints also apply to meningitis."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FDC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GAT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -22148,15 +13066,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LEX"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LMU"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LNZ"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -22165,85 +13080,55 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"NAL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PHN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SPX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TOB"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2021"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_HSTPH_SOMN"	2	"FLR"	"Florfenicol rationale"		2	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -22260,10 +13145,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	TRUE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	20	TRUE	FALSE	"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	TRUE	FALSE	"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported \"susceptible, increased exposure\" (I) to cefazolin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
@@ -22279,7 +13164,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
@@ -22289,9 +13174,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"COL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
@@ -22377,7 +13262,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
@@ -22387,7 +13272,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"ETP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FDC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FEP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_LGNLL_PNMP"	2.1	"FOS"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"GEN"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_LGNLL_PNMP"	2	"GRN"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"IMR"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
@@ -22424,7 +13309,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MNNHM_HMLY"	2	"FLR"	"ECOFF"		2	2	FALSE	FALSE	
@@ -22453,121 +13338,64 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	31	31	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] For topical use of chloramphenicol, see tables of topical agents."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For topical use of chloramphenicol, see tables of topical agents."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	31	31	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		4	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	30	30	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	23	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FDC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LMU"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -22575,285 +13403,142 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"NAL"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	28	25	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_TBRC"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2.1	"PMD"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"ERY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FDC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"GAT"	"ECOFF"		0.008	0.008	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LMU"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"LVX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"MFX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		64	64	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FDC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LMU"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"LVX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"MFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] For prophylaxis of meningitis only (refer to national guidelines)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PRBCT_DSTS"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS"	3	"CFR"	"ECOFF"		16	16	FALSE	FALSE	
@@ -22872,7 +13557,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CXM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	TRUE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"FEP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -22895,7 +13580,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TCY"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	17	TRUE	FALSE	"[C] Ignore isolated colonies within the inhibition zone."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	TRUE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PROTS_MRBL"	2	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	TRUE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TGC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
@@ -22927,201 +13612,72 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TGC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"DOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Systemic infections"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LMU"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"75 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"BPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	26	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"COL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10/4 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
@@ -23132,29 +13688,28 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"FDC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"FEP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GRN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	20	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NOR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TCC"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS-C"	2.5	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS-C"	2.5	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
@@ -23163,38 +13718,31 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility inferred from tetracycline screen test."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"FLR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"animal"	"cattle"	"MIC"	"Respiratory"	"B_PSTRL_MLTC"	2	"FLR"	"Florfenicol rationale"		2	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"P.multocida (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"CTX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -23242,7 +13790,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 ug disk. See Note B. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CXM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"DOX"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"FLM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -23256,8 +13804,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"NAL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"NEO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_SLMNL"	3.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | [2] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"STR1"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
@@ -23280,193 +13827,84 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_TYPH"	1	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"DOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Zone diameters of >=20 mm for the cefiderocol 30 ug disk correspond to MIC values below the PK-PD breakpoint of S <= 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2.1	"FDC"	"S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	22	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FDC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY"	3	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		32	32	FALSE	FALSE	"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LMU"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	26	23	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	19	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	21	21	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
@@ -23475,12 +13913,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CEP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CFP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	21	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -23497,7 +13935,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CZO"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] A disk diffusion test is not yet developed. Perform an MIC test."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -23508,18 +13945,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FLR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOS"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"KAN"	"ECOFF"		8	8	FALSE	FALSE	
@@ -23530,8 +13964,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LNZ"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	25	25	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
@@ -23539,33 +13973,34 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MSU"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"200 mcg"	30	18	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	256	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NET"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PIS"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PRL"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPT"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -23573,56 +14008,46 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_COHN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
@@ -23630,49 +14055,40 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci other than S. epidermidis')"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -23688,18 +14104,18 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -23711,16 +14127,16 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
@@ -23729,58 +14145,54 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"VIR"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"DOR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20	20	FALSE	FALSE	"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SCHL"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SCIR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SMLN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SMLN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"DOR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -23789,204 +14201,104 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"		64	64	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L'"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_XYLS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FDC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		32	32	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		32	32	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LMU"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	21	15	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.5	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	20	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -24020,31 +14332,21 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_AGLC"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"AMX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"TZP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -24057,75 +14359,39 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQNS"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQNS"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRDN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		64	64	TRUE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_GRPB"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"ORI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"AMX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CTX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"DAP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"ORI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"TZP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -24160,125 +14426,72 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMC"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	22	16	FALSE	FALSE	"[A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis)."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous, Meningitis"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	21	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[1] For chloramphenicol treatment in meningitis, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DAP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	22	19	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FDC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GAT"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LMU"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
@@ -24286,17 +14499,11 @@ ND = No ECOFF available."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MEM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -24304,58 +14511,27 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"NOR"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		4	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OXA"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20		FALSE	FALSE	"[E] For interpretation of the oxacillin disk screen, see flow chart below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"1 mcg"	20		FALSE	FALSE	"[E] For interpretation of the oxacillin disk screen, see flow chart below."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.064	0.064	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis)."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.06	0.06	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	22	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
@@ -24363,28 +14539,14 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TGC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -24430,206 +14592,77 @@ ND = No ECOFF available."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"DOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FDC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
+"EUCAST 2021"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LMU"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid of fluoroquinolone resistance mechanisms\", but not as susceptible to moxifloxacin."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25		FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		0.25		FALSE	FALSE	"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported \"wild type\" or \"devoid rifampicin resistance mechanisms\", but not as susceptible to rifampicin."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone >=18 mm or MIC <=0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -24646,57 +14679,37 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganellaceae ('Enterobacterales except Morganellaceae')"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	50	19	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2021"	"human"	"human"	"MIC"		"B_[FAM]_MORGNLLC"	4	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"20/10 mcg"	19	19	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"20/10 mcg"	16	16	TRUE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		32	32	TRUE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella spp. For wild-type isolates of both species, the MICs are <=16 mg/L and the inhibition zone diameters for the azithromycin 15 ug disk >=12 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella spp. For wild-type isolates of both species, the MICs are <=16 mg/L and the inhibition zone diameters for the azithromycin 15 ug disk >=12 mm."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	1	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		16	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	1	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	25	22	FALSE	FALSE	
@@ -24704,161 +14717,78 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	1	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30/10 mcg"	22	22	FALSE	FALSE	"[6] See table of dosages for dosing for different indications."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"DOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FDC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		1	4	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints apply to E. coli only' | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		32	32	FALSE	FALSE	"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	19	19	FALSE	FALSE	"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10/25 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LMU"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Non-meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"	"Meningitis"	"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	22	22	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	4	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"75 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		4	4	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2021"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2021"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		2	2	TRUE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2021"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2021"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 11.0)"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"	"30/6 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2021"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2021"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2021"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2021"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Aspergillus"		1	2	FALSE	FALSE	
@@ -24997,206 +14927,74 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2021"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TIC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\"."
 "EUCAST 2021"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"		0.5	0.5	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\"."
 "EUCAST 2021"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 11.0)"		8	16	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\". | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (19), R (19)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		8	8	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"DOR"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"GRN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IMR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"IPM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	20	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	23	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		2	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB"	3	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_ACNTB"	3	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (4), R (4)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_ACNTB"	3	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_BMNN"	2	"DOR"	"ECOFF"		1	1	FALSE	FALSE	
@@ -25222,25 +15020,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ACNTB_LWFF"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -25249,25 +15037,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -25291,171 +15069,78 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ATM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"AZM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"BPR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CAZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CHL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CLI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"COL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CRO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"ETP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FEP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FLC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FUS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"GEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"IMR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"IPM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LEX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LNZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LVX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		2	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MNO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NET"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ORI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OXA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"PHN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"QDA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RIF"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"SAM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TCC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TCY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TGC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TOB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TZD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TZP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"VAN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FUS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"IMR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		2	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RIF"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TGC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"VAN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_BCTRD_FRGL"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
@@ -25486,7 +15171,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_BRKHL_CEPC-C"	2.6	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
@@ -25512,37 +15197,28 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_CEPC-C"	2.6	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Burkholderia cepacia complex organisms since accurate and reproducible methods for antimicrobial susceptibility testing are lacking due to technical difficulties encountered with these species and the lack of convincing clinical outcome correlates. Users are referred to the EUCAST guidance document on Burkholderia cepacia complex.'"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"20/10 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"AMC"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CAZ"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility inferred from tetracycline disk diffusion screen test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"CHL"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"DOX"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"IPM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"MEM"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	50	17	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	23	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2.1	"TCY"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_BRKHL_PSDM"	2	"SXT"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_BRKHL_PSDM"	2	"TCY-S"	"B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	23	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline disk diffusion screen test."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AMX"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"AZM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"CLI"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
@@ -25557,18 +15233,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AMX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
@@ -25581,92 +15251,27 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CMPYL_JEJN"	2	"TLT"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"CLI"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAP"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"ERY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDX"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"FUS"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FUS"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Not used clinically. May be tested for epidemiological purposes only (ECOFF 2 mg/L)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"IMR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MFX"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"RIF"	"ECOFF"		0.004	0.004	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RIF"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [6] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.004 mg/L)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"TCY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TGC"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.25 mg/L)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"C.difficile (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
@@ -25675,9 +15280,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	20	20	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
@@ -25686,7 +15288,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	29	29	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	30	25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
@@ -25732,7 +15334,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"FEP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_CTRBC_KOSR"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -25780,210 +15381,64 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRBC_CLOC_DSSL"	1	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	10	8	FALSE	FALSE	"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"IMR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	"[B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	"[B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ENTRC"	3	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
@@ -26112,11 +15567,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [D] A disk diffusion test is not yet developed. Perform an MIC test."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_ESCHR_COLI"	2	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	TRUE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_ESCHR_COLI"	2	"DOX"	"ECOFF"		4	4	FALSE	FALSE	
@@ -26192,64 +15645,44 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"2/1 mcg"	50	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AMX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"AZM"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CDR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CEC"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CFP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	28	28	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CLR"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPO"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
@@ -26262,73 +15695,40 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	27	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation) | [2] See table of dosages for dosing for different indications."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_INFL"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[2] See table of dosages for dosing for different indications."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all cephalosporins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GAT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"IMR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LEX"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LNZ"	"ECOFF"		32	32	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all carbapenems for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -26336,133 +15736,74 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"NAL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_HMPHL_INFL"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_HMPHL_INFL"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"PHN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SPX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TOB"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_HMPHL_INFL"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_HMPHL_INFL"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all penicillins for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AMX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CDR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CEC"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CFP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CLR"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPO"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -26470,27 +15811,18 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"CXM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Pneumonia"	"B_HMPHL_PRNF"	2	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] See table of dosages for dosing for different indications."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"ERY"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"FOX"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GAT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"GEN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -26498,14 +15830,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LEX"	"ECOFF"		64	64	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LNZ"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -26514,84 +15843,54 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"NAL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PEN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"PHN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SPX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TGC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TLT"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TMP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TOB"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -26608,10 +15907,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL"	3.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	TRUE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL"	3	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	TRUE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL"	3	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
@@ -26635,11 +15933,10 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"COL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CTX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"CXM"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_KLBSL_AERG"	2.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes K. aerogenes ('E. coli, and Klebsiella spp. (except K. aerogenes)')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_KLBSL_AERG"	2	"DOX"	"ECOFF"		8	8	FALSE	FALSE	
@@ -26721,7 +16018,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CPT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CRO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CTX"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_LGNLL_PNMP"	2.1	"CXM"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZA"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZO"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LGNLL_PNMP"	2.1	"CZT"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'EUCAST has not determined breakpoints for Legionella pneumophila as there is no established reference method or any documentation of clinical outcome related to antimicrobial susceptibility testing. Users are referred to the EUCAST guidance document on Legionella pneumophila susceptibility testing.'"
@@ -26764,12 +16061,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_LISTR_MNCY"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MNNHM_HMLY"	2	"FLR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MNNHM_HMLY"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRGNL"	3.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganella spp. ('Enterobacterales except Morganella spp.')"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRGNL"	3.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Morganella spp. ('Enterobacterales except Morganella spp.')"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"AMC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"AMX"	"ECOFF"		8	8	FALSE	FALSE	
@@ -26784,7 +16080,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"GRN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRGNL_MRGN"	2	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRGNL_MRGN"	2	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRGNL_MRGN"	2	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"LEX"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"LVX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -26796,78 +16092,40 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRGNL_MRGN"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"AMX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Breakpoints relate to topical use only.' | [A] Breakpoints relate to topical use only."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Breakpoints relate to topical use only.' | [1] Breakpoints relate to topical use only."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	30	30	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		4	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	23	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
@@ -26875,36 +16133,18 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"IMR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -26912,284 +16152,139 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"NAL"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"NAL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_MRXLL_CTRR"	2	"NAL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_MRXLL_CTRR"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_MRXLL_CTRR"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	28	25	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MRXLL_CTRR"	2	"TGC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_MYCBC_TBRC"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"ERY"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"GAT"	"ECOFF"		0.008	0.008	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IMR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"LVX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"MFX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		64	64	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] See table of dosages."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CIP"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"ECOFF"		0.016	0.016	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IMR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"LVX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"MFX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] For prophylaxis of meningitis only (refer to national guidelines)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PHCCL_VLGT"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRBCT_DSTS"	2	"MEM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS"	3	"CFR"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS"	3	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PROTS"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PROTS"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PROTS"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS"	3	"TOB"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"AMP"	"ECOFF"		8	8	FALSE	FALSE	
@@ -27204,7 +16299,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"CXM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	TRUE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_MRBL"	2	"FEP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -27249,7 +16344,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PROTS_VLGR"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN"	3	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PRVDN"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PRVDN"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PRVDN"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN"	3	"NOR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_RTTG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_RTTG"	2	"TGC"	"ECOFF"		4	4	FALSE	FALSE	
@@ -27259,193 +16354,65 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TGC"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PRVDN_STRT"	2	"TZP"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (15), R (15)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (16), R (16)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	17	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	26	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Systemic infections"	"B_PSDMN"	3.1	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	50	20	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	22	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		2	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"75/10 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"75 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"30/6 mcg"	50	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		0.001	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"AMK"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"ATM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"BPR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CIP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"COL"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"CTX"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"	"10/4 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
@@ -27454,29 +16421,27 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"DOR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"FEP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	15	15	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	15	15	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"GRN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2.1	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"IMR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	20	20	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	20	20	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MEM"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"MFX"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NET"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"NOR"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"OFX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"PIP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TCC"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TGC"	"ECOFF"		64	64	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_PSDMN_AERG"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_PSDMN_AERG"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_AERG"	2	"TZP"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS-C"	2.5	"CAZ"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSDMN_FLRS-C"	2.5	"IPM"	"ECOFF"		4	4	FALSE	FALSE	
@@ -27485,37 +16450,30 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CHL"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"ECOFF"		0.032	0.032	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility inferred from tetracycline screen test."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"FLR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"GEN"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_PSTRL_MLTC"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"P.multocida (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"CTX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SERRT"	3	"DOR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -27563,7 +16521,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CIP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 ug disk. See Note B. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"CXM"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"DOX"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"FLM"	"ECOFF"		2	2	FALSE	FALSE	
@@ -27577,8 +16535,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"NAL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"NEO"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"OFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_SLMNL"	3.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species. | [2] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	24	24	FALSE	FALSE	"[2/C] The pefloxacin 5 ug breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"STR1"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL"	3	"TCY"	"ECOFF"		8	8	FALSE	FALSE	
@@ -27604,182 +16561,77 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"MNO"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	50	16	FALSE	FALSE	"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)"		0.001	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	22	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY"	3	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		32	32	FALSE	FALSE	"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IMR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and \"susceptible increased exposure\" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi, see Note C on cephalosporins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	26	23	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	19	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	21	21	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMC"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"ECOFF"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"AZM"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"BPR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
@@ -27788,12 +16640,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CEP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CFP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	21	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CLR"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -27810,29 +16662,24 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"CZO"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] A disk diffusion test is not yet developed. Perform an MIC test."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'The zone diameter breakpoint is valid for MSSA only' | [B] The zone diameter breakpoint is valid for MSSA only. For MRSA, perform an MIC test."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FEP"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FLR"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOS"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	24	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"KAN"	"ECOFF"		8	8	FALSE	FALSE	
@@ -27841,8 +16688,8 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LNZ"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	25	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
@@ -27850,35 +16697,36 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MNO"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MSU"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"MUP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"200 mcg"	30	18	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	256	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"200 mcg"	30	30	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
+ND = No ECOFF available."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] Breakpoints for nasal decontamination S <=1, R >256 mg/L (S >=30, R <18 mm for the mupirocin 200 ug disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low.
 ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NEO"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NET"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	20	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PIS"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"PRL"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"QDA"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RIF"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPT"	"ECOFF"		128	128	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SPX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
@@ -27886,56 +16734,46 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TGC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TIA"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TMP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TOB"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	18	18	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STPHY_AURS"	2	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	18	18	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STPHY_AURS"	2	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"TZP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_COHN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
@@ -27943,51 +16781,42 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"NOR"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"OFX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	1	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.001	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"OXA"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (22), R (22)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (1), R (1)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_CPTS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"CTX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"DOR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci other than S. epidermidis')"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GAT"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -28003,18 +16832,18 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"SXT"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_EPDR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"GEN"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
@@ -28026,16 +16855,16 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMLY"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HMNS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"CHL"	"ECOFF"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_HYCS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
@@ -28044,54 +16873,53 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_INTR"	2	"VIR"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"DOR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"FUS"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"MEM"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"ECOFF"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L'"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_LGDN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_SCHL"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"1 mcg"	20	20	FALSE	FALSE	"[C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2.1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"1 mcg"	20	20	FALSE	FALSE	"[C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SCIR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SMLN"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SMLN"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"DOR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[3] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
@@ -28100,198 +16928,100 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"NIT"	"ECOFF"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"		64	64	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L'"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_SPRP"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"CIP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"ERY"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"LVX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"RXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_WRNR"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STPHY_XYLS"	2	"VAN"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"FUS"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		32	32	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"FUS-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		32	32	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IMR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	19	19	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	17	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	19	19	FALSE	FALSE	"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note C."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"MUP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"MUP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12		FALSE	FALSE	"[C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	21	15	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_ABCG"	2.5	"RTP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.5	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_ABCG"	2.5	"RTP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	20	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -28325,31 +17055,21 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_AGLC"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"AMX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"BPR"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"DAP"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"TZP"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ANGN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_CNST"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -28362,73 +17082,37 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQNS"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_EQNS"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRDN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		64	64	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"ORI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPC"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"AMX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CLI"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"CTX"	"ECOFF"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"DAP"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"LVX"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"MFX"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"ORI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"TZP"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_GRPG"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] A disk diffusion test is not yet developed. Perform an MIC test."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_INTR"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	18	18	FALSE	FALSE	
@@ -28463,133 +17147,75 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_ORLS"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMC"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	22	16	FALSE	FALSE	"[A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AMX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CAZ"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"ECOFF"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	21	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	21	21	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CIP"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"ECOFF"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"CXM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DAP"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"DOR"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	22	19	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GAT"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"GRN"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"IMR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	50	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		1e-04	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.001	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MEM"	"ECOFF"		0.016	0.016	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -28597,58 +17223,27 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"NOR"	"ECOFF"		16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_STRPT_PNMN"	2	"NOR"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as \"susceptible increased exposure\" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_STRPT_PNMN"	2	"NOR-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	10	10	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"ECOFF"		4	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_STRPT_PNMN"	2	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_STRPT_PNMN"	2	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		4	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"OXA"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"PEN"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.064	0.064	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	2	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.06	0.06	FALSE	FALSE	"[1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	22	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
@@ -28656,28 +17251,14 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TGC"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"TZP"	"ECOFF"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 ug disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone >=20 mm, or benzylpenicillin MIC <=0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as \"susceptible, increased exposure\" (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -28723,199 +17304,72 @@ ND = No ECOFF available."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_SNGN"	2	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"20 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"ERY"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
+"EUCAST 2020"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"GRN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IMR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"LNZ"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"LVX"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"ECOFF"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MFX"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"MNO"	"ECOFF"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"ECOFF"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		0.25	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"TCY"	"ECOFF"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"ECOFF"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -28934,202 +17388,99 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"AMC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		32	32	TRUE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	18	18	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (18), R (18)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AMK"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (8), R (8)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC <=16 mg/L for wild-type isolates) and Shigella spp."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC <=16 mg/L for wild-type isolates) and Shigella spp."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	1	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CHL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CHL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		16	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"CIP"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"CIP-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"COL"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"COL-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	1	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	1	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30/10 mcg"	22	22	FALSE	FALSE	"[4] See table of dosages for dosing for different indications."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		1	4	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints apply to E. coli only' | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		32	32	FALSE	FALSE	"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		32	32	TRUE	FALSE	"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	FALSE	FALSE	"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	19	19	FALSE	FALSE	"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"GEN"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"GEN-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IMR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	22	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		16	16	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"LVX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"LVX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"NEO"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"NEO-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	22	22	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"OFX"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"OFX-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"PEF"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"PEF-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	24	24	FALSE	FALSE	"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	4	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline can be used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Breakpoints still under consideration."
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] Breakpoints still under consideration."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"75 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"5 mcg"	15	15	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		4	4	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2020"	"human"	"human"	"DISK"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	16	16	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (17), R (17)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
 "EUCAST 2020"	"human"	"human"	"MIC"	"Infections originating from the urinary tract"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		2	2	TRUE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"	"Topical, Screen"	"B_[ORD]_ENTRBCTR"	5	"TOB"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives breakpoints in brackets only (S (2), R (2)) | [( )] Breakpoints in brackets are based on ECOFF values for relevant species. They are used to distinguish between organisms with and without acquired resistance mechanisms. ECOFFs do not predict clinical susceptibility but in some situations and/or when the agent is combined with another active agent, therapy may be considered. | [1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: \"Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy.\" For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2020"	"human"	"human"	"DISK"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"	"10 mcg"	16	16	FALSE	FALSE	
+"EUCAST 2020"	"human"	"human"	"MIC"	"Topical"	"B_[ORD]_ENTRBCTR"	5	"TOB-S"	"Topical agents (file: Clinical Breakpoint Tables v. 10.0)"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"	"30/6 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2020"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2020"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ISV"	"ECOFF"		2	2	FALSE	FALSE	
 "EUCAST 2020"	"ECOFF"	"ECOFF"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"ECOFF"		1	1	FALSE	FALSE	
 "EUCAST 2020"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Aspergillus"		1	2	FALSE	FALSE	
@@ -29264,195 +17615,64 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2020"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TIC"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"		8	16	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\"."
 "EUCAST 2020"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TOB"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"		0.5	0.5	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\"."
 "EUCAST 2020"	"human"	"human"	"MIC"		"UNKNOWN"	7	"TZP"	"PK PD breakpoints (file: Clinical Breakpoint Tables v. 10.0)"		4	16	FALSE	FALSE	"[PK-PD] These breakpoints are used only when there are no species-specific breakpoints or other recommendations (a dash or a note) in the species-specific tables. If the MIC is greater than the PK-PD resistant breakpoint, advise against use of the agent. If the MIC is less than or equal to the PK-PD susceptible breakpoint, suggest that the agent can be used with caution. The MIC may also be reported although this is not essential. Include a note that the guidance is based on PK-PD breakpoints only, and include the dosage on which PK-PD breakpoint is based.More information is available in the guidance document \"Antimicrobial susceptibility tests on groups of organisms or agents for which there are no EUCAST breakpoints\". | [3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	17	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"AMK"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AMX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ATM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"AZM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"BPR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CAZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CFR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CHL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	50	21	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		0.064	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CLR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"CIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		0.06	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"COL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CRO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CTX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_ACNTB"	3.1	"CXM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"CZT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DAP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"DOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ERY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ETP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FEP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FLC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FOX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"FUS"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"GEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"IPM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LEX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"LNZ"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"LVX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"MEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		2	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MEV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MNO"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"MTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NAL"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	16	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"NET"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NIT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NOR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"NTR"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OFX"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"ORI"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"OXA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PEN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PHN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"PIP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"QDA"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RIF"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"RXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SAM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"SPT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"SXT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TCY"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TEM"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TGC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TIC"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLT"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TLV"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TMP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3	"TOB"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZD"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"TZP"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ACNTB"	3.1	"VAN"	"Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_SNGN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_SNGN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_SNGN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -29461,25 +17681,15 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_SNGN"	2	"VAN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"AMP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"AMX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Infer susceptibility from ampicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	21	21	TRUE	FALSE	"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note C."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"CIP"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note C."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	TRUE	FALSE	"[1] Susceptibility can be inferred from ciprofloxacin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"LVX"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	31	31	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"MEM"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"100 mcg"	16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_AERCC_URIN"	2	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NIT"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2.1	"NOR"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_AERCC_URIN"	2	"NOR-S"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	21	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERCC_URIN"	2	"PEN"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERCC_URIN"	2	"RIF"	"A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	25	25	FALSE	FALSE	
@@ -29499,283 +17709,108 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	19	16	FALSE	FALSE	"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_AERMN"	3	"SXT"	"Aeromonas (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"AMK"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"AMX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ATM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"AZM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"BPR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CAZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CFR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CHL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"CLI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CLR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"COL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CRO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CTX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-NEG"	6.1	"CXM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"CZT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DAP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"DOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ERY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"ETP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FEP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FLC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FOX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"FUS"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"GEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"IPM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LEX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LNZ"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"LVX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		2	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MEV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"MNO"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"MTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NAL"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NET"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NIT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NOR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"NTR"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OFX"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"ORI"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"OXA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PEN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"PHN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"PIP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"QDA"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RIF"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"RXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"SAM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SPT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"SXT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TCC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TCY"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TEM"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TGC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TIC"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLT"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TLV"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TMP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TOB"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"TZD"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6	"TZP"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-NEG"	6.1	"VAN"	"Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_ANAER-POS"	6.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DAP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"FUS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		2	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"MTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RIF"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TGC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ANAER-POS"	6	"VAN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	24	24	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_COLI"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"AZM"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"CIP"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"CLR"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tetracycline can be used to determine susceptibility to doxycycline."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2.1	"DOX"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	20	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"ERY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	30	30	FALSE	FALSE	"[A] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CMPYL_JEJN"	2	"TCY"	"C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Tetracycline can be used to determine susceptibility to doxycycline."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMK"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AMX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ATM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"AZM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"BPR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CAZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CFR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CHL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CLR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"COL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CRO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CTX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CXM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"CZT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DAP"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"DOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ERY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ETP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FDX"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FEP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FLC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOS"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FOX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"FUS"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [3] Not used clinically. May be tested for epidemiological purposes only (ECOFF 2 mg/L)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"GEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"IPM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LEX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LNZ"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"LVX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"MEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MEV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MFX"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Not used clinically. May be tested for epidemiological purposes only (ECOFF 4 mg/L)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"MNO"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"MTR"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NAL"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"NET"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NIT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NOR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"NTR"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OFX"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"ORI"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"OXA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PEN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PHN"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"PIP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"QDA"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RIF"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [6] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.004 mg/L)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"RXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SAM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SPT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"SXT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TCY"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TEM"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TGC"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Not used clinically. May be tested for epidemiological purposes only (ECOFF 0.25 mg/L)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TIC"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLT"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TLV"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_CRDDS_DFFC"	2.1	"TMP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TOB"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZD"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2.1	"TZP"	"Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Clostridioides difficile ('Gram-positive anaerobes except Clostridioides difficile')"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRDDS_DFFC"	2	"VAN"	"C.difficile (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CIP"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"CLI"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3.1	"ERY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"GEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"LNZ"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	25	25	FALSE	FALSE	
@@ -29785,213 +17820,65 @@ Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	29	29	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"PEN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	30	25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.5	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"RIF"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"TCY"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CRYNB"	3	"VAN"	"Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_CTRBC_KOSR"	2.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints validated for E. coli only' | [A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_CTRBC_KOSR"	2	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AMK"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	10	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ATM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"AZM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"BPR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CAZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CFR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CHL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLI"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CLR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"COL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPD"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CRO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTB"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CTX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_ENTRC"	3.1	"CXM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"CZT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DAP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [1] For more information, see http://www.eucast.org/guidance_documents/."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"DOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ERY"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ETP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FEP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FLC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOS"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FOX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"FUS"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	8	8	FALSE	FALSE	"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"GEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"GEN-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
 Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"IPM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LEX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	15	15	TRUE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"LVX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MEV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MNO"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"MTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NAL"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NET"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NIT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	12	12	FALSE	FALSE	"[B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NOR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"NTR"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	12	12	FALSE	FALSE	"[B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OFX"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"ORI"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"OXA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PEN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PHN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"PIP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"QDA"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RIF"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"RXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SPT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"300 mcg"	14	14	FALSE	FALSE	"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_ENTRC"	3	"STR1-S"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		512	512	FALSE	FALSE	"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
 Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
 Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"STR1"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. 
-Negative test: Isolates with streptomycin MIC <=512 mg/L or a zone diameter >=14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide.
-Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"SXT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TCY"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TEC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TEM"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	18	18	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TGC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TIC"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLT"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TLV"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TMP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TOB"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). 
-Negative test: Isolates with gentamicin MIC <=128 mg/L or a zone diameter >=8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZD"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3.1	"TZP"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	12	12	FALSE	FALSE	"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone  or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is >= 12 mm. Isolates must not be reported susceptible before 24 h incubation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"VAN"	"Enterococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
@@ -30003,7 +17890,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	19	TRUE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_ESCHR_COLI"	2.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_ESCHR_COLI"	2	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"200 mcg"	24	24	FALSE	FALSE	"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_ESCHR_COLI"	2	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"200 mcg"	24	24	TRUE	FALSE	"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
@@ -30025,43 +17911,22 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"2/1 mcg"	15	15	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	16	16	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	26	26	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	32	32	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
@@ -30072,152 +17937,60 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	50	27	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_INFL"	2	"CXM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	23	23	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	28	28	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	20	20	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_INFL"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[3] Meropenem is the only carbapenem used for meningitis."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	21	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	30	30	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	12		FALSE	FALSE	"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	23	20	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"	"30/6 mcg"	27	27	FALSE	FALSE	"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\", can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AMK"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"AMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_HMPHL_PRNF"	2	"AMX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ATM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"AZM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"BPR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CAZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CFM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CFR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CHL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CLR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"COL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CRO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTB"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"CTX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
@@ -30227,94 +18000,51 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"CZT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DAP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"DIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"DOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ERY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"ETP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"FEP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FLC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FOX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"FUS"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"GEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"IPM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LEX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"LNZ"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"LVX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Non-meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_HMPHL_PRNF"	2	"MEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] Meropenem is the only carbapenem used for meningitis."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MEV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"MTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NAL"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NET"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NIT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NOR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"NTR"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"ORI"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"OXA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PEN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PHN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"PIP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"QDA"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"RXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"SPT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SXT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TCC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TCY"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TEM"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TGC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TIC"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLT"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TLV"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TMP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TOB"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"TZD"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"TZP"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae. | [6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2.1	"VAN"	"H.influenzae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [Scope] In the absence of specific breakpoints, the H. influenzae MICbreakpoints can be applied to H. parainfluenzae."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"AMC"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AMX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[2] Susceptibility can be inferred from benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"AZM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	28	28	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2.1	"CLI"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from erythromycin susceptibility."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CIP"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CLR"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[1] Susceptibility can be inferred from erythromycin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CRO"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"CTX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	29	29	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_KGLLA_KING"	2	"CXM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2.1	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"DOX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"ERY"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"LVX"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	30	30	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"MEM"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	25	25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"PEN"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_KGLLA_KING"	2	"RIF"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_KGLLA_KING"	2	"SXT"	"K.kingae (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	28	28	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
@@ -30327,9 +18057,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL"	3	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	TRUE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	15	15	TRUE	FALSE	"[D] Ignore isolated colonies within the inhibition zone for E. coli."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_KLBSL"	3	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_KLBSL_AERG"	2.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST excludes Klebsiella aerogenes ('E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis')"
@@ -30342,350 +18072,145 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	13	13	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"PEN"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	29	29	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_LISTR_MNCY"	2	"SXT"	"L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRGNL_MRGN"	2	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRGNL_MRGN"	2	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.125	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"2/1 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AMC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMK"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"AMX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ATM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"AZM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"BPR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CAZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CFM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CFR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Breakpoints relate to topical use only.' | [A] Breakpoints relate to topical use only."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CHL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Breakpoints relate to topical use only.' | [1] Breakpoints relate to topical use only."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	31	31	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CLO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CLR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"COL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CRO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CTB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"CTX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	50	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		4	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_MRXLL_CTRR"	2	"CXM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"CZT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DAP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"DIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"DOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ERV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	23	20	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ERY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"ETP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"FEP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FLC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FOX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"FUS"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"GEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	29	29	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"IPM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LEX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"LNZ"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	29	29	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"LVX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	33	33	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MEV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"MTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NAL"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NET"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NIT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NOR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"NTR"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	28	28	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"ORI"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"OXA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PEN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PHN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"PIP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"QDA"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"RIF"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SAM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"SPT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"SXT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TCC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	28	25	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TCY"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TEM"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TGC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TIC"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"TLT"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TLV"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TMP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TOB"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZD"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility can be inferred from amoxicillin-clavulanic acid."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"TZP"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2.1	"VAN"	"M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"BDQ"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_MYCBC_TBRC"	2	"DLM"	"M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMK"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AMX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ATM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"AZM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"BPR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CAZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CFM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CFR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CHL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CLR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"COL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CRO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CTB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"CTX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_GNRR"	2.1	"CXM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"CZT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DAP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"DOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ERY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ETP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FEP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FLC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FOX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"FUS"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"GEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"IPM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LEX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LNZ"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"LVX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MEV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MNO"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"MTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NAL"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NET"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NIT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NOR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"NTR"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"OFX"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"ORI"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"OXA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	1	FALSE	FALSE	"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PHN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"PEN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	1	FALSE	FALSE	"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"PIP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"QDA"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RIF"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"RXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SAM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"SPT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		64	64	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"SXT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TCC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2	"TCY"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TEM"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TGC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TIC"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLT"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TLV"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TMP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TOB"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZD"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"TZP"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_GNRR"	2.1	"VAN"	"N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AMK"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"AMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"AMX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ATM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"AZM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"BPR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CAZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CFR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CHL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CLR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"COL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"CIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CRO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CTB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"CTX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_NESSR_MNNG"	2.1	"CXM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"CZT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DAP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"DOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ERY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ETP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FEP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FLC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FOX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"FUS"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"GEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"IPM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LEX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LNZ"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"LVX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_NESSR_MNNG"	2	"MEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MEV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"MNO"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"MTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NAL"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NET"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NIT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NOR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"NTR"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OFX"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"ORI"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"OXA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PHN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"PEN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"PIP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"QDA"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Prophylaxis"	"B_NESSR_MNNG"	2	"RIF"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] For prophylaxis of meningitis only (refer to national guidelines)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"RXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SAM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SPT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"SXT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TCC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2	"TCY"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TEM"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TGC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TIC"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLT"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TLV"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TMP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TOB"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZD"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"TZP"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_NESSR_MNNG"	2.1	"VAN"	"N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PROTS"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PROTS"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.125	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_PROTS_MRBL"	2	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	19	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
@@ -30696,377 +18221,151 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PROTS_MRBL"	2	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	TRUE	FALSE	"[6] Agar dilution is the reference method for mecillinam MIC determination."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PRVDN"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	50	17	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PRVDN"	3	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.125	4	FALSE	FALSE	"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	18	15	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"AMK"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AMX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	18	18	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"ATM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"AZM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"BPR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	17	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CAZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CFR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CHL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"CIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CLR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"COL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CRO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CTX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_PSDMN"	3.1	"CXM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DAP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"DOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ERY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ETP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	21	21	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"FEP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FLC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. Infections caused by wild-type isolates (ECOFF: MIC 128 mg/L; corresponding zone diameter 12 mm using the disk potency and reading instructions for E. coli) have been treated with fosfomycin in combination with other agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FOX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"FUS"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	15	15	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"GEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	20	20	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"IPM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LEX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"LNZ"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	22	22	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"LVX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	24	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"MEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		2	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MNO"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"MTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NAL"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	12	12	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"NET"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NIT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NOR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"NTR"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OFX"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"ORI"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"OXA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PEN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"PHN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	18	18	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"PIP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"QDA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RIF"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"RXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SAM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SPT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"SXT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"75/10 mcg"	18	18	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TCC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TCY"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TEM"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TGC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"75 mcg"	18	18	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TIC"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TLV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TMP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	16	16	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TOB"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"TZD"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30/6 mcg"	18	18	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3	"TZP"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		16	16	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN"	3.1	"VAN"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"10/4 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZA"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"	"30/10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"CZT"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSDMN_AERG"	2.1	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSDMN_AERG"	2	"MEV"	"Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"2/1 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMC"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMP"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Infer susceptibility from benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"AMX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CIP"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	26	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.032	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility inferred from tetracycline screen test."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"CTX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.03	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	27	27	FALSE	FALSE	"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"NAL"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23		FALSE	FALSE	"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2.1	"TCY"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"P.multocida (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	24	FALSE	FALSE	"[A] Susceptibility inferred from tetracycline screen test."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_SLMNL"	3.1	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Tests with a ciprofloxacin 5 ug disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 ug disk. See Note B. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	24	FALSE	FALSE	"[B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_SLMNL"	3.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	24	FALSE	FALSE	"[B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to  Salmonella Typhi but there are also case reports of poor response with other Salmonella species."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	"[A] Isolates showing any sign of inhibition zone >= 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"AMX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ATM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CAZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CFR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"CHL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	22	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\"."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CLO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"CLR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"COL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY"	3.1	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CRO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CTX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_STPHY"	3.1	"CXM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"CZT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"DAP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"DIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"DOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ETP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FEP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FLC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY"	3	"FOS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		32	32	FALSE	FALSE	"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"IPM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LEX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	21	21	FALSE	FALSE	"[A] Examine zone edges with transmitted light (plate held up to light)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MEV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23	20	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"MTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NAL"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NOR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [E] For screening for methicillin resistance in S. pseudintermedius, see Note C on cephalosporins. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"OXA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"PIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	26	23	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"RIF"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"RXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SAM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"SPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	17	14	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"SXT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TCC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	19	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"TCY"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TEM"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	18	18	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"TGC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TIC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	17	14	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY"	3	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		2	4	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [B] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZD"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"TZP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY"	3.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AMRC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_ARLT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	18	16	FALSE	FALSE	"[1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"BPR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	17	17	FALSE	FALSE	"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing."
@@ -31077,11 +18376,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"DISK"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	20	20	FALSE	FALSE	"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[4] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[4] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ERV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_AURS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -31092,36 +18389,29 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	20	20	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is >=26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2.1	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [Scope] EUCAST gives this for MRSA | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TLV"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[Scope] EUCAST gives this breakpoint for MRSA | [3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2.1	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_BRNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAEL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CANS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CAPR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CASE"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CHRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CLDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CNDM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_COHN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	19	FALSE	FALSE	"[1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[1] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 ug disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[Scope] EUCAST: 'If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm' | [A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"LVX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
@@ -31132,655 +18422,267 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"NET"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	24	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"OFX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [C] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.6	"PHN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [2] No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_CONS"	2.5	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [4] S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These strains have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TEC"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.6	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST excludes Staphylococcus epidermidis ('S. aureus and coagulase-negative staphylococci other than S. epidermidis')"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_CPTS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CPTS_URLY"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRCL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CRNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CSRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DBCK"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRMD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DRRL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_DVRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EDPH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EPDR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_EQRM"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_EQRM_LNNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FELS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_FLRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_GLLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HLTL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_HMNS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HMNS_NVBS"	1	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_HSNC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_KLOS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		4	4	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_LGDN"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L'"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	26	26	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2.1	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LLYD"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_LNTS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MCRT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MRYL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MSSL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_MUSC"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_NPLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRGN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PRQR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSCF"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"1 mcg"	20	20	FALSE	FALSE	"[C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDX"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTRS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PTTN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RATT"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_RSTR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCH"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCCN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCHL"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SCIR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SHIN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SMLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	18	18	FALSE	FALSE	"[A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2.1	"AMP"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"		64	64	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2.1	"NTR"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STPHY_SPRP"	2.1	"OXA-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant strains is >0.25 mg/L'"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_STPN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_TWNN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_URLY"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_VTLN"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_WRNR"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XERI"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_XYLS"	2	"FOX-S"	"Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	22	22	FALSE	FALSE	"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMK"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"AMX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ATM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"AZM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"BPR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CAZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CFR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CHL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	17	17	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: \"Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy\". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"CLR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"COL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CRO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CTX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_ABCG"	2.6	"CXM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"CZT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DAP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[2] Daptomycin MICs must be determined in the presence of Ca2+ (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated).  Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"DOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ERV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	21	18	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ERY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"ETP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FEP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FOX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"FUS"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"GEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"IPM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"LEX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	19	16	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LNZ"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	17	17	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"LVX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MEV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	19	19	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23	20	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"MTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NAL"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NET"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	12		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NOR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"NTR"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	12		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OFX"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	18	18	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"PIP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"QDA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	21	15	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RIF"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"RXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SAM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"SPT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	18	15	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"SXT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TCC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23	20	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TCY"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TEC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TEM"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	19	19	FALSE	FALSE	"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TGC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TLT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TLV"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TOB"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"TZD"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.6	"TZP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	13	13	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"VAN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_ANGN"	2.1	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Perform an MIC test."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_ANGN"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_CNST"	2.1	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Perform an MIC test."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_CNST"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPA"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"	"100 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"NIT"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		64	64	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.6	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_GRPB"	2.5	"TMP"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"		2	2	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPC"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"CLO"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"DIC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"FLC"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"OXA"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_GRPG"	2.6	"PHN"	"Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2.1	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_INTR"	2.1	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Perform an MIC test."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_INTR"	2	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"AMK"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	22	16	FALSE	FALSE	"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"AMX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ATM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"AZM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"BPR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CAZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	50	28	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.032	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CFR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.03	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	21	21	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CHL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	19	19	FALSE	FALSE	"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CLO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CLR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"COL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CRO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CTB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"CTX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral"	"B_STRPT_PNMN"	2	"CXM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"CZT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DAP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"DIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"DOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ERV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	22	19	FALSE	FALSE	"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ERY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"ETP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"FEP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FLC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FOX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"FUS"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"GEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"IPM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"LEX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LNZ"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B. | [HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"LVX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"MEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	"[3] Meropenem is the only carbapenem used for meningitis."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MEV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	22	22	FALSE	FALSE	"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	24	21	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"MTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NAL"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NET"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NIT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NOR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"NTR"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	10		FALSE	FALSE	"[B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OFX"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"ORI"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"OXA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	2	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
-"EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.064	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PHN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"1 mcg"	20		FALSE	FALSE	"[D] For interpretation of the oxacillin disk screen, see flow chart below."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	2	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages."
+"EUCAST 2019"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.06	FALSE	FALSE	"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"PIP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"QDA"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	22	17	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.064	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
+"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RIF"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.06	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"RXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SAM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter)."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"SPT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	13	10	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"SXT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TCC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	22	FALSE	FALSE	"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TCY"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	17	17	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TEC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TEM"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TGC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TIC"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"15 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"TLT"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TLV"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TMP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TOB"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZD"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2.1	"TZP"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone >=20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with \"Note\" can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter)."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	16	16	FALSE	FALSE	"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"VAN"	"S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AMK"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	21	15	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"AMX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ATM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"AZM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"BPR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CAZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CFR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CHL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"2 mcg"	19	19	FALSE	FALSE	"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CLI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CLR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"COL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	27	27	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CRO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CTB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	23	23	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CTX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	26	26	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_STRPT_VIRI"	2.5	"CXM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"CZO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"CZT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DAP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"DOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ERV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ERY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	25	FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FLC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FOX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"FUS"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
+"EUCAST 2019"	"human"	"human"	"MIC"	"Screen"	"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		128	128	FALSE	FALSE	"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
 Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
 Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"GEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LEX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LNZ"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"LVX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MEV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MNO"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"MTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NAL"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NET"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NIT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NOR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"NTR"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OFX"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"ORI"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"OXA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		0.25	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PHN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"1 unit"	18		FALSE	FALSE	"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"PIP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"QDA"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RIF"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"RXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SAM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SPT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"SXT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TCY"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	16	16	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TEM"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TGC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TIC"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLT"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TLV"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IE (insufficient evidence)"
-"EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				TRUE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TMP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TOB"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR).
-Negative test: Isolates with gentamicin MIC <=128 mg/L. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. 
-Positive test: Isolates with gentamicin MIC >128 mg/L. The isolate is high-level resistant to gentamicin and other aminoglycosides except streptomycin. There will be no synergy with penicillins or glycopeptides."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZD"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.6	"TZP"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	15	15	FALSE	FALSE	"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"VAN"	"Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
@@ -31798,179 +18700,88 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as \"Susceptible, increased exposure\". When this is the case, use the MIC breakpoint S <= 0.5 mg/L and the corresponding zone diameter breakpoint S >= 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
 Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as \"Susceptible, increased exposure\". When this is the case, use the MIC breakpoint S <= 0.5 mg/L and the corresponding zone diameter breakpoint S >= 50 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [C] Susceptibility inferred from ampicillin."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"AMX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
 Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as \"Susceptible, increased exposure\". When this is the case, use the MIC breakpoint S <= 0.5 mg/L and the corresponding zone diameter breakpoint S >= 50 mm."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	26	21	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ATM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	4	FALSE	FALSE	"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC <=16 mg/L for wild-type isolates) and Shigella spp."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"AZM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Azithromycin has been used in the treatment of infections with Salmonella Typhi (MIC <=16 mg/L for wild-type isolates) and Shigella spp."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"BPR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CAZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	17	17	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	1	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	12	12	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CFR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	17	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CHL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CLR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"COL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	2	FALSE	FALSE	"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)."
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	21	21	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	1	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CPD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CRO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	23	23	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	1	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CTB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CTX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	2	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
+"EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5.1	"CXM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10/4 mcg"	13	13	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"CZO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30/10 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"CZT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	1	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DAP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"DOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ERY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"ETP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	27	24	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		1	4	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FLC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST: 'Zone diameter breakpoints apply to E. coli only' | [C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Intravenous"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		32	32	FALSE	FALSE	"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
 "EUCAST 2019"	"human"	"human"	"MIC"	"Oral, Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		32	32	TRUE	FALSE	"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems."
-"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	19	FALSE	FALSE	"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FOX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable) | [2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"FUS"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
+"EUCAST 2019"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	19	19	FALSE	FALSE	"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	14	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	14	14	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		16	16	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LEX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"LNZ"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	23	19	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"LVX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	16	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	8	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives IP (in preparation)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MEV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"MFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MNO"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"MTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NAL"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives NA (not applicable)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	15	12	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"NET"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NIT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	22	19	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.5	1	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NOR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"NTR"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	24	22	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"OFX"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		0.25	0.5	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"ORI"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"OXA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PEN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"PHN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"PIP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"QDA"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RIF"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"RXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10/10 mcg"	14	14	FALSE	FALSE	"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
 Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as \"Susceptible, increased exposure\". When this is the case, use the MIC breakpoint S <= 0.5 mg/L and the corresponding zone diameter breakpoint S >= 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SAM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	8	FALSE	FALSE	"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. 
 Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as \"Susceptible, increased exposure\". When this is the case, use the MIC breakpoint S <= 0.5 mg/L and the corresponding zone diameter breakpoint S >= 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"SPT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"1.25/23.75 mcg"	14	11	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"SXT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"75/10 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TCC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline has been used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TCY"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended) | [1] Tetracycline has been used to predict doxycycline susceptibility for the treatment of Yersinia enterocolitica infections(tetracycline MIC <=4 mg/L for wild-type isolates). The corresponding zone diameter for the tetracycline 30 ug disk is >=19 mm."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] Breakpoints still under consideration."
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TEM"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives Note (see note) | [5] Breakpoints still under consideration."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TGC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"75 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TIC"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLT"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TLV"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"5 mcg"	18	15	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	TRUE	FALSE	
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TMP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST lists this agent in this table for other organisms only"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"10 mcg"	17	14	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TOB"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		2	4	FALSE	FALSE	"[HE] High exposure for agent (see table of dosages, last tab in breakpoint table)"
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"TZD"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"	"30/6 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"TZP"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"		8	16	FALSE	FALSE	"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
-"EUCAST 2019"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
-"EUCAST 2019"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5.1	"VAN"	"Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)"				FALSE	FALSE	"[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
 "EUCAST 2019"	"human"	"human"	"MIC"		"F_ASPRG_FLAVS"	2	"ITR"	"Aspergillus"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"AMB"	"Aspergillus"		1	2	FALSE	FALSE	
 "EUCAST 2019"	"human"	"human"	"MIC"		"F_ASPRG_MGTS"	2	"ISV"	"Aspergillus"		1	1	FALSE	FALSE	
@@ -32166,8 +18977,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -32176,12 +18987,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Enterococcus"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Enterococcus"		1	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus"		512	512	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"SXT"	"Enterococcus"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
@@ -32249,10 +19060,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H. influenzae"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"SAM"	"H. influenzae"		1	1	FALSE	FALSE	
@@ -32306,10 +19117,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H. influenzae"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"SAM"	"H. influenzae"		1	1	FALSE	FALSE	
@@ -32392,7 +19203,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M. catarrhalis"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"		1	2	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"	"5 mcg"	28	28	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M. catarrhalis"		0.5	1	FALSE	FALSE	
@@ -32471,14 +19282,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"Pasteurella multocida"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacteriaceae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphs"		1	2	FALSE	FALSE	
@@ -32493,7 +19304,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphs"		1	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOS"	"Staphs"		32	32	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX-S"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphs"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"KAN"	"Staphs"		8	8	FALSE	FALSE	
@@ -32501,7 +19312,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphs"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphs"		0.5	1	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"ORI"	"Staphs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphs"		1	2	FALSE	FALSE	
@@ -32527,7 +19338,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"DISK"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphs"	"5 mcg"	20	17	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Non-pneumonia"	"B_STPHY_AURS"	2	"CPT"	"Staphs"		1	2	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Staphs"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"KAN"	"Staphs"	"30 mcg"	18	18	FALSE	FALSE	
@@ -32551,7 +19362,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"		8	16	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphs"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphs"		1	1	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"KAN"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
@@ -32569,11 +19380,11 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Staphs"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX"	"Staphs"	"30 mcg"	20	20	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX-S"	"Staphs"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2	"FOX"	"Staphs"		8	8	FALSE	FALSE	
@@ -32599,7 +19410,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
@@ -32654,8 +19465,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"Pneumo"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"		0.5	1	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"Pneumo"	"10 mcg"	11		FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"Pneumo"	"10 mcg"	11		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"Pneumo"	"5 mcg"	22	17	FALSE	FALSE	
@@ -32688,12 +19499,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans strept"		128	128	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans strept"		128	128	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ORI"	"Viridans strept"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"		0.25	2	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"		2	2	FALSE	FALSE	
@@ -32749,7 +19560,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacteriaceae"		1	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	TRUE	FALSE	
-"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2018"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"	"10 mcg"	17	14	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"		2	4	FALSE	FALSE	
 "EUCAST 2018"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacteriaceae"	"10 mcg"	22	16	FALSE	FALSE	
@@ -32969,8 +19780,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -32979,12 +19790,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Enterococcus"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Enterococcus"		1	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus"		512	512	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"SXT"	"Enterococcus"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
@@ -33053,10 +19864,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H. influenzae"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"H. influenzae"		1	16	FALSE	FALSE	
@@ -33113,10 +19924,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H. influenzae"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"	"5 mcg"	30	30	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"H. influenzae"		1	16	FALSE	FALSE	
@@ -33201,7 +20012,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M. catarrhalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"		1	2	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M. catarrhalis"		0.5	1	FALSE	FALSE	
@@ -33279,14 +20090,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"Pasteurella multocida"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacteriaceae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphs"		1	2	FALSE	FALSE	
@@ -33301,7 +20112,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphs"		1	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOS"	"Staphs"		32	32	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX-S"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphs"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"KAN"	"Staphs"		8	8	FALSE	FALSE	
@@ -33309,7 +20120,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"LNZ"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"MNO"	"Staphs"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphs"		0.5	1	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"ORI"	"Staphs"		0.125	0.125	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"QDA"	"Staphs"		1	2	FALSE	FALSE	
@@ -33333,7 +20144,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CIP"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Staphs"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Staphs"		1	1	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Staphs"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"KAN"	"Staphs"	"30 mcg"	18	18	FALSE	FALSE	
@@ -33357,7 +20168,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"		8	16	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"CIP"	"Staphs"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"CIP"	"Staphs"		1	1	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"KAN"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
@@ -33375,11 +20186,11 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Staphs"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX"	"Staphs"	"30 mcg"	20	20	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX-S"	"Staphs"	"30 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STPHY_SPRP"	2	"FOX"	"Staphs"		8	8	FALSE	FALSE	
@@ -33405,7 +20216,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
@@ -33460,8 +20271,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"Pneumo"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"		0.5	1	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"Pneumo"	"10 mcg"	11		FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"Pneumo"	"10 mcg"	11		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"Pneumo"	"5 mcg"	22	17	FALSE	FALSE	
@@ -33494,12 +20305,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans strept"		128	128	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans strept"		128	128	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ORI"	"Viridans strept"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"		0.25	2	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"		2	2	FALSE	FALSE	
@@ -33555,7 +20366,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacteriaceae"		1	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	TRUE	FALSE	
-"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2017"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"	"10 mcg"	17	14	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"		2	4	FALSE	FALSE	
 "EUCAST 2017"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacteriaceae"	"10 mcg"	22	16	FALSE	FALSE	
@@ -33759,8 +20570,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -33769,12 +20580,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"	"5 mcg"	15	15	TRUE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Enterococcus"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Enterococcus"		1	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus"		512	512	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1"	"Enterococcus"	"300 mcg"	14	14	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"SXT"	"Enterococcus"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
@@ -33841,10 +20652,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H. influenzae"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H. influenzae"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"H. influenzae"		1	16	FALSE	FALSE	
@@ -33901,10 +20712,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H. influenzae"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenzae"		1	2	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL-S"	"H. influenzae"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenzae"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN-S"	"H. influenzae"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenzae"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"H. influenzae"		1	16	FALSE	FALSE	
@@ -33962,7 +20773,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M. catarrhalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M. catarrhalis"		1	2	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M. catarrhalis"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M. catarrhalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M. catarrhalis"		0.5	1	FALSE	FALSE	
@@ -34039,14 +20850,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"Pasteurella multocida"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacteriaceae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"		4	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphs"		1	2	FALSE	FALSE	
@@ -34064,7 +20875,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphs"		1	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOS"	"Staphs"		32	32	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX-S"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphs"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"KAN"	"Staphs"	"30 mcg"	18	18	FALSE	FALSE	
@@ -34079,7 +20890,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphs"		0.5	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"MUP"	"Staphs"	"200 mcg"	30	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"MUP"	"Staphs"		1	256	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"OFX"	"Staphs"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"OFX"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"ORI"	"Staphs"		0.125	0.125	FALSE	FALSE	
@@ -34116,7 +20927,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"	"30 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"		8	16	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"NET"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
@@ -34127,7 +20938,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX-S"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"		64	64	TRUE	FALSE	
@@ -34150,7 +20961,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"ORI"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
@@ -34207,10 +21018,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"Pneumo"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"		0.5	1	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"	"5 mcg"	50	13	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"		0.125	4	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"Pneumo"	"5 mcg"	22	17	FALSE	FALSE	
@@ -34243,12 +21054,12 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans strept"		128	128	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans strept"		128	128	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ORI"	"Viridans strept"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"		0.25	2	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"		2	2	FALSE	FALSE	
@@ -34302,7 +21113,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacteriaceae"		1	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	TRUE	FALSE	
-"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2016"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"	"10 mcg"	17	14	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"		2	4	FALSE	FALSE	
 "EUCAST 2016"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacteriaceae"	"10 mcg"	22	16	FALSE	FALSE	
@@ -34500,8 +21311,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -34509,7 +21320,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Enterococcus"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Enterococcus"		1	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
@@ -34577,10 +21388,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H. influenaza"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H. influenaza"		1	2	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H. influenaza"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenaza"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenaza"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"H. influenaza"		1	16	FALSE	FALSE	
@@ -34637,10 +21448,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenaza"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenaza"		1	2	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL-S"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenaza"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN-S"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenaza"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenaza"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"H. influenaza"		1	16	FALSE	FALSE	
@@ -34698,7 +21509,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M. cattharalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M. cattharalis"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M. cattharalis"		1	2	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M. cattharalis"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M. cattharalis"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M. cattharalis"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M. cattharalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M. cattharalis"		0.5	1	FALSE	FALSE	
@@ -34774,14 +21585,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"Pasteurella multocida"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacteriaceae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"		4	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphs"		1	2	FALSE	FALSE	
@@ -34797,7 +21608,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphs"		1	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOS"	"Staphs"		32	32	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX-S"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphs"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphs"	"10 mcg"	19	19	FALSE	FALSE	
@@ -34810,7 +21621,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphs"		0.5	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"MUP"	"Staphs"	"200 mcg"	30	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"MUP"	"Staphs"		1	256	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"OFX"	"Staphs"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"OFX"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
@@ -34843,7 +21654,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"	"30 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"		8	16	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"NET"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
@@ -34854,7 +21665,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX-S"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"		64	64	TRUE	FALSE	
@@ -34876,7 +21687,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Strep A, B, C, G"	"5 mcg"	21	15	FALSE	FALSE	
@@ -34931,10 +21742,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"Pneumo"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"		0.5	1	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"	"5 mcg"	50	13	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"		0.125	4	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"Pneumo"	"5 mcg"	22	17	FALSE	FALSE	
@@ -34966,11 +21777,11 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans strept"		128	128	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans strept"		128	128	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"		0.25	2	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"		2	2	FALSE	FALSE	
@@ -35020,7 +21831,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacteriaceae"		1	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	TRUE	FALSE	
-"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2015"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"	"10 mcg"	17	14	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"		2	4	FALSE	FALSE	
 "EUCAST 2015"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacteriaceae"	"10 mcg"	22	16	FALSE	FALSE	
@@ -35218,8 +22029,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"CIP"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -35227,7 +22038,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"LVX"	"Enterococcus"		4	4	TRUE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_ENTRC"	3	"NOR-S"	"Enterococcus"	"10 mcg"	12	12	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Enterococcus"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Enterococcus"		1	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
@@ -35295,10 +22106,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"MNO"	"H. influenaza"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"MNO"	"H. influenaza"		1	2	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"NAL-S"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_HMPHL_INFL"	2	"OFX"	"H. influenaza"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"OFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_INFL"	2	"PEN-S"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenaza"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_INFL"	2	"RIF"	"H. influenaza"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_INFL"	2	"RXT"	"H. influenaza"		1	16	FALSE	FALSE	
@@ -35355,10 +22166,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenaza"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"MNO"	"H. influenaza"		1	2	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"NAL-S"	"H. influenaza"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenaza"	"5 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"OFX"	"H. influenaza"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_HMPHL_PRNF"	2	"PEN-S"	"H. influenaza"	"1 unit"	12		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenaza"	"5 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Prophylaxis"	"B_HMPHL_PRNF"	2	"RIF"	"H. influenaza"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_HMPHL_PRNF"	2	"RXT"	"H. influenaza"		1	16	FALSE	FALSE	
@@ -35416,7 +22227,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MFX"	"M. cattharalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"MNO"	"M. cattharalis"	"30 mcg"	25	22	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"MNO"	"M. cattharalis"		1	2	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL"	"M. cattharalis"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_MRXLL_CTRR"	2	"NAL-S"	"M. cattharalis"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_MRXLL_CTRR"	2	"OFX"	"M. cattharalis"	"5 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"OFX"	"M. cattharalis"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_MRXLL_CTRR"	2	"RXT"	"M. cattharalis"		0.5	1	FALSE	FALSE	
@@ -35492,14 +22303,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"DOX"	"Pasteurella multocida"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"	"5 mcg"	27	27	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"LVX"	"Pasteurella multocida"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"NAL-S"	"Pasteurella multocida"	"30 mcg"	23		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"	"1 unit"	17	17	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"PEN"	"Pasteurella multocida"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_PSTRL_MLTC"	2	"SXT"	"Pasteurella multocida"		0.25	0.25	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_PSTRL_MLTC"	2	"TCY-S"	"Pasteurella multocida"	"30 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Enterobacteriaceae"		0.064	0.064	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_SLMNL"	3	"PEF-S"	"Enterobacteriaceae"	"5 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"	"1.25/23.75 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"SXT"	"Stenotrophomonas maltophilia"		4	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"AZM"	"Staphs"		1	2	FALSE	FALSE	
@@ -35515,7 +22326,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"ERY"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Staphs"		1	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOS"	"Staphs"		32	32	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"FOX-S"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"FUS"	"Staphs"	"10 mcg"	24	24	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"FUS"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"LNZ"	"Staphs"	"10 mcg"	19	19	FALSE	FALSE	
@@ -35528,7 +22339,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"MNO"	"Staphs"		0.5	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"MUP"	"Staphs"	"200 mcg"	30	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"MUP"	"Staphs"		1	256	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY"	3	"NOR-S"	"Staphs"	"10 mcg"	17		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"OFX"	"Staphs"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"OFX"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"QDA"	"Staphs"	"15 mcg"	21	18	FALSE	FALSE	
@@ -35561,7 +22372,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"	"30 mcg"	22	19	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"AMK"	"Staphs"		8	16	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_CONS"	2.5	"FOX-S"	"Staphs"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY_CONS"	2.5	"NET"	"Staphs"	"10 mcg"	22	22	FALSE	FALSE	
@@ -35572,7 +22383,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"	"1 unit"	26	26	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"PEN"	"Staphs"		0.125	0.125	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STPHY_PSDN"	2	"FOX-S"	"Staphs"	"30 mcg"	35	35	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"	"100 mcg"	13	13	TRUE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Staphs"		64	64	TRUE	FALSE	
@@ -35594,7 +22405,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MFX"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"	"30 mcg"	23	20	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"MNO"	"Strep A, B, C, G"		0.5	1	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_ABCG"	2.5	"NOR-S"	"Strep A, B, C, G"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"	"1 unit"	18	18	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_ABCG"	2.5	"PEN"	"Strep A, B, C, G"		0.25	0.25	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_ABCG"	2.5	"RIF"	"Strep A, B, C, G"	"5 mcg"	21	15	FALSE	FALSE	
@@ -35649,10 +22460,10 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MFX"	"Pneumo"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"	"30 mcg"	24	21	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"MNO"	"Pneumo"		0.5	1	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"NOR-S"	"Pneumo"	"10 mcg"	12		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"	"5 mcg"	50	13	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_PNMN"	2	"OFX"	"Pneumo"		0.125	4	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_PNMN"	2	"OXA-S"	"Pneumo"	"1 mcg"	20		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Non-meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Meningitis"	"B_STRPT_PNMN"	2	"PEN"	"Pneumo"		0.064	0.064	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_PNMN"	2	"RIF"	"Pneumo"	"5 mcg"	22	17	FALSE	FALSE	
@@ -35684,11 +22495,11 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"ETP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"	"30 mcg"	25	25	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"FEP"	"Viridans strept"		0.5	0.5	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEH"	"Viridans strept"		128	128	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"GEN-S"	"Viridans strept"		128	128	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"IPM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"MEM"	"Viridans strept"		2	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18	12	FALSE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_STRPT_VIRI"	2.5	"PEN-S"	"Viridans strept"	"1 unit"	18		FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"PEN"	"Viridans strept"		0.25	2	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"	"30 mcg"	16	16	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_STRPT_VIRI"	2.5	"TEC"	"Viridans strept"		2	2	FALSE	FALSE	
@@ -35738,7 +22549,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FEP"	"Enterobacteriaceae"		1	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_[ORD]_ENTRBCTR"	5	"FOS"	"Enterobacteriaceae"		32	32	TRUE	FALSE	
-"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2014"	"human"	"human"	"DISK"	"Screen"	"B_[ORD]_ENTRBCTR"	5	"FOX-S"	"Enterobacteriaceae"	"30 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"	"10 mcg"	17	14	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"MIC"		"B_[ORD]_ENTRBCTR"	5	"GEN"	"Enterobacteriaceae"		2	4	FALSE	FALSE	
 "EUCAST 2014"	"human"	"human"	"DISK"		"B_[ORD]_ENTRBCTR"	5	"IPM"	"Enterobacteriaceae"	"10 mcg"	22	16	FALSE	FALSE	
@@ -35913,8 +22724,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Enterococcus"	"2 mcg"	10	8	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Enterococcus"		4	8	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Enterococcus"		4	8	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Enterococcus"		128	128	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Enterococcus"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Enterococcus"		128	128	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Enterococcus"	"10 mcg"	21	18	FALSE	FALSE	
@@ -35922,8 +22733,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Enterococcus"	"10 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Enterococcus"		4	4	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Enterococcus"		4	8	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Enterococcus"	"300 mcg"	19	19	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Enterococcus"		512	512	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"	"300 mcg"	19	19	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1"	"Enterococcus"	"300 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Enterococcus"		512	512	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"SXT"	"Enterococcus"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
@@ -36252,7 +23063,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Staphs"	"5 mcg"	20	20	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Staphs"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"GEN"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"NET"	"Staphs"	"10 mcg"	18	18	FALSE	FALSE	
@@ -36278,7 +23089,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"Staphs"		1	1	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Staphs"		4	4	FALSE	FALSE	
+"EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Staphs"		4	4	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Staphs"		2	2	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Staphs"	"2 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2013"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"FOX"	"Staphs"	"30 mcg"	22	22	FALSE	FALSE	
@@ -36601,8 +23412,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Unknown"	"2 mcg"	10	8	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Unknown"		4	8	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Unknown"		4	8	FALSE	FALSE	
-"EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
-"EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Unknown"		128	128	FALSE	FALSE	
+"EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Unknown"		128	128	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Unknown"		128	128	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Unknown"	"10 mcg"	21	18	FALSE	FALSE	
@@ -36612,7 +23423,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"QDA"	"Unknown"	"15 mcg"	22	20	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Unknown"		1	4	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"SAM"	"Unknown"		4	8	FALSE	FALSE	
-"EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Unknown"		512	512	FALSE	FALSE	
+"EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Unknown"		512	512	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1"	"Unknown"	"300 mcg"	19	19	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Unknown"		512	512	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"SXT"	"Unknown"	"1.25/23.75 mcg"	23	23	FALSE	FALSE	
@@ -36917,7 +23728,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"AMK"	"Unknown"	"30 mcg"	18	16	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"AMK"	"Unknown"		8	16	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Unknown"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Unknown"		4	4	FALSE	FALSE	
+"EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Unknown"		4	4	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"NET"	"Unknown"	"10 mcg"	18	18	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"NET"	"Unknown"		1	1	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Unknown"		2	2	FALSE	FALSE	
@@ -36938,7 +23749,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"TOB"	"Unknown"		1	1	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_CONS"	2.5	"VAN"	"Unknown"		4	4	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Unknown"	"30 mcg"	22	22	FALSE	FALSE	
-"EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Unknown"		4	4	FALSE	FALSE	
+"EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Unknown"		4	4	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Unknown"		2	2	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"		"B_STPHY_SPRP"	2	"AMP"	"Unknown"	"2 mcg"	15	15	FALSE	FALSE	
 "EUCAST 2012"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_STPHY_SPRP"	2	"NIT"	"Unknown"	"100 mcg"	13	13	TRUE	FALSE	
@@ -37121,7 +23932,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "EUCAST 2011"	"human"	"human"	"DISK"		"B_ENTRC"	3	"AMP"	"Unknown"	"2 mcg"	10	8	FALSE	FALSE	
 "EUCAST 2011"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMP"	"Unknown"		4	8	FALSE	FALSE	
 "EUCAST 2011"	"human"	"human"	"MIC"		"B_ENTRC"	3	"AMX"	"Unknown"		4	8	FALSE	FALSE	
-"EUCAST 2011"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
+"EUCAST 2011"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2011"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN"	"Unknown"	"30 mcg"	8	8	FALSE	FALSE	
 "EUCAST 2011"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Unknown"		128	128	FALSE	FALSE	
 "EUCAST 2011"	"human"	"human"	"DISK"		"B_ENTRC"	3	"IPM"	"Unknown"	"10 mcg"	21	18	FALSE	FALSE	
@@ -38120,8 +24931,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERY"	"Table 2D"		0.5	8	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -38137,8 +24948,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"PEN"	"Table 2D"		8	16	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	TRUE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	TRUE	FALSE	
@@ -39234,7 +26045,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"DISK"		"B_SLMNL"	3	"MNO"	"Table 2A-2"	"30 mcg"	16	12	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_SLMNL"	3	"MNO"	"Table 2A-2"		4	16	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A-2"		0.125	2	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF-S"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_SLMNL"	3	"SXT"	"Table 2A-2"	"1.25/23.75 mcg"	16	10	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_SLMNL"	3	"SXT"	"Table 2A-2"		2	4	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_SLMNL"	3	"TCY"	"Table 2A-2"	"30 mcg"	15	11	FALSE	FALSE	
@@ -39325,7 +26136,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -39401,8 +26212,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_AURS"	2	"ERV"	"FDA"		0.064		FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	22	22	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	20	20	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	23	23	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	17	17	FALSE	FALSE	
 "CLSI 2026"	"animal"	"cattle"	"DISK"	"Mammary gland"	"B_STPHY_AURS"	2	"KAC"	"VET01 Table 2L"	"30/15 mcg"	21	18	FALSE	FALSE	
@@ -39470,8 +26281,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"		0.25	1	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_COPS"	2.5	"ERV"	"FDA"		0.064		FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2026"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"OMC"	"FDA"	"30 mcg"	21	18	FALSE	FALSE	
@@ -39491,7 +26302,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"Copied from EUCAST 2024"	"2 mcg"	21	21	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	24	24	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	24	24	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	24	24	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	20	20	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"LNZ"	"Copied from EUCAST 2024"	"10 mcg"	19	19	FALSE	FALSE	
@@ -39509,8 +26320,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2026"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_LGDN"	2	"DFX"	"FDA"		0.032		FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	25	25	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	25	25	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2026"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	26	26	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	22	22	FALSE	FALSE	
 "CLSI 2026"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"Copied from EUCAST 2024"	"10 mcg"	21	21	FALSE	FALSE	
@@ -40747,8 +27558,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERY"	"Table 2D"		0.5	8	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -40764,8 +27575,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"PEN"	"Table 2D"		8	16	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	TRUE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	TRUE	FALSE	
@@ -41863,7 +28674,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"DISK"		"B_SLMNL"	3	"MNO"	"Table 2A-2"	"30 mcg"	16	12	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_SLMNL"	3	"MNO"	"Table 2A-2"		4	16	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A-2"		0.125	2	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF-S"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_SLMNL"	3	"SXT"	"Table 2A-2"	"1.25/23.75 mcg"	16	10	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_SLMNL"	3	"SXT"	"Table 2A-2"		2	4	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_SLMNL"	3	"TCY"	"Table 2A-2"	"30 mcg"	15	11	FALSE	FALSE	
@@ -41954,7 +28765,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -42030,8 +28841,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_AURS"	2	"ERV"	"FDA"		0.064		FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	22	22	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	20	20	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	23	23	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	17	17	FALSE	FALSE	
 "CLSI 2025"	"animal"	"cattle"	"DISK"	"Mammary gland"	"B_STPHY_AURS"	2	"KAC"	"VET01 Table 2L"	"30/15 mcg"	21	18	FALSE	FALSE	
@@ -42099,8 +28910,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"		0.25	1	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_COPS"	2.5	"ERV"	"FDA"		0.064		FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2025"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"OMC"	"FDA"	"30 mcg"	21	18	FALSE	FALSE	
@@ -42120,7 +28931,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"Copied from EUCAST 2024"	"2 mcg"	21	21	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	24	24	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	24	24	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	24	24	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	20	20	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"LNZ"	"Copied from EUCAST 2024"	"10 mcg"	19	19	FALSE	FALSE	
@@ -42138,8 +28949,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2025"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_LGDN"	2	"DFX"	"FDA"		0.032		FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	25	25	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	25	25	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2025"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	26	26	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	22	22	FALSE	FALSE	
 "CLSI 2025"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"Copied from EUCAST 2024"	"10 mcg"	21	21	FALSE	FALSE	
@@ -43374,8 +30185,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"ERY"	"Table 2D"		0.5	8	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -43391,8 +30202,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"PEN"	"Table 2D"		8	16	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	TRUE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	TRUE	FALSE	
@@ -44490,7 +31301,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"DISK"		"B_SLMNL"	3	"MNO"	"Table 2A-2"	"30 mcg"	16	12	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_SLMNL"	3	"MNO"	"Table 2A-2"		4	16	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A-2"		0.125	2	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"	"Investigational agent"	"B_SLMNL"	3	"PEF-S"	"Table 2A-2"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_SLMNL"	3	"SXT"	"Table 2A-2"	"1.25/23.75 mcg"	16	10	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_SLMNL"	3	"SXT"	"Table 2A-2"		2	4	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_SLMNL"	3	"TCY"	"Table 2A-2"	"30 mcg"	15	11	FALSE	FALSE	
@@ -44581,7 +31392,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -44657,8 +31468,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_AURS"	2	"ERV"	"FDA"		0.064		FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	22	22	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	20	20	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	23	23	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_AURS"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	17	17	FALSE	FALSE	
 "CLSI 2024"	"animal"	"cattle"	"DISK"	"Mammary gland"	"B_STPHY_AURS"	2	"KAC"	"VET01 Table 2L"	"30/15 mcg"	21	18	FALSE	FALSE	
@@ -44725,8 +31536,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"DFX"	"FDA"		0.25	1	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"	"Intravenous"	"B_STPHY_COPS"	2.5	"ERV"	"FDA"		0.064		FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2024"	"human"	"human"	"DISK"	"Intravenous, Oral"	"B_STPHY_COPS"	2.5	"OMC"	"FDA"	"30 mcg"	21	18	FALSE	FALSE	
@@ -44746,7 +31557,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"CLI"	"Copied from EUCAST 2024"	"2 mcg"	21	21	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	24	24	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	24	24	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	24	24	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	20	20	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_EPDR"	2	"LNZ"	"Copied from EUCAST 2024"	"10 mcg"	19	19	FALSE	FALSE	
@@ -44764,8 +31575,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2024"	"human"	"human"	"MIC"	"Intravenous, Oral"	"B_STPHY_LGDN"	2	"DFX"	"FDA"		0.032		FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"ERY"	"Copied from EUCAST 2024"	"15 mcg"	25	25	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Copied from EUCAST 2024"	"30 mcg"	25	25	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2024"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"FUS"	"Copied from EUCAST 2024"	"10 mcg"	26	26	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"GEN"	"Copied from EUCAST 2024"	"10 mcg"	22	22	FALSE	FALSE	
 "CLSI 2024"	"ECOFF"	"ECOFF"	"DISK"		"B_STPHY_LGDN"	2	"NOR"	"Copied from EUCAST 2024"	"10 mcg"	21	21	FALSE	FALSE	
@@ -45950,8 +32761,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	TRUE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -45970,8 +32781,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	TRUE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"	"Uncomplicated urinary tract infection"	"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	TRUE	FALSE	
@@ -46880,7 +33691,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Table 2A"		0.064	1	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2023"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"FLR"	"VET01 Table 2A"		4	16	FALSE	FALSE	
 "CLSI 2023"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR"	2	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "CLSI 2023"	"animal"	"swine"	"DISK"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET01 Table 2A"	"30 mcg"	21	17	FALSE	FALSE	
@@ -46952,7 +33763,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"	"Investigational agent"	"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -47019,8 +33830,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2023"	"animal"	"horse"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2023"	"animal"	"horse"	"MIC"	"Skin, soft tissue, respiratory"	"B_STPHY_AURS"	2	"ENR"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2023"	"animal"	"cattle"	"DISK"	"Mammary gland"	"B_STPHY_AURS"	2	"KAC"	"VET01 Table 2L"	"30/15 mcg"	21	18	FALSE	FALSE	
 "CLSI 2023"	"animal"	"cattle"	"MIC"	"Mammary gland"	"B_STPHY_AURS"	2	"KAC"	"VET01 Table 2L"		4	16	FALSE	FALSE	
 "CLSI 2023"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_AURS"	2	"LEX"	"VET01 Table 2C"		2	4	FALSE	FALSE	
@@ -47047,8 +33858,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"	"30 mcg"	25	19	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"		1	8	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
@@ -47058,13 +33869,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TLV"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TZD"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"		0.5	1	FALSE	FALSE	
 "CLSI 2023"	"animal"	"cats"	"DISK"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"	"5 mcg"	24	19	FALSE	FALSE	
 "CLSI 2023"	"animal"	"cats"	"MIC"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"		0.25	2	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2023"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2023"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"AMP"	"VET01 Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2023"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"CEP"	"VET01 Table 2C"		2	8	FALSE	FALSE	
@@ -48095,8 +34906,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -48115,8 +34926,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -48921,7 +35732,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Table 2A"		0.064	1	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2022"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"FLR"	"VET01 Table 2A"		4	16	FALSE	FALSE	
 "CLSI 2022"	"ECOFF"	"ECOFF"	"MIC"		"B_SLMNL_ENTR"	2	"MEM"	"ECOFF"		0.064	0.064	FALSE	FALSE	
 "CLSI 2022"	"animal"	"swine"	"DISK"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET01 Table 2A"	"30 mcg"	21	17	FALSE	FALSE	
@@ -48979,7 +35790,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -49046,8 +35857,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2022"	"animal"	"horse"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2022"	"animal"	"horse"	"MIC"	"Skin, soft tissue, respiratory"	"B_STPHY_AURS"	2	"ENR"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2022"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_AURS"	2	"LEX"	"VET01 Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
@@ -49070,8 +35881,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"	"30 mcg"	25	19	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"		1	8	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
@@ -49081,13 +35892,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TLV"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TZD"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"		0.5	1	FALSE	FALSE	
 "CLSI 2022"	"animal"	"cats"	"DISK"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"	"5 mcg"	24	19	FALSE	FALSE	
 "CLSI 2022"	"animal"	"cats"	"MIC"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"		0.25	2	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2022"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2022"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"AMP"	"VET01 Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2022"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"CEP"	"VET01 Table 2C"		2	8	FALSE	FALSE	
@@ -50045,8 +36856,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -50065,8 +36876,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -50589,7 +37400,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Table 2A"		0.064	1	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2021"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"FLR"	"VET01 Table 2A"		4	16	FALSE	FALSE	
 "CLSI 2021"	"animal"	"swine"	"DISK"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET01 Table 2A"	"30 mcg"	21	17	FALSE	FALSE	
 "CLSI 2021"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET01 Table 2A"		2	8	FALSE	FALSE	
@@ -50643,7 +37454,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -50710,8 +37521,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2021"	"animal"	"horse"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2021"	"animal"	"horse"	"MIC"	"Skin, soft tissue, respiratory"	"B_STPHY_AURS"	2	"ENR"	"VET01 Table 2C"		0.125	0.5	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2021"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_AURS"	2	"LEX"	"VET01 Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
@@ -50734,8 +37545,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"	"30 mcg"	25	19	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"		1	8	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"	"20 mcg"	23		FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"LMU"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
@@ -50745,13 +37556,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TLV"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TZD"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"		0.5	1	FALSE	FALSE	
 "CLSI 2021"	"animal"	"cats"	"DISK"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"	"5 mcg"	24	19	FALSE	FALSE	
 "CLSI 2021"	"animal"	"cats"	"MIC"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET01 Table 2C"		0.25	2	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2021"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2021"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"AMP"	"VET01 Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2021"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"CEP"	"VET01 Table 2C"		2	8	FALSE	FALSE	
@@ -51589,8 +38400,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -51609,8 +38420,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -52126,7 +38937,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_SLMNL"	3	"CIP"	"Table 2A"		0.064	1	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2020"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"FLR"	"VET08 Table 2A"		4	16	FALSE	FALSE	
 "CLSI 2020"	"animal"	"swine"	"DISK"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET08 Table 2A"	"30 mcg"	21	17	FALSE	FALSE	
 "CLSI 2020"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET08 Table 2A"		2	8	FALSE	FALSE	
@@ -52178,7 +38989,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -52245,8 +39056,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2020"	"animal"	"horse"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2020"	"animal"	"horse"	"MIC"	"Skin, soft tissue, respiratory"	"B_STPHY_AURS"	2	"ENR"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2020"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_AURS"	2	"LEX"	"VET08 Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2020"	"animal"	"horse"	"MIC"	"Respiratory, skin, soft tissue"	"B_STPHY_AURS"	2	"MNO"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
@@ -52267,8 +39078,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"	"30 mcg"	25	19	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"		1	8	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"QDA"	"Table 2C"	"15 mcg"	19	15	FALSE	FALSE	
@@ -52276,13 +39087,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TLV"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TZD"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2020"	"animal"	"cats"	"DISK"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET08 Table 2C"	"5 mcg"	24	19	FALSE	FALSE	
 "CLSI 2020"	"animal"	"cats"	"MIC"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET08 Table 2C"		0.25	2	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2020"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2020"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"AMP"	"VET08 Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2020"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"CEP"	"VET08 Table 2C"		2	8	FALSE	FALSE	
@@ -53101,8 +39912,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -53119,8 +39930,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -53636,7 +40447,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2019"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"FLR"	"VET08 Table 2A"		4	16	FALSE	FALSE	
 "CLSI 2019"	"animal"	"swine"	"DISK"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET08 Table 2A"	"30 mcg"	21	17	FALSE	FALSE	
 "CLSI 2019"	"animal"	"swine"	"MIC"	"Respiratory"	"B_SLMNL_ENTR"	2	"TIO"	"VET08 Table 2A"		2	8	FALSE	FALSE	
@@ -53687,7 +40498,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -53752,8 +40563,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
 "CLSI 2019"	"animal"	"horse"	"MIC"		"B_STPHY_AURS"	2	"DOX"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2019"	"animal"	"horse"	"MIC"	"Skin, soft tissue, respiratory"	"B_STPHY_AURS"	2	"ENR"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2019"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_AURS"	2	"LEX"	"VET08 Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2019"	"animal"	"horse"	"MIC"	"Respiratory, skin, soft tissue"	"B_STPHY_AURS"	2	"MNO"	"VET08 Table 2C"		0.125	0.5	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
@@ -53772,20 +40583,20 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"	"30 mcg"	25	19	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"CPT"	"Table 2C"		1	8	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"DAL"	"Table 2C"		0.25		FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"ORI"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TLV"	"Table 2C"		0.125		FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"TZD"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_COPS"	2.5	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_EPDR"	2	"OXA"	"Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2019"	"animal"	"cats"	"DISK"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET08 Table 2C"	"5 mcg"	24	19	FALSE	FALSE	
 "CLSI 2019"	"animal"	"cats"	"MIC"	"Skin, respiratory"	"B_STPHY_FELS"	2	"PRA"	"VET08 Table 2C"		0.25	2	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2019"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2019"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"AMP"	"VET08 Table 2C"		0.25	0.5	FALSE	FALSE	
 "CLSI 2019"	"animal"	"dogs"	"MIC"	"Skin, soft tissue"	"B_STPHY_PSDN"	2	"CEP"	"VET08 Table 2C"		2	8	FALSE	FALSE	
@@ -54430,8 +41241,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -54450,8 +41261,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -54875,7 +41686,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2018"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"	"15 mcg"	13	12	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"		16	32	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"Table 2B-4"		8	32	FALSE	FALSE	
@@ -54908,8 +41719,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -54957,13 +41768,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2018"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"		0.25	0.5	FALSE	FALSE	
@@ -55403,8 +42214,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -55423,8 +42234,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -55845,7 +42656,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2017"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"	"15 mcg"	13	12	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"		16	32	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"Table 2B-4"		8	32	FALSE	FALSE	
@@ -55878,8 +42689,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -55927,13 +42738,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2017"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"		0.25	0.5	FALSE	FALSE	
@@ -56369,8 +43180,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -56389,8 +43200,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -56815,7 +43626,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2016"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"	"15 mcg"	13	12	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"		16	32	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"Table 2B-4"		8	32	FALSE	FALSE	
@@ -56848,8 +43659,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -56897,13 +43708,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"DISK"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"	"1 mcg"	18	17	FALSE	FALSE	
 "CLSI 2016"	"human"	"human"	"MIC"		"B_STPHY_PSDN"	2	"OXA"	"Table 2C"		0.25	0.5	FALSE	FALSE	
@@ -57347,8 +44158,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -57366,8 +44177,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -57791,7 +44602,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2015"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"LVX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"	"Extraintestinal"	"B_SLMNL"	3	"OFX"	"Table 2A"		0.125	2	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_SLMNL"	3	"PEF-S"	"Table 2A"	"5 mcg"	24	23	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"	"15 mcg"	13	12	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_SLMNL_TYPH"	1	"AZM"	"Table 2A"		16	32	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STNTR_MLTP"	2	"CAZ"	"Table 2B-4"		8	32	FALSE	FALSE	
@@ -57824,8 +44635,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -57873,13 +44684,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"DISK"		"B_STRPT"	3	"AMP"	"Table 2H-1"	"10 mcg"	24		FALSE	FALSE	
 "CLSI 2015"	"human"	"human"	"MIC"		"B_STRPT"	3	"AMP"	"M45 Table 1"		0.25	8	FALSE	FALSE	
@@ -58311,8 +45122,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -58330,8 +45141,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -58785,8 +45596,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -58834,13 +45645,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"DISK"		"B_STRPT"	3	"AMP"	"Table 2H-1"	"10 mcg"	24		FALSE	FALSE	
 "CLSI 2014"	"human"	"human"	"MIC"		"B_STRPT"	3	"AMP"	"M45 Table 1"		0.25	8	FALSE	FALSE	
@@ -59269,8 +46080,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -59288,8 +46099,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -59743,8 +46554,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"ERY"	"Table 2C"		0.5	8	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -59792,13 +46603,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"	"30 mcg"	24	20	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"CPT"	"Table 2C"		1	4	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"DISK"		"B_STRPT"	3	"AMP"	"Table 2H-1"	"10 mcg"	24		FALSE	FALSE	
 "CLSI 2013"	"human"	"human"	"MIC"		"B_STRPT"	3	"AMP"	"M45 Table 1"		0.25	8	FALSE	FALSE	
@@ -60225,8 +47036,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"FOS"	"Table 2D"		64	256	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GAT"	"Table 2D"	"5 mcg"	18	14	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GAT"	"Table 2D"		2	8	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEH"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEH"	"Table 2D"		512	560	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"GEN-S"	"Table 2D"	"120 mcg"	10	6	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN-S"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"GEN"	"Table 2D"		512	560	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"LNZ"	"Table 2D"	"30 mcg"	23	20	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"LNZ"	"Table 2D"		2	8	FALSE	FALSE	
@@ -60244,8 +47055,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"QDA"	"Table 2D"		1	4	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"RIF"	"Table 2D"	"5 mcg"	20	16	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"RIF"	"Table 2D"		1	4	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STH"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STH"	"Table 2D"		1024	2048	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"STR1-S"	"Table 2D"	"300 mcg"	10	6	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1-S"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"STR1"	"Table 2D"		1024	2048	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_ENTRC"	3	"TCY"	"Table 2D"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_ENTRC"	3	"TCY"	"Table 2D"		4	16	FALSE	FALSE	
@@ -60739,8 +47550,8 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"FEP"	"Table 2C"		8	32	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"FLE"	"Table 2C"	"5 mcg"	19	15	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"FLE"	"Table 2C"		2	8	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Table 2C"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Table 2C"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Table 2C"		0.5	2	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"GEN"	"Table 2C"	"10 mcg"	15	12	FALSE	FALSE	
@@ -60816,13 +47627,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZP"	"Table 2C"	"100/10 mcg"	18	17	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZP"	"Table 2C"		8	16	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY"	3	"VAN"	"Table 2C"		4	32	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Table 2C"		2	16	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Table 2C"		4	8	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Table 2C"		4	8	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Table 2C"		2	4	FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"DISK"		"B_STRPT"	3	"AMP"	"Table 2H-1"	"10 mcg"	24		FALSE	FALSE	
 "CLSI 2012"	"human"	"human"	"MIC"		"B_STRPT"	3	"AMP"	"M45 Table 1"		0.25	8	FALSE	FALSE	
@@ -61527,7 +48338,7 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"AMP"	"Unknown"	"10 mcg"	29	28	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY"	3	"AMP"	"Unknown"		0.25	0.5	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"DOX"	"Unknown"	"30 mcg"	16	12	FALSE	FALSE	
-"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX"	"Unknown"	"30 mcg"	25	24	FALSE	FALSE	
+"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"FOX-S"	"Unknown"	"30 mcg"	25	24	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"GAT"	"Unknown"	"5 mcg"	23	19	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY"	3	"GAT"	"Unknown"		0.5	2	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"LVX"	"Unknown"	"5 mcg"	19	15	FALSE	FALSE	
@@ -61541,13 +48352,13 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"TCY"	"Unknown"	"30 mcg"	19	14	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY"	3	"TZP"	"Unknown"	"100/10 mcg"	18	17	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY"	3	"TZP"	"Unknown"		8	16	FALSE	FALSE	
-"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX"	"Unknown"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX"	"Unknown"		4	8	FALSE	FALSE	
+"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"FOX-S"	"Unknown"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"FOX-S"	"Unknown"		4	8	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY_AURS"	2	"OXA"	"Unknown"	"1 mcg"	13	10	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"OXA"	"Unknown"		2	4	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_AURS"	2	"VAN"	"Unknown"		2	16	FALSE	FALSE	
-"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX"	"Unknown"	"30 mcg"	22	21	FALSE	FALSE	
-"CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX"	"Unknown"		4	8	FALSE	FALSE	
+"CLSI 2011"	"human"	"human"	"DISK"		"B_STPHY_LGDN"	2	"FOX-S"	"Unknown"	"30 mcg"	22	21	FALSE	FALSE	
+"CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"FOX-S"	"Unknown"		4	8	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STPHY_LGDN"	2	"OXA"	"Unknown"		2	4	FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"DISK"		"B_STRPT"	3	"AMP"	"Unknown"	"10 mcg"	24		FALSE	FALSE	
 "CLSI 2011"	"human"	"human"	"MIC"		"B_STRPT"	3	"AMP"	"Unknown"		0.25	8	FALSE	FALSE	
diff --git a/data-raw/datasets/clinical_breakpoints.xlsx b/data-raw/datasets/clinical_breakpoints.xlsx
index da934f514..16f2b29cd 100644
Binary files a/data-raw/datasets/clinical_breakpoints.xlsx and b/data-raw/datasets/clinical_breakpoints.xlsx differ
diff --git a/data/antibiotics.rda b/data/antibiotics.rda
index 59293bf58..81bfcfedb 100644
Binary files a/data/antibiotics.rda and b/data/antibiotics.rda differ
diff --git a/index.md b/index.md
index 0cde6f771..07a417f8f 100644
--- a/index.md
+++ b/index.md
@@ -10,7 +10,7 @@
 - Generates **antibiograms** - WISCA for empiric coverage estimates, or
   traditional/syndromic for AMR surveillance
 - Provides the **full microbiological taxonomy** of ~103 000 distinct
-  species and extensive info of ~630 antimicrobial drugs
+  species and extensive info of ~640 antimicrobial drugs
 - Applies **CLSI 2011-2026** and **EUCAST 2011-2026** clinical and
   veterinary breakpoints, and ECOFFs, for MIC and disk zone
   interpretation
@@ -60,7 +60,7 @@ in scientific research.
 
 After installing this package, R knows [**~103 000 distinct microbial
 species**](./reference/microorganisms.html) (updated October 2026) and
-all [**~630 antimicrobial and antiviral
+all [**~640 antimicrobial and antiviral
 drugs**](./reference/antimicrobials.html) by name and code (including
 ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all
 about valid SIR and MIC values. The integral clinical breakpoint
diff --git a/man/antimicrobial_selectors.Rd b/man/antimicrobial_selectors.Rd
index 359c9ba47..01d8debf5 100644
--- a/man/antimicrobial_selectors.Rd
+++ b/man/antimicrobial_selectors.Rd
@@ -247,7 +247,7 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c
 \section{Full list of supported (antimicrobial) classes}{
 
 \itemize{
-\item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin (AMK), amikacin/fosfomycin (AKF), apramycin (APR), arbekacin (ARB), astromicin (AST), bekanamycin (BEK), dibekacin (DKB), framycetin (FRM), gentamicin (GEN), gentamicin-high (GEH), habekacin (HAB), hygromycin (HYG), isepamicin (ISE), kanamycin (KAN), kanamycin-high (KAH), kanamycin/cephalexin (KAC), kasugamycin (KAS), micronomicin (MCR), neomycin (NEO), netilmicin (NET), pentisomicin (PIM), plazomicin (PLZ), propikacin (PKA), ribostamycin (RST), sisomicin (SIS), streptoduocin (STR), streptomycin (STR1), streptomycin-high (STH), tobramycin (TOB), and tobramycin-high (TOH)
+\item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin (AMK), amikacin/fosfomycin (AKF), apramycin (APR), arbekacin (ARB), astromicin (AST), bekanamycin (BEK), dibekacin (DKB), framycetin (FRM), gentamicin (GEN), gentamicin screening test (GEN-S), gentamicin-high (GEH), habekacin (HAB), hygromycin (HYG), isepamicin (ISE), kanamycin (KAN), kanamycin-high (KAH), kanamycin/cephalexin (KAC), kasugamycin (KAS), micronomicin (MCR), neomycin (NEO), neomycin screening test (NEO-S), netilmicin (NET), pentisomicin (PIM), plazomicin (PLZ), propikacin (PKA), ribostamycin (RST), sisomicin (SIS), streptoduocin (STR), streptomycin (STR1), streptomycin screening test (STR1-S), streptomycin-high (STH), tobramycin (TOB), tobramycin screening test (TOB-S), and tobramycin-high (TOH)
 \item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), and ampicillin (AMP)
 \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine (AMO), amphotericin B (AMB), amphotericin B-high (AMH), anidulafungin (ANI), butoconazole (BUT), caspofungin (CAS), ciclopirox (CIX), clotrimazole (CTR), econazole (ECO), fluconazole (FLU), flucytosine (FCT), fosfluconazole (FFL), griseofulvin (GRI), hachimycin (HCH), ibrexafungerp (IBX), isavuconazole (ISV), isoconazole (ISO), itraconazole (ITR), ketoconazole (KET), manogepix (MGX), micafungin (MIF), miconazole (MCZ), nystatin (NYS), oteseconazole (OTE), pimaricin (PMR), posaconazole (POS), rezafungin (RZF), ribociclib (RBC), sulconazole (SUC), terbinafine (TRB), terconazole (TRC), and voriconazole (VOR)
 \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid (AMA), calcium aminosalicylate (CLA), capreomycin (CAP), clofazimine (CLF), delamanid (DLM), enviomycin (ENV), ethambutol (ETH), ethambutol/isoniazid (ETI), ethionamide (ETI1), isoniazid (INH), isoniazid/sulfamethoxazole/trimethoprim/pyridoxine (IST), morinamide (MRN), p-aminosalicylic acid (PAS), pretomanid (PMD), protionamide (PTH), pyrazinamide (PZA), rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), rifapentine (RFP), sodium aminosalicylate (SDA), streptomycin/isoniazid (STI), terizidone (TRZ), thioacetazone (TAT), thioacetazone/isoniazid (THI1), tiocarlide (TCR), and viomycin (VIO)
@@ -260,22 +260,22 @@ The \code{\link[=not_intrinsic_resistant]{not_intrinsic_resistant()}} function c
 \item \code{\link[=cephalosporins_3rd]{cephalosporins_3rd()}} can select: \cr cefcapene (CCP), cefcapene pivoxil (CCX), cefdinir (CDR), cefditoren (DIT), cefditoren pivoxil (DIX), cefetamet (CAT), cefetamet pivoxil (CPI), cefixime (CFM), cefmenoxime (CMX), cefodizime (DIZ), cefoperazone (CFP), cefoperazone/sulbactam (CSL), cefotaxime (CTX), cefotaxime screening test (CTX-S), cefotaxime/clavulanic acid (CTC), cefotaxime/sulbactam (CTS), cefotiam hexetil (CHE), cefovecin (FOV), cefpimizole (CFZ), cefpiramide (CPM), cefpodoxime (CPD), cefpodoxime proxetil (CPX), cefpodoxime/clavulanic acid (CDC), cefsulodin (CFS), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftazidime/clavulanic acid (CCV), cefteram (CEM), cefteram pivoxil (CPL), ceftibuten (CTB), ceftibuten/avibactam (CTA), ceftiofur (TIO), ceftizoxime (CZX), ceftizoxime alapivoxil (CZP), ceftriaxone (CRO), ceftriaxone/beta-lactamase inhibitor (CEB), and latamoxef (LTM)
 \item \code{\link[=cephalosporins_4th]{cephalosporins_4th()}} can select: \cr cefepime (FEP), cefepime/amikacin (CFA), cefepime/clavulanic acid (CPC), cefepime/enmetazobactam (FPE), cefepime/nacubactam (FNC), cefepime/taniborbactam (FTA), cefepime/tazobactam (FPT), cefepime/zidebactam (FPZ), cefetecol (CCL), cefoselis (CSE), cefozopran (ZOP), cefpirome (CPO), and cefquinome (CEQ)
 \item \code{\link[=cephalosporins_5th]{cephalosporins_5th()}} can select: \cr ceftaroline (CPT), ceftaroline/avibactam (CPA), ceftobiprole (BPR), ceftobiprole medocaril (CFM1), and ceftolozane/tazobactam (CZT)
-\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA)
+\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin (BES), ciprofloxacin (CIP), ciprofloxacin screening test (CIP-S), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin screening test (LVX-S), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin screening test (OFX-S), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA)
 \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin (AVO), bleomycin (BLM), dalbavancin (DAL), norvancomycin (NVA), oritavancin (ORI), ramoplanin (RAM), teicoplanin (TEC), teicoplanin-macromethod (TCM), telavancin (TLV), vancomycin (VAN), vancomycin-macromethod (VAM), and zorbamycin (ZOR)
 \item \code{\link[=ionophores]{ionophores()}} can select: \cr lasalocid (LAS), monensin sodium (MON), narasin (NAR), nystatin (NYS), and salinomycin (SAL)
 \item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin (CLO), dicloxacillin (DIC), flucloxacillin (FLC), meticillin (MET), oxacillin (OXA), and oxacillin screening test (OXA-S)
 \item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin (CLI), clindamycin inducible screening test (CLI-S), lincomycin (LIN), and pirlimycin (PRL)
 \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin (DAL), oritavancin (ORI), and telavancin (TLV)
-\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), clindamycin inducible screening test (CLI-S), dirithromycin (DIR), erythromycin (ERY), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), pirlimycin (PRL), primycin (PRM), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1)
+\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin (ACM), acetylspiramycin (ASP), azithromycin (AZM), clarithromycin (CLR), clindamycin inducible screening test (CLI-S), dirithromycin (DIR), erythromycin (ERY), erythromycin screening test (ERY-S), flurithromycin (FLR1), gamithromycin (GAM), josamycin (JOS), kitasamycin (KIT), meleumycin (MEL), midecamycin (MID), miocamycin (MCM), nafithromycin (ZWK), oleandomycin (OLE), pirlimycin (PRL), primycin (PRM), rokitamycin (ROK), roxithromycin (RXT), solithromycin (SOL), spiramycin (SPI), telithromycin (TLT), tildipirosin (TIP), tilmicosin (TIL), troleandomycin (TRL), tulathromycin (TUL), tylosin (TYL), and tylvalosin (TYL1)
 \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam (ATM), aztreonam/avibactam (AZA), aztreonam/nacubactam (ANC), carumonam (CAR), and tigemonam (TMN)
 \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin (FUR), furazolidone (FRZ), nifurtoinol (NFR), nitrofurantoin (NIT), and nitrofurazone (NIZ)
 \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid (CDZ), cycloserine (CYC), linezolid (LNZ), tedizolid (TZD), and thiacetazone (THA)
 \item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), amoxicillin/sulbactam (AXS), ampicillin (AMP), ampicillin/sulbactam (SAM), apalcillin (APL), aspoxicillin (APX), azidocillin (AZD), azlocillin (AZL), bacampicillin (BAM), benzathine benzylpenicillin (BNB), benzathine phenoxymethylpenicillin (BNP), benzylpenicillin (PEN), benzylpenicillin screening test (PEN-S), carbenicillin (CRB), carindacillin (CRN), ciclacillin (CIC), clometocillin (CLM), cloxacillin (CLO), dicloxacillin (DIC), epicillin (EPC), flucloxacillin (FLC), hetacillin (HET), lenampicillin (LEN), mecillinam (MEC), metampicillin (MTM), meticillin (MET), mezlocillin (MEZ), mezlocillin/sulbactam (MSU), nafcillin (NAF), oxacillin (OXA), oxacillin screening test (OXA-S), penamecillin (PNM), penicillin/novobiocin (PNO), penicillin/sulbactam (PSU), pheneticillin (PHE), phenoxymethylpenicillin (PHN), piperacillin (PIP), piperacillin/sulbactam (PIS), piperacillin/tazobactam (TZP), piridicillin (PRC), pivampicillin (PVM), pivmecillinam (PME), procaine benzylpenicillin (PRB), propicillin (PRP), sarmoxicillin (SRX), sulbenicillin (SBC), sultamicillin (SLT6), talampicillin (TAL), temocillin (TEM), ticarcillin (TIC), and ticarcillin/clavulanic acid (TCC)
 \item \code{\link[=peptides]{peptides()}} can select: \cr avoparcin (AVO), bacitracin (BAC), bleomycin (BLM), dalbavancin (DAL), daptomycin (DAP), norvancomycin (NVA), oritavancin (ORI), ramoplanin (RAM), teicoplanin (TEC), teicoplanin-macromethod (TCM), telavancin (TLV), thiostrepton (THS), vancomycin (VAN), vancomycin-macromethod (VAM), and zorbamycin (ZOR)
-\item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol (CHL), florfenicol (FLR), and thiamphenicol (THI)
+\item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol (CHL), chloramphenicol screening test (CHL-S), florfenicol (FLR), and thiamphenicol (THI)
 \item \code{\link[=phosphonics]{phosphonics()}} can select: \cr amikacin/fosfomycin (AKF) and fosfomycin (FOS)
-\item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin (COL), polymyxin B (PLB), and polymyxin B/polysorbate 80 (POP)
-\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), ozenoxacin (OZN), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA)
+\item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin (COL), colistin screening test (COL-S), polymyxin B (PLB), and polymyxin B/polysorbate 80 (POP)
+\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin (BES), cinoxacin (CIN), ciprofloxacin (CIP), ciprofloxacin screening test (CIP-S), ciprofloxacin/metronidazole (CIM), ciprofloxacin/ornidazole (CIO), ciprofloxacin/tinidazole (CIT), clinafloxacin (CLX), danofloxacin (DAN), delafloxacin (DFX), difloxacin (DIF), enoxacin (ENX), enrofloxacin (ENR), finafloxacin (FIN), fleroxacin (FLE), flumequine (FLM), garenoxacin (GRN), gatifloxacin (GAT), gemifloxacin (GEM), grepafloxacin (GRX), lascufloxacin (LSC), levofloxacin (LVX), levofloxacin screening test (LVX-S), levofloxacin/ornidazole (LEO), levonadifloxacin (LND), lomefloxacin (LOM), marbofloxacin (MAR), metioxate (MXT), miloxacin (MIL), moxifloxacin (MFX), nadifloxacin (NAD), nalidixic acid (NAL), nalidixic acid screening test (NAL-S), nemonoxacin (NEM), nifuroquine (NIF), nitroxoline (NTR), norfloxacin (NOR), norfloxacin screening test (NOR-S), norfloxacin/metronidazole (NME), norfloxacin/tinidazole (NTI), ofloxacin (OFX), ofloxacin screening test (OFX-S), ofloxacin/ornidazole (OOR), orbifloxacin (ORB), oxolinic acid (OXO), ozenoxacin (OZN), pazufloxacin (PAZ), pefloxacin (PEF), pefloxacin screening test (PEF-S), pipemidic acid (PPA), piromidic acid (PIR), pradofloxacin (PRA), premafloxacin (PRX), prulifloxacin (PRU), rosoxacin (ROS), rufloxacin (RFL), sarafloxacin (SAR), sitafloxacin (SIT), sparfloxacin (SPX), temafloxacin (TMX), tilbroquinol (TBQ), tioxacin (TXC), tosufloxacin (TFX), and trovafloxacin (TVA)
 \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin (RIB), rifampicin (RIF), rifampicin/ethambutol/isoniazid (REI), rifampicin/isoniazid (RFI), rifampicin/pyrazinamide/ethambutol/isoniazid (RPEI), rifampicin/pyrazinamide/isoniazid (RPI), rifamycin (RFM), and rifapentine (RFP)
 \item \code{\link[=spiropyrimidinetriones]{spiropyrimidinetriones()}} can select: \cr zoliflodacin (ZFD)
 \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr ostreogrycin (OST), pristinamycin (PRI), quinupristin/dalfopristin (QDA), and virginiamycine (VIR)
diff --git a/man/antimicrobials.Rd b/man/antimicrobials.Rd
index dbb6b382a..d11a6b438 100644
--- a/man/antimicrobials.Rd
+++ b/man/antimicrobials.Rd
@@ -50,7 +50,7 @@ LOINC:
 }
 }
 
-An object of class \code{deprecated_amr_dataset} (inherits from \code{tbl_df}, \code{tbl}, \code{data.frame}) with 506 rows and 14 columns.
+An object of class \code{deprecated_amr_dataset} (inherits from \code{tbl_df}, \code{tbl}, \code{data.frame}) with 519 rows and 14 columns.
 
 An object of class \code{tbl_df} (inherits from \code{tbl}, \code{data.frame}) with 120 rows and 11 columns.
 }
diff --git a/man/as.sir.Rd b/man/as.sir.Rd
index d6711082f..6a5f3be9e 100644
--- a/man/as.sir.Rd
+++ b/man/as.sir.Rd
@@ -182,7 +182,7 @@ The default \code{"standard"} setting ensures cautious handling of uncertain val
 
 \item{conserve_capped_values}{Deprecated, use \code{capped_mic_handling} instead.}
 
-\item{site}{The site or route that the isolate is interpreted for: a \link{character} vector or a column name, in the fixed codes \code{"meningitis"}, \code{"non-meningitis"}, \code{"endocarditis"}, \code{"non-endocarditis"}, \code{"pneumonia"}, \code{"non-pneumonia"}, \code{"systemic"}, \code{"extraintestinal"}, \code{"other"}, \code{"intestinal"}, \code{"skin"}, \code{"inhaled"}, \code{"oral"}, \code{"prophylaxis"}, \code{"uti"}, \code{"iv"} and \code{"topical"}, which can be combined with a comma, e.g. \code{"iv, meningitis"}. If \code{site} is \code{NA} (default), any breakpoint matching all other criteria can apply, taken from most to least systemic site in the order just given, with \code{"iv"} directly after \code{"endocarditis"}; a breakpoint without a site is taken after \code{"other"}. If \code{site} is set, a breakpoint for a contradicting site is left out, e.g. \code{"meningitis"} leaves out \code{Non-meningitis}, while a breakpoint without a site still applies. The result is \code{NA} if only contradicting sites are available, also when PK/PD breakpoints exist. All choices are noted in \code{\link[=sir_interpretation_history]{sir_interpretation_history()}}.}
+\item{site}{The site or route that the isolate is interpreted for: a \link{character} vector or a column name, in the fixed codes \code{"systemic"}, \code{"iv"}, \code{"meningitis"}, \code{"endocarditis"}, \code{"pneumonia"}, \code{"mastitis"}, \code{"respiratory"}, \code{"metritis"}, \code{"genital"}, \code{"intestinal"}, \code{"other"}, \code{"non-meningitis"}, \code{"non-endocarditis"}, \code{"non-pneumonia"}, \code{"extraintestinal"}, \code{"soft tissue"}, \code{"skin"}, \code{"wounds"}, \code{"inhaled"}, \code{"oral"}, \code{"prophylaxis"}, \code{"uti"} and \code{"topical"}, which can be combined with a comma, e.g. \code{"iv, meningitis"}. If \code{site} is \code{NA} (default), any breakpoint matching all other criteria can apply, taken from most to least systemic site in the order just given; a breakpoint without a site takes the position of \code{"other"}, as both mean any site that is not listed next to it. If \code{site} is set, a breakpoint for a contradicting site is left out, e.g. \code{"meningitis"} leaves out \code{Non-meningitis}, while a breakpoint without a site still applies. \code{"other"} leaves out every breakpoint limited to an indication, and prefers a breakpoint without a site. Related sites do not contradict each other: \code{"pneumonia"} and \code{"respiratory"}, \code{"metritis"} and \code{"genital"}, and \code{"soft tissue"}, \code{"skin"} and \code{"wounds"}. The code \code{"mastitis"} includes \verb{Mammary gland}, and \code{"wounds"} includes \code{Abscesses}. The result is \code{NA} if only contradicting sites are available, also when PK/PD breakpoints exist. All choices are noted in \code{\link[=sir_interpretation_history]{sir_interpretation_history()}}.}
 
 \item{col_mo}{Column name of the names or codes of the microorganisms (see \code{\link[=as.mo]{as.mo()}}) - the default is the first column of class \code{\link{mo}}. Values will be coerced using \code{\link[=as.mo]{as.mo()}}.}
 
diff --git a/man/custom_interpretive_rules.Rd b/man/custom_interpretive_rules.Rd
index 87d1ec057..c01e39d94 100644
--- a/man/custom_interpretive_rules.Rd
+++ b/man/custom_interpretive_rules.Rd
@@ -101,7 +101,7 @@ x
 These 43 antimicrobial groups are allowed in the rules (case-insensitive) and can be used in any combination:
 \itemize{
 \item aminocoumarins\cr(clorobiocin, novobiocin, and penicillin/novobiocin)
-\item aminoglycosides\cr(amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, kasugamycin, micronomicin, neomycin, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin-high, tobramycin, and tobramycin-high)
+\item aminoglycosides\cr(amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin screening test, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, kasugamycin, micronomicin, neomycin, neomycin screening test, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin screening test, streptomycin-high, tobramycin, tobramycin screening test, and tobramycin-high)
 \item aminopenicillins\cr(amoxicillin, amoxicillin/clavulanic acid, and ampicillin)
 \item antifungals\cr(amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole)
 \item antimycobacterials\cr(4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin)
@@ -116,25 +116,25 @@ These 43 antimicrobial groups are allowed in the rules (case-insensitive) and ca
 \item cephalosporins_4th\cr(cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefetecol, cefoselis, cefozopran, cefpirome, and cefquinome)
 \item cephalosporins_5th\cr(ceftaroline, ceftaroline/avibactam, ceftobiprole, ceftobiprole medocaril, and ceftolozane/tazobactam)
 \item cephalosporins_except_caz\cr(cefacetrile, cefaclor, cefadroxil, cefalexin, cefaloridine, cefalotin, cefamandole, cefapirin, cefatrizine, cefazedone, cefazolin, cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefetamet, cefetamet pivoxil, cefetecol, cefetrizole, cefiderocol, cefixime, cefmenoxime, cefmetazole, cefodizime, cefonicid, cefoperazone, cefoperazone/sulbactam, ceforanide, cefoselis, cefotaxime, cefotaxime screening test, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotetan, cefotiam, cefotiam hexetil, cefovecin, cefoxitin, cefoxitin screening test, cefozopran, cefpimizole, cefpiramide, cefpirome, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefprozil, cefquinome, cefroxadine, cefsulodin, cefsumide, ceftaroline, ceftaroline/avibactam, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftezole, ceftibuten, ceftibuten/avibactam, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftobiprole, ceftobiprole medocaril, ceftolozane/tazobactam, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, cefuroxime, cefuroxime axetil, cephradine, latamoxef, and loracarbef)
-\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin)
-\item fusidanes\cr(fusidic acid)
+\item fluoroquinolones\cr(besifloxacin, ciprofloxacin, ciprofloxacin screening test, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin screening test, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin screening test, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin)
+\item fusidanes\cr(fusidic acid and fusidic acid screening test)
 \item glycopeptides\cr(avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, vancomycin-macromethod, and zorbamycin)
 \item glycopeptides_except_lipo\cr(avoparcin, bleomycin, norvancomycin, ramoplanin, teicoplanin, teicoplanin-macromethod, vancomycin, vancomycin-macromethod, and zorbamycin)
 \item ionophores\cr(lasalocid, monensin sodium, narasin, nystatin, and salinomycin)
 \item isoxazolylpenicillins\cr(cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test)
 \item lincosamides\cr(clindamycin, clindamycin inducible screening test, lincomycin, and pirlimycin)
 \item lipoglycopeptides\cr(dalbavancin, oritavancin, and telavancin)
-\item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin)
+\item macrolides\cr(acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, erythromycin screening test, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin)
 \item monobactams\cr(aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam)
 \item nitrofurans\cr(furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone)
 \item oxazolidinones\cr(cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone)
 \item penicillins\cr(amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid)
 \item peptides\cr(avoparcin, bacitracin, bleomycin, dalbavancin, daptomycin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, thiostrepton, vancomycin, vancomycin-macromethod, and zorbamycin)
-\item phenicols\cr(chloramphenicol, florfenicol, and thiamphenicol)
+\item phenicols\cr(chloramphenicol, chloramphenicol screening test, florfenicol, and thiamphenicol)
 \item phosphonics\cr(amikacin/fosfomycin and fosfomycin)
-\item pleuromutilins\cr(retapamulin and tiamulin)
-\item polymyxins\cr(colistin, polymyxin B, and polymyxin B/polysorbate 80)
-\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin)
+\item pleuromutilins\cr(retapamulin, retapamulin screening test, and tiamulin)
+\item polymyxins\cr(colistin, colistin screening test, polymyxin B, and polymyxin B/polysorbate 80)
+\item quinolones\cr(besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin screening test, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin screening test, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin screening test, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin)
 \item rifamycins\cr(rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine)
 \item spiropyrimidinetriones\cr(zoliflodacin)
 \item streptogramins\cr(ostreogrycin, pristinamycin, quinupristin/dalfopristin, and virginiamycine)
diff --git a/man/custom_mdro_guideline.Rd b/man/custom_mdro_guideline.Rd
index 85300ac7d..30579451a 100644
--- a/man/custom_mdro_guideline.Rd
+++ b/man/custom_mdro_guideline.Rd
@@ -96,7 +96,7 @@ You can define antimicrobial groups instead of single antimicrobials for the rul
 
 All 43 antimicrobial selectors are supported for use in the rules:
 \itemize{
-\item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, kasugamycin, micronomicin, neomycin, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin-high, tobramycin, and tobramycin-high
+\item \code{\link[=aminoglycosides]{aminoglycosides()}} can select: \cr amikacin, amikacin/fosfomycin, apramycin, arbekacin, astromicin, bekanamycin, dibekacin, framycetin, gentamicin, gentamicin screening test, gentamicin-high, habekacin, hygromycin, isepamicin, kanamycin, kanamycin-high, kanamycin/cephalexin, kasugamycin, micronomicin, neomycin, neomycin screening test, netilmicin, pentisomicin, plazomicin, propikacin, ribostamycin, sisomicin, streptoduocin, streptomycin, streptomycin screening test, streptomycin-high, tobramycin, tobramycin screening test, and tobramycin-high
 \item \code{\link[=aminopenicillins]{aminopenicillins()}} can select: \cr amoxicillin, amoxicillin/clavulanic acid, and ampicillin
 \item \code{\link[=antifungals]{antifungals()}} can select: \cr amorolfine, amphotericin B, amphotericin B-high, anidulafungin, butoconazole, caspofungin, ciclopirox, clotrimazole, econazole, fluconazole, flucytosine, fosfluconazole, griseofulvin, hachimycin, ibrexafungerp, isavuconazole, isoconazole, itraconazole, ketoconazole, manogepix, micafungin, miconazole, nystatin, oteseconazole, pimaricin, posaconazole, rezafungin, ribociclib, sulconazole, terbinafine, terconazole, and voriconazole
 \item \code{\link[=antimycobacterials]{antimycobacterials()}} can select: \cr 4-aminosalicylic acid, calcium aminosalicylate, capreomycin, clofazimine, delamanid, enviomycin, ethambutol, ethambutol/isoniazid, ethionamide, isoniazid, isoniazid/sulfamethoxazole/trimethoprim/pyridoxine, morinamide, p-aminosalicylic acid, pretomanid, protionamide, pyrazinamide, rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, rifapentine, sodium aminosalicylate, streptomycin/isoniazid, terizidone, thioacetazone, thioacetazone/isoniazid, tiocarlide, and viomycin
@@ -109,22 +109,22 @@ All 43 antimicrobial selectors are supported for use in the rules:
 \item \code{\link[=cephalosporins_3rd]{cephalosporins_3rd()}} can select: \cr cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefetamet, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoperazone, cefoperazone/sulbactam, cefotaxime, cefotaxime screening test, cefotaxime/clavulanic acid, cefotaxime/sulbactam, cefotiam hexetil, cefovecin, cefpimizole, cefpiramide, cefpodoxime, cefpodoxime proxetil, cefpodoxime/clavulanic acid, cefsulodin, ceftazidime, ceftazidime/avibactam, ceftazidime/clavulanic acid, cefteram, cefteram pivoxil, ceftibuten, ceftibuten/avibactam, ceftiofur, ceftizoxime, ceftizoxime alapivoxil, ceftriaxone, ceftriaxone/beta-lactamase inhibitor, and latamoxef
 \item \code{\link[=cephalosporins_4th]{cephalosporins_4th()}} can select: \cr cefepime, cefepime/amikacin, cefepime/clavulanic acid, cefepime/enmetazobactam, cefepime/nacubactam, cefepime/taniborbactam, cefepime/tazobactam, cefepime/zidebactam, cefetecol, cefoselis, cefozopran, cefpirome, and cefquinome
 \item \code{\link[=cephalosporins_5th]{cephalosporins_5th()}} can select: \cr ceftaroline, ceftaroline/avibactam, ceftobiprole, ceftobiprole medocaril, and ceftolozane/tazobactam
-\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin
+\item \code{\link[=fluoroquinolones]{fluoroquinolones()}} can select: \cr besifloxacin, ciprofloxacin, ciprofloxacin screening test, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin screening test, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin screening test, ofloxacin/ornidazole, orbifloxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pradofloxacin, premafloxacin, prulifloxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin
 \item \code{\link[=glycopeptides]{glycopeptides()}} can select: \cr avoparcin, bleomycin, dalbavancin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, vancomycin, vancomycin-macromethod, and zorbamycin
 \item \code{\link[=ionophores]{ionophores()}} can select: \cr lasalocid, monensin sodium, narasin, nystatin, and salinomycin
 \item \code{\link[=isoxazolylpenicillins]{isoxazolylpenicillins()}} can select: \cr cloxacillin, dicloxacillin, flucloxacillin, meticillin, oxacillin, and oxacillin screening test
 \item \code{\link[=lincosamides]{lincosamides()}} can select: \cr clindamycin, clindamycin inducible screening test, lincomycin, and pirlimycin
 \item \code{\link[=lipoglycopeptides]{lipoglycopeptides()}} can select: \cr dalbavancin, oritavancin, and telavancin
-\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin
+\item \code{\link[=macrolides]{macrolides()}} can select: \cr acetylmidecamycin, acetylspiramycin, azithromycin, clarithromycin, clindamycin inducible screening test, dirithromycin, erythromycin, erythromycin screening test, flurithromycin, gamithromycin, josamycin, kitasamycin, meleumycin, midecamycin, miocamycin, nafithromycin, oleandomycin, pirlimycin, primycin, rokitamycin, roxithromycin, solithromycin, spiramycin, telithromycin, tildipirosin, tilmicosin, troleandomycin, tulathromycin, tylosin, and tylvalosin
 \item \code{\link[=monobactams]{monobactams()}} can select: \cr aztreonam, aztreonam/avibactam, aztreonam/nacubactam, carumonam, and tigemonam
 \item \code{\link[=nitrofurans]{nitrofurans()}} can select: \cr furazidin, furazolidone, nifurtoinol, nitrofurantoin, and nitrofurazone
 \item \code{\link[=oxazolidinones]{oxazolidinones()}} can select: \cr cadazolid, cycloserine, linezolid, tedizolid, and thiacetazone
 \item \code{\link[=penicillins]{penicillins()}} can select: \cr amoxicillin, amoxicillin/clavulanic acid, amoxicillin/sulbactam, ampicillin, ampicillin/sulbactam, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, benzathine benzylpenicillin, benzathine phenoxymethylpenicillin, benzylpenicillin, benzylpenicillin screening test, carbenicillin, carindacillin, ciclacillin, clometocillin, cloxacillin, dicloxacillin, epicillin, flucloxacillin, hetacillin, lenampicillin, mecillinam, metampicillin, meticillin, mezlocillin, mezlocillin/sulbactam, nafcillin, oxacillin, oxacillin screening test, penamecillin, penicillin/novobiocin, penicillin/sulbactam, pheneticillin, phenoxymethylpenicillin, piperacillin, piperacillin/sulbactam, piperacillin/tazobactam, piridicillin, pivampicillin, pivmecillinam, procaine benzylpenicillin, propicillin, sarmoxicillin, sulbenicillin, sultamicillin, talampicillin, temocillin, ticarcillin, and ticarcillin/clavulanic acid
 \item \code{\link[=peptides]{peptides()}} can select: \cr avoparcin, bacitracin, bleomycin, dalbavancin, daptomycin, norvancomycin, oritavancin, ramoplanin, teicoplanin, teicoplanin-macromethod, telavancin, thiostrepton, vancomycin, vancomycin-macromethod, and zorbamycin
-\item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol, florfenicol, and thiamphenicol
+\item \code{\link[=phenicols]{phenicols()}} can select: \cr chloramphenicol, chloramphenicol screening test, florfenicol, and thiamphenicol
 \item \code{\link[=phosphonics]{phosphonics()}} can select: \cr amikacin/fosfomycin and fosfomycin
-\item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin, polymyxin B, and polymyxin B/polysorbate 80
-\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin
+\item \code{\link[=polymyxins]{polymyxins()}} can select: \cr colistin, colistin screening test, polymyxin B, and polymyxin B/polysorbate 80
+\item \code{\link[=quinolones]{quinolones()}} can select: \cr besifloxacin, cinoxacin, ciprofloxacin, ciprofloxacin screening test, ciprofloxacin/metronidazole, ciprofloxacin/ornidazole, ciprofloxacin/tinidazole, clinafloxacin, danofloxacin, delafloxacin, difloxacin, enoxacin, enrofloxacin, finafloxacin, fleroxacin, flumequine, garenoxacin, gatifloxacin, gemifloxacin, grepafloxacin, lascufloxacin, levofloxacin, levofloxacin screening test, levofloxacin/ornidazole, levonadifloxacin, lomefloxacin, marbofloxacin, metioxate, miloxacin, moxifloxacin, nadifloxacin, nalidixic acid, nalidixic acid screening test, nemonoxacin, nifuroquine, nitroxoline, norfloxacin, norfloxacin screening test, norfloxacin/metronidazole, norfloxacin/tinidazole, ofloxacin, ofloxacin screening test, ofloxacin/ornidazole, orbifloxacin, oxolinic acid, ozenoxacin, pazufloxacin, pefloxacin, pefloxacin screening test, pipemidic acid, piromidic acid, pradofloxacin, premafloxacin, prulifloxacin, rosoxacin, rufloxacin, sarafloxacin, sitafloxacin, sparfloxacin, temafloxacin, tilbroquinol, tioxacin, tosufloxacin, and trovafloxacin
 \item \code{\link[=rifamycins]{rifamycins()}} can select: \cr rifabutin, rifampicin, rifampicin/ethambutol/isoniazid, rifampicin/isoniazid, rifampicin/pyrazinamide/ethambutol/isoniazid, rifampicin/pyrazinamide/isoniazid, rifamycin, and rifapentine
 \item \code{\link[=spiropyrimidinetriones]{spiropyrimidinetriones()}} can select: \cr zoliflodacin
 \item \code{\link[=streptogramins]{streptogramins()}} can select: \cr ostreogrycin, pristinamycin, quinupristin/dalfopristin, and virginiamycine
diff --git a/tests/testthat/test-sir.R b/tests/testthat/test-sir.R
index 2d5e84250..90756ce64 100644
--- a/tests/testthat/test-sir.R
+++ b/tests/testthat/test-sir.R
@@ -663,15 +663,20 @@ test_that("as.sir() takes the site of a breakpoint into account", {
   sir <- function(x, mo, ab, ..., guideline = "EUCAST 2026") {
     as.character(suppressMessages(suppressWarnings(as.sir(x, mo = mo, ab = ab, guideline = guideline, info = FALSE, ...))))
   }
-  # every site for humans in the data set must be known, so that none can be overlooked
-  sites <- unique(clinical_breakpoints$site[!is.na(clinical_breakpoints$site) & clinical_breakpoints$type == "human"])
+  # every site in the data set, for humans and for animals, must be known, so that none can be overlooked
+  sites <- unique(clinical_breakpoints$site[!is.na(clinical_breakpoints$site)])
   for (s in sites) {
-    expect_true(length(setdiff(sir_site_parts(s), SIR_SITE_NOT_A_SITE)) == length(sir_site_tokens(s)), info = s)
+    known <- vapply(setdiff(sir_site_parts(s), SIR_SITE_NOT_A_SITE), function(part) length(sir_site_tokens(part)) == 1, logical(1))
+    expect_true(all(known), info = s)
   }
-  expect_identical(sort(c(names(SIR_SITE_PATTERNS), NA), na.last = TRUE), sort(SIR_SITE_ORDER, na.last = TRUE))
+  expect_identical(sort(names(SIR_SITE_PATTERNS)), sort(SIR_SITE_ORDER))
+  expect_identical(
+    SIR_SITE_ORDER,
+    c("systemic", "iv", "meningitis", "endocarditis", "pneumonia", "mastitis", "respiratory", "metritis", "genital", "intestinal", "other", "non-meningitis", "non-endocarditis", "non-pneumonia", "extraintestinal", "soft tissue", "skin", "wounds", "inhaled", "oral", "prophylaxis", "uti", "topical", "screen")
+  )
 
   # the fixed codes, all other values give an error
-  expect_identical(sir_site_normalise(c("Meningitis", "iv, meningitis", NA)), c("meningitis", "meningitis,iv", NA))
+  expect_identical(sir_site_normalise(c("Meningitis", "iv, meningitis", NA)), c("meningitis", "iv,meningitis", NA))
   expect_error(as.sir(as.mic(1), mo = "E. coli", ab = "AMC", site = "brain", info = FALSE))
   expect_error(as.sir(as.mic(1), mo = "E. coli", ab = "AMC", site = "uti", uti = FALSE, info = FALSE))
 
@@ -687,12 +692,56 @@ test_that("as.sir() takes the site of a breakpoint into account", {
   expect_true(sir_site_fits("systemic", "meningitis"))
   expect_false(sir_site_fits("systemic", "uti"))
 
+  # veterinary sites: the same rules, where sites that are part of each other do not contradict
+  expect_identical(sir_site_tokens("Mammary gland"), "mastitis")
+  expect_identical(sir_site_tokens("Wounds, abscesses"), "wounds")
+  expect_false(sir_site_fits("mastitis", "respiratory"))
+  expect_false(sir_site_fits("respiratory", "uti"))
+  expect_true(sir_site_fits("respiratory", "pneumonia"))
+  expect_true(sir_site_fits("pneumonia", "respiratory"))
+  expect_true(sir_site_fits("metritis", "genital"))
+  expect_true(sir_site_fits(c("skin", "soft tissue"), "wounds"))
+
+  # "other" means any site not listed: it fits no breakpoint limited to an indication, but it does fit the rest
+  expect_false(sir_site_fits("meningitis", "other"))
+  expect_false(sir_site_fits("uti", "other"))
+  expect_false(sir_site_fits("mastitis", "other"))
+  expect_true(sir_site_fits(character(0), "other"))
+  expect_true(sir_site_fits("other", "other"))
+  expect_true(sir_site_fits("non-meningitis", "other"))
+  expect_true(sir_site_fits("iv", "other"))
+  expect_true(sir_site_given(character(0), "other"))
+  expect_false(sir_site_given(character(0), "uti"))
+
   # site = NA takes the most systemic site, also compared to a breakpoint without a site
-  expect_true(sir_site_rank("Meningitis") < sir_site_rank("Non-meningitis"))
-  expect_true(sir_site_rank("Intravenous") < sir_site_rank(NA))
-  expect_true(sir_site_rank(NA) < sir_site_rank("Oral"))
+  expect_true(sir_site_rank("Systemic infections") < sir_site_rank("Intravenous"))
+  expect_true(sir_site_rank("Intravenous") < sir_site_rank("Meningitis"))
+  expect_true(sir_site_rank("Pneumonia") < sir_site_rank("Mastitis"))
+  expect_identical(sir_site_rank("Mastitis"), sir_site_rank("Mammary gland"))
+  expect_true(sir_site_rank("Mastitis") < sir_site_rank("Intestinal"))
+  # "other" and no site are one position: below meningitis, and above UTI
+  expect_identical(sir_site_rank(NA), sir_site_rank("Other infections"))
+  expect_true(sir_site_rank("Meningitis") < sir_site_rank("Other infections"))
+  expect_true(sir_site_rank("Other infections") < sir_site_rank("Uncomplicated urinary tract infection"))
+  expect_true(sir_site_rank("Intestinal") < sir_site_rank(NA))
+  expect_true(sir_site_rank(NA) < sir_site_rank("Non-meningitis"))
   expect_true(sir_site_rank("Oral") < sir_site_rank("Uncomplicated urinary tract infection"))
-  expect_identical(sir_site_rank("Intravenous, Meningitis"), sir_site_rank("Meningitis"))
+  # a second site breaks a tie on the first one
+  expect_true(sir_site_rank("Intravenous, Meningitis") < sir_site_rank("Intravenous, Non-meningitis"))
+  expect_true(sir_site_rank("Intravenous, Non-meningitis") < sir_site_rank("Meningitis"))
+
+  # "other" in as.sir(): takes the breakpoint for other infections, or without a site
+  expect_identical(sir(as.mic(0.25), "Streptococcus pneumoniae", "PEN", site = "other", guideline = "EUCAST 2012"), "I")
+  expect_identical(sir(as.mic(0.25), "Streptococcus pneumoniae", "PEN", site = "meningitis", guideline = "EUCAST 2012"), "R")
+  # only breakpoints limited to an indication: no result
+  expect_identical(sir(as.mic(1), "Escherichia coli", "NTR", site = "other"), NA_character_)
+  # veterinary: per site for the host, and no result for another site
+  vet <- function(x, mo, ab, ...) {
+    sir(x, mo, ab, guideline = "CLSI 2026", breakpoint_type = "animal", host = "cattle", ...)
+  }
+  expect_identical(vet(as.mic(2), "Staphylococcus aureus", "KAC", site = "mastitis"), "S")
+  expect_identical(vet(as.mic(32), "Staphylococcus aureus", "KAC", site = "mastitis"), "R")
+  expect_identical(vet(as.mic(2), "Staphylococcus aureus", "KAC", site = "meningitis"), NA_character_)
 
   # S. pneumoniae and benzylpenicillin, with breakpoints for meningitis and for other infections
   pen <- as.mic(0.25)